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Bacteria belonging to the genus Bifidobacterium are key members of the gut 
microbiota. They are widely distributed in the animal kingdom, with over 80 
recognised species and subspecies, and a host range spanning from insects to 
mammals. Bifidobacterium are among the earliest colonisers of the human 
gastrointestinal tract and have been associated with health-promoting benefits. 
However, investigations of infant-associated Bifidobacterium across early-life 
changing dietary periods are lacking. In addition, there is limited information on the 
diversity and the saccharolytic properties of this important microbiota member in 
diverse animal hosts. Thus, in this work I sought to comprehensively explore 
human- and animal-associated Bifidobacterium strains using both genomic and 
phenotypic approaches. 
Whole genome sequencing (WGS) and bioinformatic analyses were employed to 
examine a unique collection of Bifidobacterium longum strains (n=75) isolated from 
nine either exclusively breast- or formula-fed infants across their first 18 months, 
encompassing pre-weaning, weaning and post-weaning dietary stages, as well as a 
novel collection of animal-associated Bifidobacterium isolates and publicly available 
sequences recovered from a diverse range of hosts (n=433). These genomes were 
analysed either in combination or as discrete subsets to determine their genomic 
diversity and predicted functional properties related to carbohydrate metabolism.  
To complement bioinformatic analyses, a subset of infant-associated B. longum 
isolates were characterised phenotypically using experimental approaches to 
determine their carbohydrate metabolism capabilities, which linked to genomic 
analysis. Glycan uptake analysis and proteomics resulted in the determination of 
the mechanisms employed by selected B. longum strains to metabolise different 
carbohydrates.  
Bacterial isolation resulted in the recovery of a substantial collection of animal-
associated Bifidobacterium isolates (over 100) and the identification of potential 
novel species. The results of the bioinformatic analysis indicated a highly diverse 
“open” pan-genome and an overall very broad repertoire of carbohydrate 
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utilisation genes that could be associated with the host diet. This work represents 
the largest phylogenetic and comparative genomic analysis of animal-associated 
Bifidobacterium isolates to date. 
Overall, this work enhances our current understanding of genomic and phenotypic 
properties of Bifidobacterium and lays the foundation for subsequent in-depth 
research aiming at further assessment of animal and human-associated 
Bifidobacterium diversity, and their functional potential for both therapeutic and 
industrial applications. 
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1.1 Bifidobacterium: history and general features 
 
The genus Bifidobacterium belongs to phylum Actinobacteria, order 
Bifidobacteriales, family Bifidobacteriaceae (1). Bifidobacteria were first isolated in 
1899 from faeces of breast-fed children by Henri Tissier, a French paediatrician, and 
named Bacillus bifidus due to their “bifid” Y-shape (Figure 1.1) (1-3). Because of 
their physiological and morphological similarity to lactobacilli, bifidobacteria were 
first classified under the genus Lactobacillus (1). In 1960s, de Vries and Stouthamer 
(4) reported the absence of catabolic enzymes aldolase and glucose-6-phosphate 
dehydrogenase in bifidobacteria, and showed the presence of a specific catabolic 
route involving fructose-6-phosphate phosphoketolase in these organisms. This 
observation led to re-classification of bifidobacteria as a separate genus in the 8th 
edition of Bergey’s Manual of Determinative Bacteriology (3). Currently, the genus 
Bifidobacterium encompasses 87 taxa (July 2020) (5). 
 
 
Figure 1.1 Electron microscopy image of vegetative cells of Bifidobacterium breve UCC2003. 
Courtesy of Mrs. Kathryn Cross (QIB). 
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Bifidobacteria are non-motile, non-spore-forming, non-gas-producing, and catalase-
negative Gram-positive rods with high DNA G+C% content (42-67 mol%), suggested 
to be universally distributed among animals exhibiting parental care, including 
mammals, birds, reptiles, and social insects (1, 6). On solid media, bifidobacteria 
form smooth, convex colonies with entire edges, which are cream or white in 
colour and have soft consistency (1). The optimum growth temperature for the 
majority of Bifidobacterium species ranges between 37 and 41 oC, with the 
minimum and the maximum growth temperature reported at 25 and 45 oC, 
respectively (1). The literature suggests that members of the genus Bifidobacterium 
do not grow at pH below 4.5-5.0 and above 8.0, with the optimum pH for initial 
growth reported at 6.5 to 7.0 (1). 
 
1.2 Isolation of bifidobacteria 
 
Since the discovery of Bifidobacterium, various media formulations have been 
proposed and used for the isolation, culture and enumeration of these organisms 
from the gastrointestinal tract or faecal samples of humans and animals (7). It has 
been suggested that selection of an appropriate culture medium should be based 
on several specific parameters, namely: adequate supply of nutrients and growth 
substances, low oxidation–reduction potential, the final pH of the medium and the 
maintenance of the pH value during bacterial growth (7). 
Hartemink and Rombouts (8) suggested that media suitable for bifidobacterial 
isolation and culture can be grouped into as many as five different classes, including 
non-selective media, media with elective carbohydrates, media with propionate, 
media with antibiotics and media with elective substance and/or low pH. 
Commercially available, non-selective media, such as reinforced clostridial agar 
(RCA) and de Man, Rogosa and Sharpe (MRS) have been shown to constitute 
excellent sources of nutrients required for Bifidobacterium growth and provide 
optimal growth conditions, including the adequate pH. The addition of L-cysteine 
aims at lowering the oxido-reduction potential in the medium and thus improves its 
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anaerobicity. Formulations with L-cysteine have been recommended for 
enumeration of Bifidobacterium from pure cultures (9).  
Methods to isolate and enumerate bifidobacteria in samples with mixed bacterial 
populations have largely been based on the supplementation of known non-
selective media with either a single carbon source or various selective agents that 
inhibit or reduce the growth of other bacteria. Raffinose is one example of a 
carbohydrate found to improve elective properties of both non-selective and 
selective media (9). The latter group contains formulations of varying complexity, 
whose selectivity is based either on antibiotics or on other appropriate ingredients, 
or both. For example, Beerens (10) established that the addition of propionate to 
Columbia agar at pH 5.0 stimulated the growth of bifidobacteria. Other studies 
found that Wilkins-Chalgren agar with added mupirocin was both more elective and 
selective for Bifidobacterium than that containing a combination of neomycin, 
paromomycin, nalidixic acid and lithium chloride (11). Overall, a large number of 
different types of media for isolation, cultivation and enumeration of 
Bifidobacterium have been developed over the years, however there is no standard 
formulation recommended for these purposes. 
 
1.3 Approaches to bifidobacterial phylogeny 
 
Until recently, the field of taxonomy and identification of new prokaryotic species 
relied on polyphasic characterisation based on a combination of phenotypic, 
chemotaxonomic and genotypic characteristics (12). The development of DNA 
amplification and sequencing techniques constituted an important step forward in 
determination of the taxonomic status of prokaryotes (13), and considerably 
increased the rate of the discovery of novel bacterial species (14). For many years, 
the analysis of the 16S ribosomal RNA gene was used as the primary tool for 
taxonomic assignment and phylogenetic trees, based on its presence in all bacteria, 
functional constancy and highly conserved structure (15). In 1994, Stackebrandt 
and Goebel (16) proposed a value of 97% 16S rRNA gene similarity as a threshold 
for the identification of new bacterial species. Since then, it has been demonstrated 
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that the discriminatory power of 16S rRNA gene sequences at this threshold could 
be insufficient at the species level (17, 18). More recently a cut-off value of 98.65% 
has been proposed (19), determined based on the pairwise comparison of 6787 
prokaryotic genomes. However, independent studies have shown that for a number 
of bacterial species, including Clostridium botulinum and Clostridium sporogenes, 
Rickettsia prowazekii and Rickettsia rickettsia, or Nocardia paucivorans and 
Nocardia brevicatena, the inter-species 16S rRNA gene sequence similarity values 
are greater than 98.7 % (20-22). Thus, it has been postulated that the proposed 
97% and 98.7% inter-species 16S rRNA gene sequence similarity thresholds should  
be used as indicators, rather than a definite tool for the classification of bacterial 
isolates (23). 
Concerning the genus Bifidobacterium, the 16S rRNA gene allows for discrimination 
of most bifidobacterial species, however closely related taxa have been reported to 
exhibit high sequence homologies (24, 25). Thus, it is proposed that variation in the 
16S rRNA gene alone, in the case of closely related bifidobacterial strains, is 
insufficient for clearly determining evolutionary distances, and the use of 
complementary phylogenetic markers for taxonomic differentiation has been 
advocated (12, 24). A phylogenetic approach using seven Bifidobacterium 
housekeeping genes (clpC, dnaB, dnaG, dnaJ1, purF, rpoC, xfp) has been found to 
allow a high level of discriminatory resolution between closely related 
bifidobacterial taxa, providing a robust means to infer phylogenetic relationships 
(26). In addition, the analysis of a non-coding 16S-23S internally transcribed spacer 
(ITS) has been shown to provide a greater level of resolution with regard to 
intraspecific phylogenetic relationships than the 16S rRNA gene (24). The procedure 
of concatenation has also been proposed as a measure of increasing efficacy and 
the robustness of phylogeny. The concatenated tree has been shown to allow for 
simultaneous phylogenetic inference at inter- and intraspecific level, and provides 
an increase in deep-node bootstrap values, thus increasing overall robustness (24). 
Initial studies using a multilocus approach have identified six phylogenetic groups in 
the genus Bifidobacterium, namely the Bifidobacterium adolescentis, 
Bifidobacterium asteroides, Bifidobacterium boum, B. longum, Bifidobacterium 
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pseudolongum and Bifidobacterium pullorum groups (26). More recent 
investigations of 16S rRNA and 23S rRNA genes of type representatives of 47 
described species and subspecies have recognised one more phylogenetic group, 
the Bifidobacterium bifidum group (25). The evaluation of DNA identity between 
analysed strains has shown that all bifidobacterial subspecies have the 16S rRNA 
and the 23S rRNA gene sequence homology above 97%. This analysis also revealed 
a high 16S rRNA and 23S rRNA gene sequence identity (>97%) between 
bifidobacterial taxa that are currently recognised as separate species (25). 
 
1.4 Genomic characteristics of Bifidobacterium 
 
The overall Bifidobacterium genome structure has recently been explored in studies 
that compared whole genome sequences of isolates representative of described 
bifidobacterial species, with the number of genomes included in these analyses 
ranging from 14 to 215 (27-31). The results revealed that bifidobacterial genomes 
ranged approximately from 1.63 Mb (Bifidobacterium commune) to 3.25 Mb 
(Bifidobacterium biavatii) in size, which corresponds to 1,237 and 2,557 predicted 
protein-encoding open reading frames (ORFs), respectively. Considering very close 
phylogenetic relationships between bifidobacterial taxa, it has been suggested, that 
the evolution of genomes has been driven by gene acquisition and/or loss events 
(27, 32, 33). Further analyses have suggested that those events may have 
contributed to the development of specific metabolic traits in bifidobacteria, 
allowing for transport and degradation of a vast range of carbohydrates (27, 33).   
The functional annotation of ORFs has provided the basis for the Bifidobacterium 
pan-genome. The bacterial pan-genome represents both genes that appear to be 
conserved among bacteria in a particular taxonomic unit (core-genome) and genes 
that vary among them, either absent from the genome of at least one member of a 
taxonomic unit or unique to a single member of that taxonomic unit (34, 35). The 
size of pan-genome and recombination rates have been proposed to reflect 
differences in lifestyle and niche of different bacterial species (34). Considering the 
dynamic nature of bacterial populations and their tendency to evolve and exchange 
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genetic material, one limitation of pan-genome analysis is the difficulty of assessing 
whether a pan-genome is “closed” or not. In general, an “open” pan-genome of a 
specific bacterial group indicates that genomes in this group are evolving and 
diversify, whereas a “closed” pan-genome implies a low gene exchange (36). 
The work of Milani et al. (27) laid the foundation for Bifidobacterium genomic 
analyses. The functional analysis of 47 genome sequences identified 18,181 
Bifidobacterium-specific clusters of orthologous genes (BifCOGs), which represent 
the pan-genome, and 551 BifCOGs constituting the core-genome (Figure 1.2) (27). 
Overall, the majority of the conserved core genes have been determined to encode 
housekeeping functions and functions involved in the adaptation to or in the 
interaction with a particular environment. The authors of this study were primarily 
interested in carbohydrate utilisation by bifidobacteria, and in this context, it has 
been estimated that only 5.5% of the core-genome has functions associated with 
carbohydrate metabolism, whereas the carbohydrate metabolism functional family 
is the most represented in the pan-genome (13.7%). These results indicated the 
existence of selective pressure with regard to the acquisition and retention of genes 
for carbohydrate utilization by bifidobacteria (27).  
 
 
Figure 1.2 The pan-genome of genus Bifidobacterium. 
The pan-genome (a) and core-genome (b) are represented as sizes of their gene pools versus the 
analysed 47 bifidobacterial genomes. The x axes represent the number of genomes, whereas the y 
axes represent the number of genes. Reproduced from Milani et al., 2014, Applied and 
Environmental Microbiology, DOI: 10.1128/AEM.02308-14 (27), with the authorisation from the 





The pan-genome and the core-genome power trends can be visualised by plotting 
the pan-genome and core-genome sizes as functions of the number of analysed 
genomes. The results of such analysis have shown that the pan-genome trend line 
for bifidobacteria has not reached a plateau (Figure 1.2). Although the number of 
new genes discovered by sequential addition of new genome sequences has 
recently decreased, the addition of new genomes is expected to further reduce the 
number of new gene discoveries. This indicates the existence of an “open” pan-
genome within the Bifidobacterium genus (27). Thus, it has been suggested that 
additional studies are needed in order to identify all genes present in the members 
of genus Bifidobacterium. In contrast, the trend line for the core gene set in 
bifidobacteria has been shown to reach a plateau, which suggests that the number 
of core genes is not expected to be significantly reduced by the addition of new 
genome sequences (27). 
The pan-genome analysis has also determined the bifidobacterial variome, 
encompassing truly unique genes (TUGs) present in just one genome. The mean 
number of TUGs in bifidobacteria has been identified as 249, but a large deviation 
from the mean has been observed within the genus, with Bifidobacterium indicum 
and Bifidobacterium cuniculi having 47 and 595 TUGs, respectively. These 
observations have suggested a high degree of genome diversity between 
bifidobacterial species, which has been proposed to reflect individual adaptations 
to different environments. Over 14% of TUGs have been found to be involved in 
carbohydrate transport or degradation, thus it has been suggested that the analysis 
of unique genes may prove a useful tool in studying bifidobacterial metabolism of 
host- or diet-derived components (27). 
The availability of complete genome sequences and pan-genomic analyses have 
facilitated a more robust phylogeny reconstruction. Conserved genes in bacterial 
core-genomes are relatively unlikely to experience horizontal gene transfer events, 
which makes them appropriate targets for phylogenetic inference (37). 
Concatenated protein sequences based on core-genomes can be used to create 
phylogenetic supertrees. Such analysis of 47 bifidobacterial genomes has revealed 
the discriminatory power of the concatenated protein tree to be significantly higher 
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than that observed for the tree based on 16S rRNA gene, with much higher 
bootstrap support (25). The increase in sequence length, as well as the use of 
protein-based sequences has resulted in a considerable increase in tree robustness. 
Thus, it has been advocated that the analysis based on bifidobacterial core-genome 
provides a more reliable phylogenetic method than the analysis of the 16S rRNA 
gene sequences (25). 
To date, a limited number of studies attempting global genomic and phylogenetic 
analyses of members of genus Bifidobacterium have been published (25, 27, 28, 30, 
31, 33). One caveat of these studies is that they either focused on a subset of 
genomes, or only included genomes of bifidobacterial type strains isolated from a 
limited host range. Some of the more recently recognised Bifidobacterium species 
were not represented in these analyses. The incorporation of new genome 
sequences obtained from additional host sources into these types of analysis could 
provide a more comprehensive and robust insight into the progression and 
functional characterisation of pan- and core-genomes of the genus. With 
carbohydrate metabolism being a key feature of bifidobacteria, the focus of a 
number of published genus-wide genomic comparisons has primarily been on 
functional gene groups involved in carbohydrate utilisation (27, 33, 38). However, 
more analyses are needed to encompass the diversity of the members of 
Bifidobacterium and assess the extent of their potential in terms of carbohydrate 
metabolism. 
 
1.5 An overview of carbohydrate metabolism in bifidobacteria 
 
Most simple sugars are absorbed or metabolised in the upper parts of the intestinal 
tract, whereas complex carbohydrates, for which the host lacks digestive capacity, 
are utilised by intestinal bacteria in the lower parts of the gut (39). The ability of 
commensal bacteria to degrade complex carbohydrates, such as dietary 
compounds (e.g. resistant starch, hemicellulose, glycogen), host-derived 
compounds (e.g. mucin, glycosphingolipids, chondroitin sulphate, hyaluronic acid), 
or carbon sources produced by other members of the gut microbial community has 
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been well established (40-42). It has been suggested that the amount and nature of 
complex carbohydrates in human diet directly impacts the metabolic activity and 
composition of the gastro-intestinal microbiota (43).  
Bifidobacteria are saccharolytic and utilise carbohydrates as their sole source of 
carbon and energy. As such, they are believed to play a key role in carbohydrate 
metabolism in the colon, where they are most prevalent. Bifidobacterial genomes 
have been suggested to reflect adaptations of members of this group to the 
environment of the host gastro-intestinal tract (33, 44-46), and are characterised by 
the presence of genes that encode a variety of carbohydrate-modifying enzymes, 
e.g. glycosyl hydrolases, ABC transporters, and the components of PEP-PTS 
(phosphoenolpyruvate-phosphotransferase) system involved in the concomitant 
transport and phosphorylation of carbohydrates (47).  
Phenotypic studies have confirmed that bifidobacteria can metabolise a wide range 
of complex carbohydrates, including host-derived gastric mucin, and plant-derived 
oligosaccharides, such as xylo-oligosaccharides, fructo-oligosaccharides, or pectin, 
but the bifidobacterial metabolic capacity for specific carbohydrates has been 
suggested to be species- and strain-dependent (42). Many of the characterised 
bifidobacteria can metabolise ribose, galactose, fructose, glucose, sucrose, maltose, 
melibiose and raffinose, but generally cannot utilise L-arabinose, rhamnose,  
N-acetylglucosamine, sorbitol, melezitose, trehalose, glycerol, xylitol and inulin 
(42). In general, gastro-intestinal bacteria degrade complex polymeric 
carbohydrates to low molecular weight oligosaccharides, which can subsequently 
be degraded to monosaccharides (4, 42). In bifidobacteria, these monosaccharides 
are converted to intermediates of a particular hexose fermentation pathway, 
termed the ‘‘bifid shunt’’, and ultimately converted to metabolic end products, 
which include lactate, short-chain fatty acids (SCFAs), e.g. acetate and formate, and 
other organic compounds (Figure 1.3) (4, 42, 48).  
The key enzyme in the “bifid shunt” is fructose-6-phosphate phosphoketolase (EC 
4.1.2.2). It has been shown to be present in all members of the family 
Bifidobacteriaceae, and is thus considered to be a taxonomic marker for members 
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of this group (49). Fermentation through the “bifid shunt” provides an advantage 
for bifidobacteria over, for example, lactic acid bacteria, as it yields 2.5 moles of 
ATP, 1.5 mole of acetate and 1 mole of lactate from every 1 mole of fermented 
glucose (50). The ratio of lactate to acetate may depend on the specific 
carbohydrate being metabolised, and on the bifidobacterial species. In addition, it 
has been shown that rapid fermentation of carbohydrates results in the production 
of substantial amounts of lactate, whereas acetate, formate and ethanol 
production increases when carbohydrates are degraded at a slower rate (51).  
The produced SCFAs are believed to be beneficial to the host. They provide around 
10% of the daily caloric requirement and are used as energy source by colonocytes 
and hepatocytes (52, 53).  In addition, SCFAs modulate the development and 
function of intestinal epithelial cells and cells of the innate and adaptive immune 
system, including neutrophils, macrophages and T cells, through activation of G 
protein coupled receptors (54). Additionally, SCFAs stimulate adsorption of sodium 
and water in the colon and are known to induce enzymes promoting mucosal 
restitution (53). Furthermore, they can be used as co-substrates in the production 
of butyrate by other colonic bacteria through cross-feeding interactions (55). These 
kinds of interactions have been suggested to favour the co-existence of specific 
Bifidobacterium species and strains with other bifidobacteria and with butyrate-
producing bacteria, e.g. Faecalibacterium prausnitzii and Roseburia species, in the 
colon (38, 55). 
Approximately half of the genes functionally annotated as involved in carbohydrate 
metabolism in each bifidobacterial genome have been estimated to take part in 
carbohydrate uptake, as either ABC transporters, permeases or proton symporters 
(56). The uptake of most of the complex sugars is thought to be facilitated through 
the ABC transporter system, and only a small number of the carbohydrates 
fermented by bifidobacteria are believed to be transported via PEP-PTS system 
(57). Following internalization, complex carbohydrates can be hydrolysed, 







Figure 1.3 A representation of carbohydrate degradation through the “bifid shunt” in bifidobacteria. 
Reproduced from O’Callaghan and van Sinderen, 2016, Frontiers in Microbiology, DOI: 
10.3389/fmicb.2016.00925 (45), with the permission from Frontiers under the Creative Commons 
Attribution License. 
 
Glycosyl hydrolases (GHs) appear to be the most prevalent and critical group of 
carbohydrate-modifying enzymes for bifidobacteria (38). In general, their mode of 
action involves hydrolysing the glycosidic bond between two or more sugars, or 
between a sugar and a non-sugar moiety in the presence of water (42, 48). 
However, when a high concentration of sugar is used in the reaction, specific GHs, 
termed retaining glycosyl hydrolases, can use the carbohydrate molecule as an 
acceptor molecule instead of water, which results in the exchange of the sugar 
residues, and can lead to formation of new oligosaccharides with a higher degree of 





Figure 1.4 A representation of hydrolysis (A) and transglycosylation (B) reactions performed by 
glycosyl hydrolases.  
Reproduced from Pokusaeva et al., 2011, Genes & Nutrition, DOI: 10.1007/s12263-010-0206-6 (39), 
with the permission obtained from Springer Nature through Copyright Clearance Center’s RightsLink® 
service. 
 
The analysis of the bifidobacterial pan-genome, based on 47 Bifidobacterium type 
strains, and subsequent classification according to the Carbohydrate Active 
Enzymes (CAZy) system have revealed that members of the genus Bifidobacterium 
encompass one of the largest predicted glycobiomes among known gastro-
intestinal commensals (38). In total, 3,385 genes have been identified that 
represent carbohydrate-active enzymes, including 57 families of glycosyl hydrolases 
(GHs), 13 families of glycosyl transferases (GTs), and 7 families of carbohydrate 
esterases (CEs). The genus Bifidobacterium have been shown to possess an 
extensive repertoire of enzymes belonging to GH13, GH43, GH3 and GH51 families 
(2.0 fold-, 2.6 fold-, 5.8 fold-, 7.0 fold more, respectively, compared to the average 
GH arsenal of the gut microbiome), along with Bacteroides spp. (Bacteroidales 
family) and members of the Clostridiales family (38) . The enzymes belonging to 
GH13 family of glycosyl hydrolases have been found to dominate in the 
bifidobacterial glycobiome. These enzymes have the capacity to hydrolyse a wide 
range of complex plant-derived carbohydrates, such as starch and related 
substrates (e.g. amylose and maltodextrin), as well as palatinose, stachyose, 
raffinose, and melibiose, which are commonly present in the adult mammalian diet 
(58).  
In addition, the bifidobacterial glycobiome has been shown to comprise members 
of GH families crucial for host glycan breakdown, for example those of families 
GH33 and GH34 (exo-sialidases), family GH29, which encompasses a-fucosidases, 
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as well as family GH20, which includes enzymes with hexosaminidase and  
lacto-N-biosidase activities (38). An example of host-produced glycans metabolised 
by bifidobacteria are human milk oligosaccharides (HMOs), which are present in 
human breast milk, but are not utilized by the infant host. Genomic analysis of a 
typical faecal isolate from breast-fed infants, B. longum subsp. infantis (B. infantis), 
has revealed the presence of a 43-kb gene cluster predicted to encode GHs and 
carbohydrate transporters necessary for the import and metabolism of HMOs, 
including a-fucosidases, sialidases and β-galactosidases, as well as secreted solute 
binding proteins and permeases (33, 59, 60)  
The evaluation of the bifidobacterial GH repertoire also involved the clustering of 
bifidobacterial species and subspecies based on their predicted GHs and 
carbohydrate degradation pathways (38). This analysis has allowed the 
identification of three distinct groups, which the authors designated GHP/A, GHP/B, 
and GHP/C. Group GHP/A has been found to encompass bifidobacterial species and 
subspecies with a considerable range of predicted GH43 family members. These 
enzymes are involved in the breakdown of complex plant glycans such as xylan and 
arabinoxylans, which represent substantial components of plant cell wall-derived 
dietary fibres. This suggests that members of the group GHP/A have evolved 
adaptations to hosts with vegetarian or omnivorous diet (38). Members of the 
second group, GHP/B, have been shown to have a limited number of enzymes 
belonging to families GH43 and GH3, with members of the latter family involved in 
the bacterial cell wall biosynthesis and hydrolysis of such sugars as cellodextrin, 
(arabino)xylan and (arabino)galactan. This indicates adaption to an omnivorous 
host for members of this group (38). Finally, bifidobacterial taxa isolated from social 
insects clustered to form the GHP/C group and have been found to have a distinct 
set of enzymes belonging to GH43 and GH3 family, but a limited repertoire of GH13 
family.  
Part of the predicted bifidobacterial glycobiome has been found to be extracellular 
and involved in the degradation of polysaccharide polymers too large to be 
internalized. Approximately 11% of the total GH repertoire has been estimated to 
be located extracellularly. The extracellular GHs encompass members of the GH13 
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family (annotated as pullulanases and α-amylases), members of the GH43 family  
(β-xylosidases and α-L-arabinofuranosidases), and members of the GH51 family  
(α-L-arabinofuranosidases). Predicted secreted GHs have been found to be present 
in 43 out of 47 recognised species and subspecies of the genus Bifidobacterium.  
The genomes of B. biavatii, Bifidobacterium scardovii, and B. bifidum have been 
found to encompass the highest number of extracellular enzymes. Interestingly, the 
genome of B. bifidum has been predicted to include members of GH83 and GH33, 
which are putative sialidases. This finding has suggested advanced genetic 
adaptation of B. bifidum to the mammalian gut, as sialidases are crucial for the 
degradation of HMOs and intestinal glycoproteins, such as mucin (61, 62). However, 
B. bifidum has been shown to be unable to use sialic acid as its sole carbon source 
thus the activity of sialidases has been suggested to provide access to other 
carbohydrates associated with sialylated host glycans (63). In addition, it has been 
proposed that sialic acid released as a result of sialidase activity can be utilised by 
other bifidobacteria, for example B. breve, in cross-feeding interactions (63, 64). 
 
1.6 Bifidobacterium as members of the wider gut microbiota of humans 
 
Infancy lasts from birth to approximately two years of age and is characterised by 
rapid growth, development and maturation of organs and systems (65). It has been 
well recognised that the numbers of bifidobacteria in humans decrease over 
lifetime, however the observations on bifidobacterial abundance and species 
diversity during infancy have not been consistent (66). Findings from a number of 
studies have indicated that members of Bifidobacterium dominate the infant gut 
microbiota (67, 68), however, other reports have shown fluctuations in numbers of 
these bacteria, including very low abundance or even absence in particular 
individuals (66, 69, 70). These inconsistent results could potentially be explained by 
variation in cohort age, size, geographical location or methodology between 
studies, including differences in experimental protocols, sequencing technology and 
data analysis. For example, the accuracy of studies based on the identification of 
the 16S rRNA gene strongly depends on the choice of primers and the balance 
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between efficiency, specificity and sensitivity in the targeting of the different 
bacterial 16S rRNA gene sequences in samples (71). Overall, B. longum subsp. 
infantis, B. longum subsp. longum and B. bifidum have been indicated to dominate 
the infant microbiota, while B. adolescentis and B. longum subsp. longum have 
mainly been associated with the “adult” gut (72). The results of a longitudinal study 
that followed Japanese infants during the first three years of life showed that at the 
age of 3, B. longum and B. breve followed by Bifidobacterium catenulatum and B. 
bifidum constituted the predominant Bifidobacterium species in the microbiota 
(66). Another investigation of healthy Japanese adults revealed that the 
bifidobacterial community was dominated by B. longum, B. catenulatum and B. 
adolescentis (73). These findings suggested that at the age of 3, the Bifidobacterium 
population is in transition and stabilises later in life (66). 
 
1.7 Diet and early life development 
 
According to the concept of “nutritional programming”, first introduced in the early 
1990s, the quality and the quantity of nutrients consumed by infants during the 
first year of life can permanently affect, or “programme” the early-life 
developmental outcomes (74). It has been proposed that exposure to specific 
stimuli or insults during infancy, considered a critically important period of 
development, can exert long-lasting effects on the host. 
The scientific evidence gathered over the years linking nutrition in early life to 
health in adulthood, was the basis for health promotion and the establishment of 
nutrition programmes around the world. In their 2009 report, the British Medical 
Association Board of Science (75) recognised the importance of infant nutrition and 
its association with the lifelong health. The 2011 report of the UK Scientific Advisory 
Committee on Nutrition (76) recommended the optimisation of the diet and the 
body composition of young women, and the promotion and support of 
breastfeeding, based on the compelling evidence for a role of early-life nutrition in 
modulating risk of such medical conditions as coronary heart disease, type-2 
diabetes, osteoporosis, asthma, lung disease and certain types of cancer. 
 
 32 
More recently, additional evidence has been provided linking balanced  
co-maturation of the gut microbiota and the host with infant wellness and 
development, resulting in lifelong health benefits. It is now well established that 
diet, along with factors such as genetics, mode of birth and antibiotic use, plays a 
significant role in shaping bacterial communities across different body sites. 
Crucially, establishment of the early life microbiota within the infant 
gastrointestinal tract drives key aspects of host development, occurring alongside 
host growth and immune development (77-80). Notably, recent studies have 
associated the composition of the gut microbiota with the risk of developing a 
number of chronic diseases, including type-2 diabetes (81, 82) cardiovascular 
disease (83), and cancer (84, 85).  
 
1.8 Diet as a factor modulating the gut microbiota development – an 
overview 
 
Diet has been proposed to be one of the major factors modulating the 
development of human microbiota. The type of feeding (breast vs formula) and the 
time of the introduction of solid foods (86) were suggested to be crucial to 
maturation of the early life microbial communities. The infant gut microbiota is 
highly unstable until the age of 2-3, when it reaches composition similar to that of 
an adult. Compared to infants, adults harbour a “hardier” microbiota, which is not 
as prone to external factors that might cause large changes in its structure, 
however, recent studies have shown that changes in diet can lead to temporary 
microbial shifts within hours even in adults (87). These finding are in line with the 
replacement of milk-based diet with one that is more diverse and based on solid 
foods during weaning (86).  
Transition from breastfeeding to a more complex diet, coupled with the 
introduction of complementary foods is considered to lead to an overall increase in 
the bacterial diversity in the infant gut, with the establishment of Firmicutes and 
Bacteroidetes as dominant phyla (88-90). Thompson et al. (91) compared the 
composition of the microbiota between infants that were exclusively breast-fed and 
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those that were non-exclusively breast-fed during weaning and found differences in 
bacterial diversity between these two groups. Species such as Veillonella, 
Roseburia, and members of the Lachnospiraceae family were found present in 
exclusively breast-fed infants following the start of complementary feeding, while 
Streptococcus and Coprobacillus were identified in non-exclusively breast-fed 
infants after solid foods were introduced. Interestingly, an increase in the relative 
abundance of Bifidobacterium during complementary feeding was observed in  
non-exclusively breast-fed infants, while the relative abundance of this genus in the 
exclusively breast-fed infants showed a decrease. These results may indicate 
differential modulatory effects of starches and other complex carbohydrates 
introduced in diet during weaning (91).  
Several studies have reported shifts in the composition of the infant microbiota 
during the complementary feeding period in late infancy (+9 months). In line with 
previous studies (70, 92), Laursen et al. (90) have shown an increase in the relative 
abundance of families Lachnospiraceae, Ruminococcaceae, Eubacteriaceae, 
Rikenellaceae, Sutterellaceae, and a decrease in Bifidobacteriaceae, 
Actinomycetaceae, Veillonellaceae, Enterobacteriaceae, Lactobacillaceae, 
Enterococcaceae, Clostridiales incertae sedis XI, Carnobacteriaceae, and 
Fusobacteriaceae in infants over time. The overall increase in the bacterial diversity 
during weaning has been linked to functional changes in the microbiome. The 
results of the analysis of predicted metabolic pathways between infants that were 
exclusively and non-exclusively breast-fed indicated a higher abundance  of genes 
encoding sugar transporters in breast-fed infants compared to those that were not 
exclusively breast-fed, which can possibly be linked to the abundance of HMOs in 
the diet of breast-fed infants (91). In contrast, infants that were non-exclusively 
breast-fed showed an enrichment in genes involved in nitrogen and methane 
metabolism, as well as peptidases, which could potentially be attributed to the 
higher protein content in their diet (91). 
The transition from milk-based diet to solid foods has been considered to initiate 
the development of a more stable, and functionally more complex, adult-like 
microbiome harbouring genes involved in the degradation of complex 
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carbohydrates, starches, and xenobiotics, as well as vitamin production (88). 
Several studies reported increased total levels of SCFAs during weaning, in 
particular butyrate and propionate, which has been associated with an increase in 
abundance of Firmicutes and Bacteroidetes (88, 92). Widely reported increase in 
the abundance of members of family Lachnospiraceae and a decrease in 
saccharolytic Bifidobacterium associated with the introduction of complementary 
feeding have been correlated with the increased protein content of the diet, while 
higher numbers of Prevotellaceae have been linked to the presence of fibre in 
complementary foods (93).  
 
1.9 Prebiotics and their role in optimising early life nutrition 
 
The manipulation of the intestinal microbiota for health improvement is currently 
being investigated worldwide. The introduction of specific dietary components i.e. 
prebiotics, with the potential to preferentially “feed” and act upon beneficial 
members of the gut microbiota is one widely used approach. Gibson and Roberfroid 
(94) first introduced the concept of prebiotics, and defined them as “non-digestible 
food ingredients that beneficially affect the host by selectively stimulating the 
growth and/or activity of one or a limited number of bacteria in the colon, thus 
improving host health”. In 2010, the International Scientific Association for 
Prebiotics and Probiotics (ISAPP) updated this definition to incorporate the 
functional aspect of these substances and described them as “selectively fermented 
ingredient that results in specific changes in the composition and/or activity of the 
gastrointestinal microbiome, thus conferring benefit(s) upon host health” (95). 
Bindels et al. (96) have suggested an even more comprehensive definition: “a non-
digestible compound that, through its metabolization by microorganisms in the gut, 
modulates composition and/or activity of the gut microbiome, thus conferring a 
beneficial physiologic effect on the host”. The newest definition of prebiotics 
accommodates scientific considerations and reflects its importance for regulatory 
bodies, industry, and consumers worldwide (97, 98). According to Bindels et al. 
(96), all well-known prebiotics are complex carbohydrates. Other nutrients, for 
example bioactive secondary plant metabolites such as polyphenols, may also have 
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prebiotic properties. Since prebiotics are stable compounds, they can easily be 
added to different types of food, such as yogurt, ice cream, biscuits, breads, cereals, 
spreads and drinks (99). To be classified as a prebiotic, a compound needs to fulfil 
the following criteria (i) it needs to resist gastric acidity, degradation by mammalian 
digestive enzymes, and gastrointestinal absorption; (ii) it has to be metabolised by 
intestinal bacteria; and (iii) it needs to selectively stimulate the growth and/or 
activity of intestinal bacteria linked with health and well-being (100). 
To date, a number of prebiotics originating from different sources and displaying 
various chemical properties have been named, reviewed and classified based on a 
set of common criteria (101). Examples will be discussed in more detail below, but 
briefly; properties of breast milk-derived HMOs as first prebiotics available to 
infants have been widely recognised (102-104). Other well-established compounds 
with prebiotic properties include inulin, fructo-oligosaccharides (FOS), galacto-
oligosaccharides (GOS), and lactulose, while isomalto-oligosaccharides (IMO), xylo-
oligosaccharides (XOS), and lactitol are categorised as emerging prebiotics (101, 
105-108). Inulin-derived FOS from chicory root, as well as wheat bran-derived XOS 
and arabinoxylo-oligosaccharides (AXOS) have been shown to have applications in 
human and animal welfare (109, 110). Mannitol, maltodextrin, raffinose, lactulose, 
and sorbitol have been identified to exert beneficial effects on members of the 
human gut microbiota, including promotion of growth and production of 
antimicrobial compounds (111-113). In addition, resistant starches and other 
dietary fibres, such as beta-glucan and guar gum, can be degraded by intestinal 
bacteria to SCFAs, which indicates potential prebiotic application of these 
compounds in promoting human well-being (114-116).  
 
1.10 Breast milk: gold standard infant nutrition and a source of beneficial 
microbes 
 
Human milk is perfectly adapted to neonatal nutritional requirements and supports 
infant growth and development. Hence, it has been considered the gold standard 
for infant nutrition during the first months of life (117, 118). Breastfeeding drives 
beneficial microbial, metabolic and immunological programming, and thus 
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represents a key postnatal link between mother and infant (119-121). A large 
number of biologically active components are present in human milk, including 
immunoglobulins, chemokines, growth factors, cytokines, bioactive lipids, 
oligosaccharides, microRNAs, hormones, immune cells and microorganisms (120, 
122-124). Crucially, breastfeeding has been linked to decreased risk for numerous 
diseases, which has been attributed to differences in immune system development 
(124, 125). Biologically active factors in human milk have been shown to directly 
impact immune responses (124, 126). Milk glycoproteins have been reported to 
prevent intestinal pathogens, such as Vibrio cholerae and Escherichia coli, from 
colonising (127). Human milk oligosaccharides have been shown to prevent 
attachment of respiratory pathogens, such as Streptococcus pneumoniae, to 
respiratory epithelium (128). In particular, lacto-N-neotetraose and lacto-N-
tetraose have been proposed as receptors for attaching pneumococci, with the 
disaccharide GIcNAcβ1à3Galβ identified as the principal binding site (129). HMOs 
have also been found to directly interact with glycan-binding proteins expressed on 
the epithelial cells and cells of the innate immune system (130). For example, 2ʹ-
fucosyllactose (2’-FL) has been reported to bind human DC-SIGN (Dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin), a C-type lectin 
receptor present on the surface of macrophages and dendritic cells (131). Breast 
milk components have also been found to facilitate the establishment of early 
bacterial colonisers which further modulate immunity and enhance the synthesis 
and secretion of polymeric IgA, the coating antibody that protects mucosal surfaces 
against bacterial invasion, and helps drive homeostatic immune cell programming 
including the balance between Th1 vs. Th2 responses. Notably, unbalanced 
immunological T helper cell responses (Th1 > Th2 or Th2 > Th1) have been 
associated with certain clinical outcomes, such as atopic disease (Th2 imbalance) 
and Crohn's disease (Th1 imbalance) (126).  
The dogma that breast milk is sterile was challenged after viable bacteria were 
isolated from breast milk samples obtained from healthy women (132, 133). 
Traditional culture methods have reported the presence of lactic acid bacteria with 
potential beneficial or “probiotic” properties such as Lactobacillus, Lactococcus, 
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Leuconostoc, and also in some cases Bifidobacterium, as well as other bacteria 
including Streptococcus, Enterococcus and Staphylococcus (132-135). Studies 
involving sequencing have indicated high microbial diversity, and detected bacteria 
that typically inhabit the oral cavity, such as Veillonella and Prevotella, skin bacteria 
such as Staphylococcus and Propionibacterium, lactic acid bacteria, including 
Enterococcus, Streptococcus, Leuconostoc and Weissella, and Gram negative 
bacteria, such as Pseudomonas, Ralstonia, and Klebsiella, with high inter- and intra-
individual specific profiles (134, 136-141). Breast milk, the maternal gut and infant 
faeces and oral samples have been reported to share specific bacteria or bacterial 
DNA (133, 142-145), including specific strains belonging to Bifidobacterium and 
Staphylococcus spp. (142, 146-148). These findings support the notion of vertical 
transmission of breast milk bacteria to the infant gut, whose roles likely include 
enhancement of the development of the early life immune system, maintenance of 
tolerance to commensal microbial members, and intestinal host defence to 
pathogens. Currently there is limited evidence with regard to the potential effect of 
breast milk microorganisms on infant health, but it has been speculated that they 
may act as key early life colonisers, and help to shape the developing mucosal 
immune system (123, 149, 150). More specifically, the breast milk bacterial 
communities may promote intestinal immune homeostasis, encouraging a shift 
from the predominant intrauterine T helper cell 2 (Th2) immune milieu, to a 
Th1/Th2 balanced response, and to trigger regulatory T cell differentiation (123, 
151). 
 
1.11 Breast milk “feeds” specific members of the infant gut microbiota  
 
Maternal breast milk acts as a natural prebiotic and feeds certain bacterial strains 
and species of the gut microbiota during the early life developmental window. 
Particular breast-milk components, e.g. HMOs, are poorly digested by the infant but 
are suitable growth substrates mainly for Bifidobacterium, but also a few strains of 
Bacteroides and Lactobacillus that can enzymatically degrade these complex dietary 
components. The term “human milk oligosaccharides” collectively refers to non-
digestible carbohydrates with the degree of polymerisation (DP) equal or above 3, 
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that are the third most abundant component of breast milk after lactose and lipids 
(152). More than 200 different HMOs can be found in the milk of a single mother, 
each composed of a common lactose reduced end linked to N-acetyllactosamine 
(Galβ1-4GlcNAc) or lacto-N-biose I units (LNB) (Galβ1-3GlcNAc) (153). Several 
HMOs comprise the major types in breast-milk, for example 2’-FL and  
lacto-N-tetraose (LNT). These structures can additionally be sialylated or/and 
fucosylated. HMO fucosylation depends on the presence of functional enzymes, 
fucosyltransferases, in the mother’s mammary glands, which is regulated by Lewis 
and secretor genes (153, 154).  
Predominance of Bifidobacterium in the gut microbiota during infancy and lower 
overall bacterial diversity have been associated with nutrient availability. The high 
abundance of Bifidobacterium in breast-fed infants has been linked to the 
enrichment of members of this genus in genes required for the degradation of 
HMOs (70, 155). Several infant gut-associated Bifidobacterium species have been 
found to harbour genes encoding enzymes necessary for the metabolism of HMOs, 
including B. breve, B. bifidum, B. longum subsp. longum (B. longum), B. longum 
subsp. infantis (B. infantis), and more rarely Bifidobacterium pseudocatenulatum 
(59, 156-158). Strategies for HMO degradation vary among Bifidobacterium species, 
and the metabolic capabilities for HMOs within the species are strain specific. 
Overall, conserved consumption of HMOs has been attributed to B. bifidum and  
B. infantis, while more variable and strain-dependent degradation of these 
carbohydrates has been demonstrated in B. breve and B. longum (152, 159).  
Recent experimental evidence has suggested that bifidobacteria utilise two main 
strategies for HMO metabolism (152, 160). The first one relies on presence of 
functional membrane-associated extracellular glycosyl hydrolases, lacto-N-
biosidases. These enzymes hydrolyse HMOs, particularly LNT, into mono- and 
disaccharides, which are then imported into the cell by solute binding proteins 
(SBP) (159). This strategy seems to be widely employed by B. bifidum, but also by 
those B. longum strains that harbour the gene encoding lacto-N-biosidase (LnbX) 
(152, 160). The second strategy relies on the SBP-mediated import of intact HMOs 
inside the cell and their degradation by intracellular glycosyl hydrolases, including 
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for example α-fucosidases, sialidases, β-galactosidases and  
β-N-acetylhexosaminidases with affinities for a wide spectrum of milk 
oligosaccharides (159). This mode of action has been demonstrated in B. infantis,  
B. breve and those B. longum strains that are LnbX-negative (152, 160).  
Certain Bifidobacterium members, for example B. bifidum, seem to only partially 
degrade HMOs, which raised a question of possible cross-feeding within infant-
associated Bifidobacterium communities (161). Gotoh et al. (152) found that wild-
type strain of B. longum 105-A (LnbX-positive), which showed very limited growth 
on LNT in mono-culture, grew very well in co-culture with an extracellular HMO 
degrader B. bifidum. In addition, supplementation of B. bifidum in HMO-containing 
stool cultures stimulated the growth of other Bifidobacterium species, especially in 
samples which did not initially contain B. bifidum. Most recently, our own results 
suggested similar co-operation between HMO degraders that employ the 
intracellular degradation system and other members of Bifidobacterium community 
(162). We demonstrated that conditioned media from B. longum grown on 2’-FL 
used as a carbon source for other non-HMO degrading Bifidobacterium strains 
could support growth of other isolates within the same infant host. These results 
were further confirmed in co-culture experiments. Altogether, these results suggest 
that bifidobacterial degradation products resulting from HMO metabolism may 
influence the acquisition and abundance of Bifidobacterium in an ecosystem (152, 
162). 
Previous studies have indicated that members of genus Bifidobacterium strongly 
modulate specific immune cells and pathways. Acquisition of specific strains and 
species of Bifidobacterium seem to correlate with a critical period of immune 
maturation and programming. It has been shown that the metabolism of maternal-
derived glycans, i.e. HMOs, by Bifidobacterium results in increased levels of SCFAs, 
in particular acetate (162-164). These compounds have been reported to play 
regulatory roles within the gut-associated mucosal immune system. They have also 
been found to provide energy to epithelial cells, which in turn helps maintain the 
coherence of tight junctions and the intestinal barrier, thus providing mechanisms 
of defence against pathogens. SCFAs have also been implicated in regulating 
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mucosal cells of the innate immune system such as macrophages or dendritic cells, 
as well as neutrophils, and the antigen-triggered adaptive immunity activities 
mediated by T and B lymphocytes (165-168). 
1.12 The formula effect: impact on the infant gut microbiota  
 
Factors such as mode of birth (i.e. vaginal delivery vs. Caesarean-section), antibiotic 
treatment, and skin-to-skin contact determine the composition of early life 
microbiota and the resulting gastrointestinal function (93, 169). However, the 
infant diet is proposed to play a major role and induce the most significant changes. 
Over the years, numerous studies have reported notable differences in the 
composition of intestinal microbiota between breast- and formula-fed infants (92, 
170-174). Compared to breast-fed infants, formula-fed infants are characterised by 
an overall higher microbial diversity, elevated levels of potentially pathogenic 
organisms, such as Escherichia coli and Clostridioides difficile and reduced levels of 
beneficial Bifidobacterium (70, 175, 176).  
Formula feeding has been linked to increased risk for a number of diseases in 
adulthood, attributed to microbiota profiles and the previously mentioned 
development of the immune system in early life (125). Numerous epidemiological 
studies have suggested that the type of feeding in infancy may contribute to 
obesity or the development of type-2 diabetes later in life (177-180). Some studies 
have also suggested an increased risk of high blood pressure (181) and high 
cholesterol (182, 183).  
Over the years, improved formulations of infant formulas have been researched, 
designed and produced as an alternative to breast milk. These products must 
contain water, carbohydrates, protein, fat, vitamins and minerals in adequate 
proportions (184). The composition of infant formulas is tightly regulated, and 
manufacturers around the world are obliged to follow guidelines set by government 
agencies (184). All major components (protein, lipids, carbohydrates) added to the 
formula must have a proven history of safe use (185). Fructose should be avoided 
as a carbohydrate source, as it may lead to fructose intolerance in infants, and only 
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the L forms of amino acids are approved as ingredients, as D forms may cause  
D-lactic acidosis (186). Further, hydrogenated fats are also not allowed, nor is the 
use of the ionizing radiation on the product (187).  
Currently available infant formulas can be grouped in three major classes: cow-milk 
based formula, soy-based formula and specialized formula. They differ in nutritional 
and caloric values, taste, digestion, and cost. Special formulas have been designed 
and are available to meet needs of infants with intolerances, where rice, amino 
acids and extensively hydrolysed whey or casein proteins have been used as cow’s 
milk substitutes (184). HMOs are characteristic of human milk and are not present 
in the same composition in animal milk nor plant proteins that are normally used as 
the basis for formula (188). Synthesising HMOs is expensive, therefore formula 
supplementation with compounds that might mimic some of the HMO functions 
described above has been widely investigated in the recent years. Affordable  
non-digestible carbohydrates (NDC) that have been used for this purpose include 
galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS) and pectin oligomers 
(POS) (189). 
 
1.13 Optimisation of infant formulas with pre- and probiotics  
 
Galacto-oligosaccharides (GOS): are produced by microbial glycosyl hydrolases by 
the transglycosylation of lactose and are comprised of galactosyl residues ranging 
from 2 to 10 units, and a terminal glucose linked by β-glycosidic bonds, whose type 
is determined by the source of enzyme (190). The β-glycosidic linkages are resistant 
to the action of gastrointestinal enzymes, which allows GOS to reach the colon and 
undergo degradation by bacteria (191). 
Positive effects of adding GOS to the formula on the numbers of bifidobacteria and 
lactobacilli have been shown previously. Ben et al. (192) and Fanaro et al. (193) 
have reported that feeding formula supplemented with GOS to infants increases 
the numbers of Bifidobacterium spp. after 3 months, compared to infants fed 
unsupplemented formula. Using an in vitro model of the proximal colon,  
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Maathuis et al. (194) showed that representatives of genera Bifidobacterium and 
Lactobacillus, namely B. longum, B. bifidum, B. catenulatum, Lactobacillus gasseri, 
and Lactobacillus salivarius directly degraded GOS. Other bacteria, including 
members of Bacteroidetes and Firmicutes could also ferment these carbohydrates, 
but to a lesser degree (194). In another study, Watson et al. (195) have 
demonstrated that particular strains of bifidobacteria and lactobacilli can 
selectively metabolise GOS in vitro. Sierra et al. (196) conducted a clinical trial, 
whose results have indicated a significant increase in the proportion of acetic acid 
and the decrease in butyric acid in infants fed with formula supplemented with 
GOS. This pattern is similar to that described in breast-fed infants and can be 
correlated with higher abundance of Bifidobacterium. Further, the same study has 
shown that a significantly higher proportion of infants fed the GOS-containing 
formula were colonised with B. adolescentis at 4 months of age (196). 
Fructans: are polymers, whose structure consists of a linear chain of fructose units 
with a terminal glucose. The chains are linked by β-glycosidic bonds, which make 
these carbohydrates resistant to digestive enzymes (190). Chains vary in length 
between specific fructans and can contain up to 200 residues. Fructans are 
heterogeneous and have been organised into subclasses based on the length of 
chain; short-chain fructo-oligosaccharides (scFOS) with 3 to 5 residues per chain, 
fructo-oligosaccharides (FOS) containing 6 to 10 residues, and structurally similar 
inulin and levan with a DP ranging from below 10 to 200 residues (190). Short-chain 
FOS and FOS are produced by transfructosylation of sucrose from sugar beet. They 
can also be directly extracted from such plants as onions, garlic, wheat and 
bananas. Additionally, fructans can be commercially produced by enzymatic 
digestion of long-chain inulin (190).   
Bifidobacteria and lactobacilli have been shown to selectively metabolise scFOS and 
fructo-oligosaccharides in vitro. Marx et al. (197) have demonstrated that particular 
strains of B. adolescentis, B. longum, B. breve and B. pseudocatenulatum are 
capable of metabolising FOS. Interestingly, B. adolescentis demonstrated the best 
growth, the highest degree of acidification and was the only strain capable of 
degrading both short- and long-chain FOS. Growth of other strains either slowed or 
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stopped once short-chain fructans were consumed. Rossi and co-workers (198) 
screened a significant number of human- and animal-associated Bifidobacterium 
strains for growth on FOS (n=55), and concluded that while all strains fermented 
fructo-oligosaccharides, most of them could not degrade inulin. In line with 
previous studies, tested Bifidobacterium strains showed preference for scFOS as a 
substrate. Similarly, Kaplan and Hutkins (199) have assessed the ability of different 
strains of lactobacilli to ferment scFOS, and found that the majority of tested strains 
were able to ferment scFOS to SCFAs.  
Studies looking at the effects of fructan supplementation on the composition of the 
gut microbiota in both infants and adults have associated fermentation of FOS, or 
mixtures of FOS and GOS, with increased numbers of beneficial bacteria, namely 
genera Bifidobacterium and Lactobacillus, and a decrease in abundance of 
potentially pathogenic bacteria, such as Clostridium perfringens and E. coli (200-
203). These results have been explained by the increased production of SCFAs as a 
result of fructan degradation. SCFAs lower pH in the gut, which in turn inhibits the 
growth of a number of pH-sensitive pathogens, members of Enterobacteriaceae 
and Clostridia (204, 205). Furthermore, Paineau et al.(206) found that infants who 
were fed formula containing scFOS had increased abundance of bifidobacteria at 2 
and 3 months of age compared to the placebo group. 
Pectins: are structurally complex polysaccharides with backbone mainly composed 
of galacturonic acid linked by α−1,4 glycosidic bonds. The backbone, as well as side 
chains, can incorporate other monosaccharides, including arabinose, rhamnose and 
galactose (207). It has been estimated that over 67 transferases are involved in the 
biosynthesis of pectins, due to the complexity of these carbohydrates. Pectins are 
classified according to the degree of methyl esterification, which affects the plant 
cell wall structure and properties (207).  
Di et al. (208) evaluated the potential prebiotic effects of five pectic 
oligosaccharides (POS) produced by enzymatic treatment and acid hydrolysis of 
citrus peel. The results indicated that POS had bifidogenic effect in in vitro batch 
fermentation experiment, resulting in the increase in the numbers of 
Bifidobacterium over time. The authors indicated that the prebiotic activity of POS 
 
 44 
was structure-dependent and linked to arabinose-rich oligosaccharides. Several 
species of Bacteroides, as well as the Firmicutes Eubacterium eligens and 
Faecalibacterium prausnitzii have also been shown to degrade pectins (209, 210). 
Recently, it has been suggested that prebiotic formulations containing pectin-
derived acidic oligosaccharides have the ability to mimic the effects of the acidic 
fraction of HMOs and may have similar effects to those of HMOs in terms of 
immune modulation and the development of immune responses in infants (190). 
Stam et al. (211) have demonstrated that a formulation comprised of GOS, long-
chain FOS, and acidic pectic oligosaccharides had no adverse effects on vaccine 
specific antibody levels in healthy term infants. Furthermore, authors postulated 
that this formulation could promote Th1- and Treg-dependent immune responses 
and induce a downregulation of IgE allergic responses. The results from animal 
studies were in line with these observations and demonstrated that a mixture of 
GOS, FOS and arabino-oligosaccharides gave an optimal Th1-dependent delayed-
type hypersensitivity (DTH) response and reduced Th2 cytokine production in young 
adult mice, compared to a GOS/FOS-containing formulation (212). Another study 
suggested that the same combination of oligosaccharides decreased symptoms of 
allergic asthma in mice (213). Some pectins have been suggested to exert undesired 
effects in in vitro models (190). The work of Bosscher et al. (214) indicated that the 
supplementation of infant formulas with either esterified pectin or locust bean gum 
resulted in decreased availability of calcium, iron, and zinc compared to standard 
infant formula and human milk. These results may suggest a decreased 
bioavailability of these nutrients in vivo. 
Human Milk Oligosaccharides (HMOs): Although supplementation of infant 
formulas with NDC has been a cost-effective method to provide health benefits 
associated with complex carbohydrates to infants not consuming maternal breast-
milk, prebiotic plant-derived oligosaccharides cannot substitute all the beneficial 
functions of HMOs (191). Globally, much effort has been directed towards 
production of HMOs on a commercial scale. Chemical synthesis is one approach 
that could deliver well-defined carbohydrate structures, however reliable methods 
for large-scale production are not available (191). Instead, enzymatic and 
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chemoenzymatic HMO synthesis methods have been researched. A number of 
studies successfully accomplished production of HMOs in vitro using bacterial 
transferases (215, 216). The use of engineered bacteria for HMO production has 
been approved by the U.S. Food and Drug Administration (FDA) and led to the 
commercialisation of large-scale production of one of the major HMOs, 2’-FL (191). 
A number of expression systems have been designed and made available in E. coli 
and Saccharomyces cerevisiae (217-219). In addition, bacterial glycosyl hydrolases, 
widely used to produce GOS on an industrial scale, have been researched as an 
alternative for the production of HMOs (220, 221). The transglycosylation activity of 
these enzyme can be exploited to attach carbohydrate moieties to existing sugars, 
resulting in the formation of fucosylated or sialylated glycans mimicking HMOs 
(222). This approach could potentially be employed to manufacture rare complex 
polysaccharides that are currently commercially unavailable (191). 
Several companies have implemented these innovative methods to produce 
synthetic HMOs to date. In 2016, Glycom A/S (DK) received authorisation from the 
European Commission to introduce two of their products obtained through 
fermentation by engineered bacteria, 2’-O-fucosyllactose and lacto-N-neotetraose 
(LNnT), as new food ingredients on the European market (223, 224). This was 
followed in 2017 by an authorisation for sialic acid manufactured by enzymatic 
synthesis to be used in infant nutrition, follow-on formulas, and baby foods (225). 
Similarly, Jennewein Biotechnology GmbH (DE) and FrieslandCampina (NL) received 
the Novel Food authorization for 2’-FL (226). This technology has already been 
implemented in infant formulas. Abbot was the first company to launch a product 
(Similac Pro-Advance) containing one of these HMOs, 2’-FL, in the US in 2016. 
Nestlé followed with Nan Optipro Supreme containing both 2’-FL and LNnT, which 
was launched in Spain, formulas containing 2’-FL introduced in Asia under the 
Illuma brand, and SMA Nutrition products containing 2-FL and LNnT available in the 
UK and Ireland. 
Probiotics: have been defined by the World Health Organisation (WHO) and the 
Food and Agricultural Organisation of the United Nations (FAO) as “live 
microorganisms (bacteria or yeasts), which when ingested or locally applied in 
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sufficient numbers confer one or more specified demonstrated health benefits for 
the host” (227). Following recent scientific and clinical developments, the 
International Scientific Association for Probiotics and Prebiotics (ISAPP) have 
reviewed and updated this definition, with a minor grammatical correction, to “live 
microorganisms that, when administered in adequate amounts, confer a health 
benefit on the host” (228). The consensus statement published in 2014 has 
proposed a set of benchmark standards for the differentiation of probiotic products 
and clarified the proper scope and appropriate use of the term probiotic (228). 
Probiotic bacteria typically belong to the genera Lactobacillus and Bifidobacterium 
(229, 230). Health benefits associated with these organisms resulted in their 
widespread use as ingredients in functional foods, including a broad range of dairy 
and non-dairy products (231, 232). 
Probiotic supplementation of infant formulas has been explored as a method to 
replicate the health benefits associated with breastfeeding (and the transfer of 
breast milk microbial communities) and to establish an intestinal microbiota similar 
to that of breast-fed infants in those infants that are not consuming mother’s milk 
(169, 233). In their position paper, the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) has recommended that 
infant formulas with added probiotics should not be marketed unless their health 
benefits and safety have been fully documented (234). Production of infant 
formulas falls under strict regulations globally, and the probiotics aimed to be used 
as supplements in infant foods are subject to a range of regulatory requirements 
(169). In Europe, the European Food Safety Authority (EFSA) has introduced a 
premarket system for safety assessment of microorganisms used in food and feed 
(235), while in the U.S., the FDA has implemented Evidence-Based Review System 
for the Scientific Evaluation of Health Claims to provide guidelines for producers 
(236).  
Since beneficial effects of probiotics are strain specific, manufacturers are obliged 
to scientifically prove probiotic properties and cell viability when making a health 
claim related to a specific product (169, 233, 234, 237). According to Kent and 
Doherty (169), four probiotic strains whose functions have been documented in 
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numerous scientific studies, namely Bifidobacterium animalis subsp. lactis (B. lactis) 
BB-12, Lactobacillus rhamnosus GG, Lactobacillus acidophilus NCFM (along with  
BB-12) and Lactobacillus reuteri DSM 17938, are routinely used by large formula 
producers, such as Nestle and Heinz. Furthermore, dried probiotic formulations 
containing cocktails of lactobacilli and bifidobacteria that can be added to breast-
milk, human milk fortifiers and formulas have been made commercially available in 
recent years, however their health claims often prove difficult to validate due to the 
lack of strain designations and scientific evidence for health benefits (169, 238). 
Concerns regarding the safety of administering probiotics to infants have been 
raised in terms of their immunogenic effects and their impact on infant growth, as 
well as potential bacterial infection due to the underdeveloped immune system 
(169, 239). The widespread use of probiotic formulations in infants requires careful 
and comprehensive surveillance to monitor for unintended consequences. Van den 
Nieuwboer at al. (240) conducted a systematic analysis of 57 clinical trials and eight 
follow-up studies, and concluded that the use of probiotics in infants between zero 
and two years of age is safe with regard to the evaluated strains in infants with a 
particular health status or susceptibility. However, long-term effects of probiotic 
administration to infants have rarely been measured. In addition, questions remain 
about the ability to identify infants at risk at the time of birth (239). 
 
1.14 Life after milk: the influence of additional complex dietary 
components on the early life gut microbiota during the crucial 
weaning window   
 
The composition of complementary foods plays a major role in the transition from 
simple to adult-like microbiota during weaning, providing essential nutrients to the 
infant and the developing intestinal microbial communities while stimulating the 
immune development (241). Starchy foods constitute a common group of 
complementary foods due to their texture and palatability (241). Plant-derived 
complex carbohydrates in complementary foods have been proposed to exert 
beneficial health effects on infants through their bifidogenic and prebiotic 
properties and the resulting modulation the intestinal microbiota and metabolic 
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end products (55, 242). Examples of such non-digestible carbohydrates with 
prebiotic effects include poly- and oligosaccharides composed of fructose and a 
terminal glucose (e.g. inulin-type fructans (ITF)), or arabinose and xylose  
(e.g. arabinoxylans (AX) or arabinoxylo-oligosaccharides (AXOS)) (243, 244). 
Inulin: is widely distributed in nature and can be found in fruit and plants such as 
chicory roots, onions, bananas and leeks (243). Structurally, inulin is composed of a 
backbone of fructose monomers linked by b-2,1 bonds with a DP between 2 and 65, 
often linked to a terminal glucose monomer by an α-1,2 bond. Oligofructose is a 
subgroup of inulin and consists of polymers with a DP below 10 (245).  
b-fructofuranosidases, which cleave terminal fructose residues from the non-
reducing ends of the fructose polymers, have been shown to act on inulin (246). 
Several of these enzymes have been characterised in several species of 
Bifidobacterium, including B. infantis (247), B. lactis (248) and B. adolescentis (249). 
The ability of Bifidobacterium to degrade inulin are species- and strain-specific. 
Falony et al. (250) identified four different clusters of strains representing ten 
different Bifidobacterium species based on their inulin degradation capabilities. 
Cluster A could only metabolise fructose, while cluster B was able to degrade both 
fructose and oligofructose after importing the latter inside the cell. Clusters C and D 
were found to degrade both inulin and oligofructose extracellularly, followed by the 
release of fructose into the medium. Selak et al. (251) examined the ITF 
fermentation capabilities of 190 strains of Bifidobacterium, representing five 
species and originating from different regions of the intestine, and discovered that 
the degradation properties of different strains were not correlated to the region in 
the intestine. Interestingly, strains with different ITF metabolism capabilities were 
found coexisting in the same intestinal region, which suggested bacterial 
cooperation in the degradation of ITF, and a potential for cross-feeding interactions 
between strains or at the species level (251). Several previous reports indicated 
cross-feeding activities between bifidobacteria and butyrate producing bacteria 
grown simultaneously on ITF, where the consumption of ITF by bifidobacteria 
resulted in production of acetate, which was in turn used as a co-substrate to 
produce butyrate by colonic butyrate producers Roseburia intestinalis DSM 14610 
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(252), Roseburia inulinivorans DSM 16841T (253), and Faecalibacterium 
prausnitzii DSM 17677T (254). Proposed effects of the consumption of ITF on 
human health include increased absorption of calcium and magnesium in the colon, 
increased secretion of satiety hormones, increased stool frequency and a decrease 
in proteolytic fermentation in distant colon (255). 
Arabinoxylan (AX) and arabinoxylo-oligosaccharides (AXOS): have also received 
scientific attention in recent years due to their prebiotic and bifidogenic properties. 
Arabinoxylan (AX) is a hemicellulose consisting of a linear backbone of β-1,4 xylose 
residues with arabinose substitution, found in all major cereal grains, with the 
highest content found in rye followed by wheat, barley, oats, rice, and sorghum 
(256). The cleavage of the internal β-xylosidic linkages of AX by endo-1,4-b-
xylanases to xylo-oligosaccharides results in production of arabinose-substituted 
xylo-oligosaccharides (AXOS) (257). Complete degradation of complex structures of 
AX and AXOS requires a cooperation of a number of enzymes with debranching and 
depolymerising actions, including afore-mentioned endo-β-xylanases, as well as  
β-xylosidases, exo-oligoxylanases and α-arabinofuranosidases (55). 
Bioinformatic analyses have identified genes encoding enzymes involved in the 
cleavage of the AX and AXOS backbones in genomic sequences of several 
bifidobacterial strains, some of which have been expressed and characterised (258). 
Examples include α-arabinofuranosidases in B. adolescentis ATCC 15703T,  
B. adolescentis DSM 20083, B. longum B667, and B. longum NCC2705; β-xylosidases 
in B. adolescentis ATCC 15703T and B. lactis BB-12; and exo-oligoxylanases in  
B. adolescentis LMG 10502 (259-261). According to Riviere et al. (55) no endo-β-
xylanases have been characterised in Bifidobacterium, so it is likely that members of 
this genus have to cooperate with other bacterial species, for example Roseburia or 
Bacteroides, to achieve complete degradation of AX and AXOS.  
The bifidogenic properties of AX and AXOS have been reported in a number of 
studies. Hughes et al. (262) demonstrated in vitro that fermentation of wheat-
derived AX resulted in proliferation of members of the genera Bifidobacterium, 
Lactobacillus and Eubacterium. Following a clinical study, Chung et al. found that in 
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addition to an increase in Bifidobacterium during AXOS supplementation, the 
proportional abundance of Prevotella species increased significantly when these 
organisms were present in the baseline microbiota (263). In an in vivo study with 
rats, Van Craeyveld et al. (264) showed that the bifidogenic effect was only caused 
by AXOS with low average DPs ≤ 5 and A/X ≤ 0.27, while another study reported a 
60-fold increase in Bifidobacterium in the cecum of rats fed long-chain AX with 
average DP = 60 and A/X of 0.70 (265.). The findings from the latter study were 
further validated by another study which reported the presence of two different B. 
longum species during the fermentation of long-chain AX in an in vitro model of the 
proximal colon (266). Riviere et al. (267) demonstrated that the ability of 
Bifidobacterium to metabolise AX and AXOS is strain-dependent. The authors 
identified five bacterial clusters capable of differential degradation of AXOS. Cluster 
I contained fifteen strains, representatives of 7 different bifidobacterial species (B. 
adolescentis, Bifidobacterium angulatum, B. bifidum, B. breve, Bifidobacterium 
dentium, B. longum, and Bifidobacterium thermophilum), which were not able to 
metabolise neither arabinose substitutions nor the xylan backbone of AXOS, 
although some strains could utilise arabinose and xylose. Members of the identified 
Cluster II, eight B. longum strains, could not utilise the xylan backbone of AXOS, but 
were able to degrade the arabinose substitutions. Cluster III was comprised of ten 
strains spanning six bifidobacterial species (B. adolescentis, B. angulatum, B. 
longum, B. animalis, Bifidobacterium gallicum, and B. pseudolongum), which were 
capable of utilising the xylan backbone of AXOS up to xylotetraose but could not 
metabolise the arabinose substitutions or showed limited capabilities to do so. 
Cluster IV contained only two strains of B. longum, which shared the ability to 
degrade AXOS, while Cluster V was comprised of a single strain of B. catenulatum 
LMG 11043, which could use all XOS fractions in a non-preferential way and 
displayed broad degradation capabilities for arabinose substitutions (267). 
Being slowly-fermentable carbohydrates, AX and AXOS have been associated with a 
number of health benefits. These polysaccharides have been suggested to affect 
the production of toxic metabolites by protein- and lipid-fermenting microbes in 
the distal colon through stimulation of saccharolytic bacterial species, such as 
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Bifidobacterium, which results in increased production of SCFAs leading to the 
lowering of the luminal pH (264, 268, 269). In obese mice, AXOS consumption and 
the resulting increase in Bifidobacterium has been proposed to help restore gut 
barrier functions and cure endotoxemia (270). Furthermore, consumption of AX 
and AXOS has been linked to increased colonic absorption of dietary minerals, 
increased antioxidant capacity, reduced post-prandial glycaemic response and 
reduced blood cholesterol (244, 271-273).  
Resistant starches (RS): are homo-polysaccharides of glucose that escape the 
digestion in the upper gastrointestinal track (274). They have been categorised into 
four main types. RS1 is physically indigestible, for example starches in whole grains. 
RS2 is a granular starch that is present in such foods as green bananas, uncooked 
potato or high amylose maize. RS3 are retrograded starches produced by cooking 
and cooling processes, whereas RS4 are starches that have been chemically 
modified by esterification, crosslinking, or transglycosylation and are not found in 
nature (274, 275). 
Modulatory effects of resistant starches on the host gut microbiota have previously 
been reported by a number of in vivo studies. Tachon et al. (276) demonstrated 
that mice fed diets containing RS2 type starch from high-amylose maize were 
colonized by higher numbers of Bacteroidetes and species of Bifidobacterium, 
Akkermansia, and Allobaculum in proportions dependent on the starch 
concentration. For example, mice fed 18% resistant starch were mostly colonized 
by close relatives of B. pseudolongum subsp. pseudolongum and globosum, 
whereas those fed 36% RS were enriched with Bifidobacterium most closely related 
to B. animalis. Additionally, the levels of Bifidobacterium and Akkermansia were 
associated with expression levels of proglucagon, the precursor of the gut anti-
obesity/diabetic hormone GLP-1, mice feeding responses and the weight of the gut 
(276). The prebiotic effects of resistant starches were also demonstrated in adult 
humans. Martinez et al. (277) reported varying effects of starch types on the 
composition of the human faecal microbiota. Type RS4 was associated with changes 
at the phylum level, significantly increasing Actinobacteria and Bacteroidetes while 
decreasing Firmicutes. In addition, at the species level, consumption of RS4 was 
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correlated with an increase in B. adolescentis and Parabacteroides distasonis, while 
RS2 and RS3 significantly raised the numbers of Ruminococcus bromii and 
Eubacterium rectale (277, 278).  
Abilities of Bifidobacterium to ferment starch and starch derivatives were tested in 
vitro by Duranti et al. (279) using representatives of 47 known bifidobacterial taxa. 
The results indicated that B. adolescentis, B. angulatum, B. boum, B. breve,  
B. cuniculi, B. dentium, B. longum, B. infantis, Bifidobacterium merycicum, 
Bifidobacterium minimum, Bifidobacterium reuteri, B. pseudocatenulatum, 
Bifidobacterium ruminantium, and B. thermophilum grew substantially (OD > 0.5) 
on RS2 resistant starch as sole carbon source. The study identified two strains 
which exhibited very good growth among representatives of human-associated  
B. adolescentis, out of which B. adolescentis 22L, isolated from human milk, could 
grow on starch and all starch derivatives (maltodextrin, maltotriose, pullulan, and 
glycogen). Genomic and transcriptomic analyses of B. adolescentis 22L revealed the 
presence of a number of glycosyl hydrolases putatively implicated in degradation of 
starch, as well as starch-derived glycans (279). They included four proteins with 
predicted α-amylase activity, a glycogen/starch phosphorylase, putative 
phosphoglucomutase and 4-α-glucanotransferase, as well as two genes predicted 
to encode amylopullulanases, similar to the extracellular starch-degrading enzyme 
previously characterised in B. breve UCC2003 (280). In addition, genomic analyses 
identified two genes predicted to encode α-1,4- and α-1,6-glucosidases, an ABC-
type system, and a gene encoding a LacI-type regulator flanking the gene encoding 
an amylopullulanase, whose products may also be involved in starch utilization 
using mechanisms similar to those described for B. breve UCC2003 (279, 280). More 
recently, Jung et al. (281) have also identified genes encoding enzymes implicated 
in direct or indirect degradation of RS and its derivatives in another Bifidobacterium 
strain, Bifidobacterium choerinum FMB-1 isolated from rumen fluids of cattle. The 
putative enzymes included α-amylase, maltosyltransferase, pullulanase type I, 
glycogen phosphorylase, glycogen debranching enzyme, 4-α-glucanotransferase, 
and glucan branching enzyme. Interestingly, the above-mentioned study by Duranti 
et al. (279) did not identify the representative type strain of B. choerinum LMG 
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10510T as one that could utilise starch, which could further suggest that RS 
utilisation in Bifidobacterium is strain-dependent. 
Maintenance of healthy blood glucose levels has been widely proposed as an 
important health benefit of starch fermentation by a number of studies (282) (283, 
284). Bacterial fermentation of RS and associated changes in the gut microbiota 
composition have also been associated with the increase in the production of 
SCFAs, and a reduction in secondary bile acids, phenol and ammonia (277, 285). 
Although the above refers to human hosts, these dietary components are also 
present in the diets of different animal hosts and will be described in more detail in 
Chapters 4 and 5. 
 
1.15 Bifidobacterium as members of the animal gut microbiota  
 
In recent years, the use of next-generation sequencing has significantly facilitated 
the investigations of the bifidobacterial diversity and contributed to the discovery 
of novel Bifidobacterium species. The majority of described Bifidobacterium type 
strains have been isolated from animal hosts, however sufficient genomic 
information for the non-human-associated taxa is lacking (31, 286, 287). Human-
derived strains, in particular those associated with infancy and belonging to  
B. longum, B. bifidum, B. breve and B. pseudocatenulatum species, have received 
much attention in recent years due to their potential probiotic properties, leading 
to considerable isolation and characterisation efforts (152, 159, 162, 288-291). As a 
result, data on human-associated bifidobacteria are currently overrepresented in 
databases. For example, out of a total of around 2,100 Bifidobacterium genomes 
deposited at the NCBI Genome database (July 2020) (5), more than 400 sequences 
are available for B. longum, more than 100 for both B. breve and B. bifidum, and 
more than 90 for B. pseudocatenulatum. 
With regard to animal-associated Bifidobacterium, only two species, namely B. 
animalis (both subsp. animalis and subsp. lactis) and B. pseudolongum (both subsp. 
pseudolongum and subsp. globosum), have been more widely studied to date (292, 
293). The isolation and sequencing efforts resulted in the availability of 
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considerable amount of data on these species, with more than 90 sequences 
available for B. animalis and more than 70 genomes available for B. pseudolongum 
(NCBI Genome, July 2020). Recent genomic investigations into these data 
confirmed that both B. animalis and B. pseudolongum are widely distributed among 
animal hosts belonging to different animal classes, e.g. mammals and birds, and 
thus appear to be generalist in terms of host-specificity (292, 293). In addition, 
experimental approaches indicated subspecies-specific differences in carbohydrate 
metabolism capabilities within B. animalis and B. pseudolongum species and 
suggested that these differences may result from evolutionary adaptations of 
members of particular subspecies to their respective environmental niches. For 
example, strains of B. animalis subsp. animalis, isolated primarily from rodents, 
were shown to metabolise a broad range of carbohydrates, including arabinose, 
galactose, glucose, maltose, melibiose, sucrose, and xylose, whereas those 
identified as B. animalis subsp. lactis, recovered mainly from humans and primates, 
seemed to be more specialised in the fermentation of lactose, maltose, raffinose, 
and sucrose. Similarly, strains of B. pseudolongum subsp. globosum isolated from 
ruminants displayed higher growth performances on carbohydrates such as 
cellobiose, rhamnose, starch and trehalose, with limited growth on glucose and 
lactose. The latter sugars are metabolised in the rumen and are scarce in the 
ruminant large intestine. In contrast, B. pseudolongum subsp. pseudolongum 
strains isolated from pigs were shown to grow significantly better on such 
carbohydrates as glucose, glycogen, lactose, maltodextrin, maltose and melibiose 
(292, 293).   
Widespread Bifidobacterium distribution across mammals have also been 
suggested for species other than B. animalis and B. pseudolongum, based on the ITS 
profiling of the 45 type strains of the genus Bifidobacterium across 291 faecal 
samples collected from 67 host species spanning 10 mammalian taxonomic orders 
(294). Sequences corresponding to B. longum and B. adolescentis were shown to be 
ubiquitously distributed in the profiled mammalian species, with a prevalence of 
95.5% and 91%, respectively, followed by B. pseudolongum and B. bifidum with a 
prevalence of 85%. In addition, sequences corresponding to species traditionally 
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associated with particular groups of hosts, for example Bifidobacterium 
actinocoloniiforme, Bifidobacterium asteroides or Bifidobacterium indicum 
associated with insects, were shown to be present among mammals belonging to 
different taxonomic groups. In contrast, sequences corresponding to the type 
strains of more recently characterised Bifidobacterium species isolated from non-
human primates, namely Bifidobacterium aesculapii and Bifidobacterium tissieri, 
were associated with hosts belonging to the order Primates. Moreover, this analysis 
revealed the presence of 89 sequences with an identity level of <93% to the 45 
analysed bifidobacterial species in the faecal samples of mammals, suggesting that 
a considerable number of putative novel Bifidobacterium species and subspecies 
remain to be discovered (294).  
Indeed, the number of recognised Bifidobacterium species has significantly 
increased in recent years, from 47 in October 2016 (start of my PhD) to 87 in July 
2020, with the majority of newly characterised species recovered from non-human 
primates. A recent analysis of the distribution of recognised primate-associated 
Bifidobacterium in faecal samples collected from 57 human and non-human 
primates revealed a further potential for the discovery of novel species in this 
group of animals based on the 16S rRNA profiling, with the average relative 
abundance of putative new species in human and monkey faecal samples estimated 
at 6% and 28%, respectively (295). The members of the primate family Cebidae 
have been predicted to harbour the highest number of predicted novel 
Bifidobacterium species, with an average percentage of putative novel taxa 
estimated at 46%. In addition, the analysis of co-phylogenetic relationships 
between 24 primates and 23 bifidobacterial species suggested the existence of 
strong co-phylogenetic patterns between human-associated Bifidobacterium (B. 
adolescentis, B. bifidum, B. breve, B. catenulatum, B. dentium, B. longum spp. and B. 
pseudocatenulatum) and the members of Hominidae family (Gorilla gorilla, Homo 
sapiens and Pan troglodytes). Furthermore, B. adolescentis, B. biavatii and B. 
ramosum were indicated as the taxa most commonly shared among primates (295). 
Despite an increase in the availability of genomic data, robust studies focusing on 
the diversity and the functional properties of members of Bifidobacterium in animal 
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hosts remain lacking, with the pan-genome and the phylogenetic relationship of the 
genus unresolved. The majority of previous studies investigating the diversity of 
Bifidobacterium have either focused on a subset of human-associated isolates or 
examined single type strains as representatives of species, and in consequence 
included a limited number of the isolates from different habitats (27, 38, 93, 159, 
162, 286, 289). The sampling among host animals is quite uneven, and 
Bifidobacterium species isolated from certain host groups are significantly 
underrepresented in the databases (e.g. those from insects and reptiles). Further 
isolation efforts and genomic investigations into the diversity of Bifidobacterium are 
crucial for the comprehensive understanding of the distribution of members of this 
genus across the animal kingdom, the mechanisms behind their beneficial 




1.16.1 Overarching hypothesis 
 
Bacteria belonging to the genus Bifidobacterium are important members of the gut 
microbiota of humans and animals, with specific strains displaying beneficial 
properties associated with their capabilities to ferment complex carbohydrates.  
 
1.16.2 Study specific hypotheses 
 
Chapter 3: Whole genome sequences of Bifidobacterium longum display particular 
genomic features related to carbohydrate metabolism. These features may play a 
role in the establishment and persistence of members of this species in individual 
hosts during infancy despite dietary changes associated with transition from breast 




Chapter 4: Whole genome sequences of Bifidobacterium isolated from small 
mammals display particular genomic features related to carbohydrate metabolism, 
host modulation and defence mechanisms. 
 
Chapter 5: The diversity of Bifidobacterium in animal hosts is not fully explored. 
Experimental and computational methods (bacterial isolation and genomic analysis, 
respectively) contribute to the discovery of true diversity within the genus. Whole 
genome sequences of animal-associated isolates display particular traits related to 
their isolation source and functional capabilities, e.g. degradation of carbohydrates.  
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Chapter 2  
 
Materials and methods 
 
2.1 Materials  
 
2.1.1 Equipment and reagents  
Primary reagents, kits, equipment and tools used or mentioned in this chapter are 
listed below: 
 




Table 2.2 Primary materials and kits used in experiments 
 
 
2.1.2 Faecal samples, bacterial isolates and isolate DNA extracts  
Samples (faecal samples, bacterial isolates and DNA) were obtained through 
collaboration with the following organisations:  
 
Table 2.3 Sample sources for particular projects 
Equipment Model Supplier
Anaerobic chamber Ruskinn Concept Plus Baker Ruskinn, Bridgend, UK
Autoclave (portable) Classic 2100 Standard (9-litre) Prestige Medical, Blackburn, UK
Centrifuge Eppendorf 5810R Eppendorf, Stevenage, UK 
Homogeniser for DNA extraction samples FastPrep-24 MP Biomedicals, Santa Ana, USA
Microcentrifuge Prism Labnet, New Jersey, USA
Microplate reader Tecan infinite F50 Tecan, Männedorf, Switzerland 
PCR station UV HEPA PCR Systems UVP, Upland, USA
PCR thermal cycler Applied Biosystems Veriti 96- well thermal cycler Thermo Fisher Scientific, Loughborough, UK
pH meter Martini MI 151 Rocky Mount, USA
Qubit meter Qubit 2.0 Thermo Fisher Scientific, Loughborough, UK
Safety cabinet Walker Class II MSC Walker Safety Cabinets, Glossop, UK 
Shaking Incubator Stuart Cole-Palmer, Illinois, USA
Item Supplier
Agar Oxoid (Thermo Fisher Scientific), Loughborough, UK 
Brain Heart Infusion (BHI) Oxoid (Thermo Fisher Scientific), Loughborough, UK 
DNA lo-bind tubes (1.5 and 2.0ml) Eppendorf, Stevenage, UK 
FastDNASPIN kit for Soil MP Biomedicals, Santa Ana, USA 
Inoculation sterile loop (disposable) Microspec, Wirral, UK
KAPA 2G Robust PCR kit KAPA Biosystems, Wilmington, USA 
Qubit dsDNA BR assay Invitrogen (Thermo Fisher Scientific), Loughborough, UK 
Reinforced Clostridial Medium (RCM) Oxoid (Thermo Fisher Scientific), Loughborough, UK 
Spreader (disposable) Microspec, Wirral, UK
BD Difco™ Lactobacilli MRS Broth BD Biosciences, New Jersey, USA
Sodium iododacetate Oxoid (Thermo Fisher Scientific), Loughborough, UK 
Mupirocin PanReac AppliChem (VWR), Pennsylvania, USA  
Cysteine HCl Sigma-Aldrich, Dorset, UK 
Collaborator Organisation Sample cohort Sample type Location
Breast- and formula-fed infants DNA from bacterial isolates
Breast- and formula-fed infants Bacterial isolates
Dr Sarah Knowles University of Oxford Wild small mammals Faecal samples Oxford, UK
Dr Laima Baltrūnaitė Nature Research Centre Wild small mammals Faecal samples Vilnius, Lithuania
Sara Goatcher Banham Zoo and Africa alive Captive animals Faecal samples Suffolk, UK
Dr Anne McCartney University of Reading Reading, UK
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 Faecal sample collection for breast- and formula-fed infant study  
(B. longum) (Chapter 3) 
 
Faecal sample collection was performed by Dr Anne McCartney. Infants were 
recruited between 2005 and 2007: five were exclusively breast-fed and four were 
exclusively formula-fed. Faecal samples were obtained from infants at specific 
intervals during the first 18 months of life. For inclusion in the study, infants had to 
meet the following criteria: have been born at full-term (>37 weeks gestation); be 
of normal birth weight (>2.5 kg); be <5 weeks old and generally healthy; and be 
exclusively breast-fed or exclusively formula-fed [SMA Gold or SMA White (Wyeth 
Pharmaceuticals), to avoid supplemented formulae and to keep consistency within 
the formula group]. The mothers of the breast-fed infants had not consumed any 
antibiotics within the 3 months prior to the study and had not taken any prebiotics 
and/or probiotics. Ethical approval was obtained from the University of Reading 
Ethics Committee (296). For details, refer to paper by Rogers and McCartney from 
2010 (296). All faecal samples were processed by members of Dr Anne McCartney’s 
research team; for the purpose of this project I was provided with bacterial isolates 
and DNA samples from the isolates.  
 
 Faecal sample collection for wild mammal study (Chapter 4) 
 
Rodent trapping and faecal sample collection were performed by Dr Sarah Knowles, 
Miss Aura Raulo and Dr Laima Baltrūnaitė. In the UK, live rodent trapping was 
carried out at two sites of mixed deciduous woodland approximately 50km apart: 
Wytham Woods (51° 46’N, 1°20’W) and Nash’s Copse, Silwood Park (51°24'N, 
0°38'W). All animals were live-trapped using a standard protocol across both sites, 
using small Sherman traps baited with peanuts and apple and provisioned with 
bedding, set at dusk and collected at dawn the following day. All newly captured 
individuals were marked with subcutaneous PIT-tags for permanent identification, 
and all captures were weighed and various morphometric measurements taken. 
Faecal samples were collected using sterilised tweezers from the base of Sherman 
traps into sterile tubes. Samples from Silwood were frozen within 8 hours of 
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collection at -80oC and sent frozen to the Quadram Institute (Norwich, UK) for 
Bifidobacterium culturing; samples from Wytham were posted on the day of 
sampling at room temperature to the same address for culturing. Upon reception of 
samples, they were immediately frozen at -80oC. To ensure no cross-contamination 
and identification of samples to specific individuals, any traps that showed signs of 
rodent presence (captures and trigger failures) were washed thoroughly in a bleach 
solution and autoclaved between uses.  
In Lithuania, small mammals were trapped in October 2017 and between May - 
November in 2018 using live- and snap-traps at twelve locations: Site 1: 54.92878, 
25.33333; Site 2: 55.02814, 25.27380; Site 3: 54.92866, 25.31524, Site 4: 55.05938, 
25.35643, Site 5: 54.96362, 25.35640; Site 6: 54.93026, 25.24138; Site 7: 54.99276,  
25.24909, Site 8: 55.02700, 25.35867; Site 9: 55.06756, 25.29782; Site 10: 
54.76482, 25.31283; Site 11: 54.76322, 25.35052; Site 12: 54.93650, 25.28442. 
Traps baited with bread soaked in sunflower oil (in case of live-traps, apple and 
bedding were also added) were set in the evening and retrieved in the morning. 
Small mammals trapped with snap-traps were placed in separate bags and 
transported to the lab on ice. Live-trapped animals were transported to the lab and 
humanely killed by cervical dislocation. Species, sex, age, reproduction status of 
small mammals were identified. Content of distal part of colon (~20-30 mm) was 
removed, placed in Eppendorf tube and stored at –80°C. Frozen samples were sent 
to the Quadram Institute (Norwich, UK) for Bifidobacterium culturing. 
The distance between trapping sites in both the UK and Lithuania was far enough 
for the animals not to move between them on a regular basis. All studied species 
have small home ranges – Apodemus spp. have the widest range and rarely move 
more than 0.25 km (297). 
 
 Faecal sample collection for captive animal study (Chapter 5) 
 
Samples were collected by animal-care staff at either Banham Zoo and Africa Alive! 
into sterile Sterilin specimen containers with spoon and stored under anaerobic 
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conditions using Oxoid AnaeroGen 2.5L sachets at 4 °C. Samples were transported 
to the laboratory and stored at -80 °C within 48 hours.  
2.1.3 Media and bacterial isolation 
 
 Testing of alternative agar media 
 
Depending on the amount of available faecal material, samples (~50mg or ~100mg) 
were re-suspended in either 450µl or 900µl of sterile Phosphate Buffer Saline and 
used to produce serial dilutions (neat to 10-4). The samples were vortexed for 30s 
and mixed on a shaker at 1600rpm. The dilutions were plated on media composed 
of either MRS broth, BHI (Brain Heart Infusion) broth or RCM broth with addition of 
bacteriological agar (15g/l), antibiotic mupirocin (50mg/l) and L-cysteine 
hydrochloride monohydrate (50mg/l). Furthermore, all three abovementioned agar 
plate types were prepared with the addition of sodium iodoacetate (25mg/l) to test 
whether the addition of this reagent to the media would increase their selectivity. 
Sodium iodoacetate inhibits the glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), whose activity is not an obligate requirement for 
carbohydrate metabolism in heterolactic bacteria, including Bifidobacterium (298, 
299). The plates were incubated for 48 to 72 hours at 37oC in an anaerobic cabinet, 
after which single colonies with morphology consistent with that of bifidobacteria 
were re-streaked with disposable sterile culture loops onto fresh agar plates and 
incubated. To obtain pure colonies, the re-streaking process was repeated 3 times. 
 
 Bacterial isolation – wild mammal study (Chapter 4) 
 
Faecal samples were prepared as above and plated onto BHI agar supplemented 
with mupirocin (50mg/l), L-cysteine hydrochloride monohydrate (50mg/l) and 
sodium iodoacetate (7.5mg/l) and incubated in an anaerobic cabinet for 48-72 
hours. Three colonies from each dilution were randomly selected and streaked to 
purity on BHI agar supplemented with L-cysteine hydrochloride monohydrate 




 Bacterial isolation – captive animal study (Chapter 5) 
 
Faecal samples were prepared as above and plated onto either BHI agar 
supplemented with mupirocin (50mg/l), L-cysteine hydrochloride monohydrate 
(50mg/l) and sodium iodoacetate (7.5mg/l) or MRS agar supplemented with 
mupirocin (50mg/l) and L-cysteine hydrochloride monohydrate (50mg/l). Plates 
were incubated in an anaerobic cabinet for 48-72 hours. Three colonies from each 
dilution were randomly selected and streaked to purity on either BHI agar or MRS 
agar supplemented with L-cysteine hydrochloride monohydrate (50mg/l). Pure 
cultures were stored in cryogenic tubes at -80oC. 
 
2.1.4 Bacterial cultures 
 
Pure colonies were grown in 20ml of MRS broth in sterile 50ml centrifuge tubes to 
obtain numbers of bacteria sufficient for further procedures. 
 
2.1.5 Bacterial stocks 
 
Stocks were made in cryovials using RCM with glycerol (30% V/V) and stored at -
80oC. 
 
2.2 DNA extraction 
 
2.2.1 FastDNATM SPIN kit method 
This method was employed for preliminary strain identification based on partial 16S 
rRNA gene sequences. Bacterial pellets were re-suspended in 980µl of sodium 
phosphate buffer, transferred to Lysing Martix E tube and 120µl of MT buffer was 
added to the suspension. Bacteria were then homogenised for 3min at speed 6.0, 
using FastPrep® 24 instrument, and centrifuged at 14000g for 15min. 250µl of PPS 
was added to a clean microcentrifuge tube, sample supernatant was transferred to 
this, after which the tubes were mixed by hand 10 times and centrifuged at 14000g 
for 10 min. 1ml of Binding Matrix was added to clean 15ml tubes, and sample 
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supernatant was transferred to this. The samples were inverted for 2 min and 
placed on a rack for 3 min to allow the Binding Matrix to settle. 500µl of the 
supernatant was removed and discarded, after which the Binding Matrix was re-
suspended in the remaining supernatant. 700µl of the mixture was transferred to 
SPIN filter and centrifuged at 14000g for 2min, after which catch tubes were 
emptied. This procedure was repeated until all the Binding Matrix mixture was 
used. The pellet in the SPIN filter was re-suspended in 500µl of SEWS-M, and 
centrifuged at 14000g for 5 min. Catch tubes were then emptied and samples were 
centrifuged a second time (dry spin) for 5 min at 14000g. Catch tubes were 
discarded, replaced with clean Eppendorf LoBind microcentrifuge tubes, and the 
samples were air dried for 10min at room temperature. 65µl of DES was then 
added to the samples, and the samples were incubated at room temperature for 
5min. Finally, the samples were centrifuged at 6600g for 2min to bring eluted DNA 
into Eppendorf tubes. Extracted DNA was stored at 4°C until required for PCR. 
2.2.2 Phenol-chloroform method 
 
This method was used to extract high-quality bacterial genomic DNA from strains 
identified as Bifidobacterium based on the 16S rRNA gene. Bacterial pellets were re-
suspended in 2ml of 25% sucrose in 10mM Tris and 1mM EDTA at pH 8.0. Cells 
were then treated using 50μl of 100mg/ml lysozyme. Further, 100μl of 20mg/ml 
Proteinase K, 30μl of 10mg/ml RNase A, 400μl of 0.5 M EDTA (pH 8.0) and 250μl of 
10% Sarkosyl NL30 were added into the lysed bacterial suspension. The samples 
were then incubated on ice for 2 hours, followed by 50°C overnight water bath. 
Next, samples were subject to three rounds of Phenol:Chloroform:Isoamyl Alcohol 
(25:24:1) extraction using Qiagen MaXtract High Density tubes. Further two rounds 
of extractions with Chloroform:Isoamyl Alcohol (24:1) were then performed to 
remove residual phenol, followed by ethanol precipitation and 70% ethanol wash, 
after which DNA pellets were resuspended in 300μl of 10mM Tris (pH8.0). Sample 
DNA concentration was quantified using Qubit dsDNA BR Assay Kit in Qubit 2.0 
Fluorometer according to the manufacturer’s protocol. Extracted DNA was stored in 
-20°C until further analysis.  
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Phenol-chloroform DNA extraction for the breast- and formula-fed infant study (B. 
longum) (Chapter 3) was carried out by Dr Anne McCartney. 
 
Table 2.4 Materials used in phenol-chloroform DNA extraction for whole genome sequencing. 
 
2.3 DNA Sequencing  
 
2.3.1 Sequencing of the 16S rRNA gene for preliminary bacterial identification 
 
 PCR, primers, conditions 
 
Concentration of extracted DNA was adjusted for PCR to 10-20ng/µl using 
molecular H2O. Kapa2G Robust PCR reagents and molecular H2O were used to 
prepare the PCR master mix (10mM of dNTP mix (1µl/sample), Kapa2G GC buffer 
with MgCl2 (10µl/sample), molecular H2O (31.6µl/sample), Kapa2G Robust – Taq 
polymerase (0.4µl/sample), with addition of 10 µM primers (1µl/sample; Table 2.5) 
(300).   
 
Table 2.5 Primers used for PCR amplification of 16S rDNA.  
Primer abbreviations: f - forward; r - reverse; D - distal; P - proximal. Reverse primers produce sequences 
complimentary to the rRNA. 
 
5µl of diluted bacterial DNA was mixed with 45µl of the master mix and amplified 
using Veriti™ 96 well thermal cycler as follows: polymerase activation at 94°C for 
5min, followed by 35 cycles of denaturation at 94°C for 1min, primer annealing at 
Item Components and conditions Supplier
25% sucrose in TE buffer TE buffer: 10mM Tris and 1mM EDTA pH8.0 Sigma-Aldrich, Dorset, UK 
Chloroform:IAA 24:1 Chloroform:IAA Sigma-Aldrich, Dorset, UK 
E buffer 10mM Tris pH8.0 Sigma-Aldrich, Dorset, UK 
EDTA 0.5M EDTA, pH8.0 (pH adjusted) Sigma-Aldrich, Dorset, UK 
Ethanol Absolute ethanol (>99.5%) MaXtract High Density tubes Sigma-Aldrich, Dorset, UK 
Lysozyme Lysozyme re-suspended in 0.25M Tris pH8.0 Roche, West Sussex, UK
Phase-lock gel tubes MaXtract High Density Qiagen, Manchester, UK
Phenol-Chloroform-Isoamyl alcohol (IAA) solution 25:24:1 (Phenol-Chloroform-Isoamyl Alcohol) Sigma-Aldrich, Dorset, UK 
Phosphate Buffer Saline (PBS) PBS, pH7.2 Sigma-Aldrich, Dorset, UK 
Proteinase K ~15-20mg/ml proteinase K Roche, West Sussex, UK
RNase A 10mg/ml RNase A (boiled before use) Roche, West Sussex, UK
Sarkosyl NL30 30% Sarkosyl Sigma-Aldrich, Dorset, UK 
Primers Sequence
fD1 5’- AGA GTT TGA TCC TGG CTC AG - 3’
fD2 5’- AGA GTT TGA TCA TGG CTC AG - 3’
rP1 5’- ACG GTT ACC TTG TTA CGA CTT - 3’
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43°C for 1min, strand extension at 72°C for 2min and final strand extension at 72°C 
for 7min. 
 16S rRNA gene sequencing 
 
Un-purified PCR products were prepared according to sample submission guide for 
Value Read sequencing service (Sanger sequencing, Eurofins, Luxembourg). Most 
final 16S rRNA gene product sizes ranged between 900-1000bp. 
 
 Whole genome sequencing 
 
This work was performed at the Wellcome Trust Sanger Institute (Hinxton, UK) and 
at the Quadram Institute Bioscience (Norwich, UK). 
At Hinxton, DNA libraries were prepared as detailed in Table 2.6 and Table 2.7 
below and subjected to WGS pipeline on Illumina HiSeq 2500 platform to generate 
125bp paired-end reads.  
 
Table 2.6 Library preparation for whole genome sequencing (Illumina HiSeq 2500). 
 
Table 2.7 PCR conditions for WGS libraries (Illumina HiSeq 2500). 
 
At Quadram Institute Bioscience, genomic DNA was normalised to 0.5ng/µl with EB 
(10mM Tris-HCl). 0.9µl of TD Tagment DNA Buffer (Illumina Catalogue No. 
15027866) was mixed with 0.09µl TDE1, Tagment DNA Enzyme (Illumina Catalogue 
Step Description Details
1 Quantitation of DNA Biotium Accuclear Ultra high sensitivity dsDNA Quantitative kit
2 DNA shearing Mechanical shearing using Covaris LE220 instrument 
3 Purification of sheared samples Agencourt AMPure XP SPRI beads on Agilent Bravo WS
4 Library construction (end-repair, A-tailing and ligation) ‘NEB Ultra II custom kit’ on an Agilent Bravo WS automation system 
5 PCR KapaHiFi Hot start mix and IDT 96 iPCR tag barcodes on Agilent Bravo WS automation system 
6 Post-PCR purification Agencourt AMPure XP SPRI beads on Beckman BioMek NX96 liquid handling platform 
7 Quantitation of libraries Biotium Accuclear Ultra high sensitivity dsDNA Quantitative kit
8 Pooling libraries Pool in equimolar amounts on a Beckman BioMek NX-8 liquid handling platform 
9 Normalisation Libraries normalised to 2.8nM
10 Loading to sequencer Loading on requested Illumina sequencing platform 
PCR Step Temperature Duration Cycles
Initial denaturation 95 5 min 1
Denaturation 98 30 s 5
Annealing 65 30 s
Extension 72 1 min
Final extension 72 10 min 1
 
 66 
No. 15027865) and 2.01µl PCR grade water in a master mix and 3µl added to a 
chilled 96 well plate. 2µl of normalised DNA (1ng total) was pipette mixed with the 
3µl of the tagmentation mix and heated to 55 ⁰C for 10 minutes in a PCR block. A 
PCR master mix was made up using 4µl kapa2G buffer, 0.4µl dNTPs, 0.08µl 
Polymerase and 6.52µl PCR grade water, contained in the Kap2G Robust PCR kit 
(Sigma Catalogue No. KK5005) per sample and 11µl added to each well need to be 
used in a 96-well plate. 2µl of each P7 and P5 of Nextera XT Index Kit v2 index 
primers (Illumina Catalogue No. FC-131-2001 to 2004) were added to each well. 
Finally, the 5µl of Tagmentation mix was added and mixed. The PCR was run with 
72⁰C for 3 minutes, 95⁰C for 1 minute, 14 cycles of 95⁰C for 10s, 55⁰C for 20s and 
72⁰C for 3 minutes. Following the PCR reaction, the libraries were quantified using 
the Quant-iT dsDNA Assay Kit, high sensitivity kit (Catalogue No. 10164582) and run 
on a FLUOstar Optima plate reader. Libraries were pooled following quantification 
in equal quantities. The final pool was double-SPRI size selected between 0.5 and 
0.7X bead volumes using KAPA Pure Beads (Roche Catalogue No. 07983298001). 
The final pool was quantified on a Qubit 3.0 instrument and run on a High 
Sensitivity D1000 ScreenTape (Agilent Catalogue No. 5067-5579) using the Agilent 
Tapestation 4200 to calculate the final library pool molarity. The pool was run at a 
final concentration of 10pM on an Illumina MiSeq instrument. 
 
2.4 Bioinformatics  
 
2.4.1 Computing environment and resources  
 
Norwich Bioscience Institutes (NBI) High-Performing Computing Cluster (HPC) with 
CentOS Linux operating system and MacBook Pro with MacOS High Sierra updated 
to MacOS Catalina v10.15.4 were used to run command line bioinformatic tools. On 
HPC, all software and dependencies were loaded on to the shell environment 
before usage. SLURM workload manager (301) (v16.05.8) was used to submit 




2.4.2 Preliminary 16S rRNA gene sequence analysis  
 
For primary bacterial strain identification, the 16S rRNA gene sequencing results 
were compared with NCBI 16S ribosomal RNA sequences database (Bacteria and 
Archaea) using the Nucleotide BLAST algorithm 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). Classification was assigned based on 
highest identity hits and similarity scores (≥97% threshold was used as an indicator 
that the isolate belongs to the genus Bifidobacterium).  
 
2.4.3 Genome assembly and annotation 
 
Bacterial genomes were either assembled at Wellcome Trust Sanger Institute using 
Velvet v1.2.10 (302) or in-house using SPAdes v3.11 (303). Velvet assemblies were 
submitted to screen using Kraken v1.1 (MiniKraken) (304) to check for 
contamination at 5% threshold. Genome assemblies found to be contaminated with 
>5% of other bacterial species were excluded from analyses. Contigs below 500bp 
were filtered out of the assemblies. 
The remaining sequencing reads, generated on both Illumina 2500 and MiSeq 
instruments, were screened for contamination using Kraken v1.1 (MiniKraken) at 
5% threshold and pre-processed with fastp v0.20 with default settings (305). 
SPAdes v3.11 with “careful” option was used to produce assemblies, after which 
contigs below 500bp were filtered out. All genomes were annotated with Prokka 
v1.13 (306). 
 
2.4.4 Publicly available genomes 
 
Lists of publicly available genomes downloaded from NCBI and used in this work are 
included in supplementary material associated with respective thesis chapters: 
Table S3.2, Table S4.1 and Table S5.2. Where used for comparative analysis, 




2.4.5 Average Nucleotide Identity calculation 
 
Python3 module pyANI v0.2.7 (breast- and formula-fed infant study) updated to 
v0.2.10 (wild mammal study and captive animal study) with default BLASTN+ 
settings was employed to calculate the average nucleotide identity (ANI) (307). 
Species delineation cut-off was set at 95% identity (308). Genomes displaying ANI 
value >99.9% were considered identical (309). 
2.4.6 Phylogenetic analysis of strain LH_867 - wild mammal study (Chapter 4) 
 
As experimental 16S rRNA gene amplification only yielded a partial gene sequence 
(987bp), the location of 16S rRNA genes was predicted in whole genome sequence 
of strain LH_867 as well as the genomes of type strains using barrnap v0.9 (310) 
and extracted in silico. In the case of Bifidobacterium simiarum the 16S rRNA gene 
sequence could not have been predicted, and as it is not available for download 
from public databases, this strain was excluded from the 16S rRNA gene analysis. 
The predicted 16S rRNA gene sequences of strain LH_867 and those of 69 
Bifidobacterium type strains were aligned using the SILVA Incremental Aligner (SINA 
aligner) v1.2.11 (311) and trimmed for quality using trimAl v1.4.1 (312) with -
automated1 option optimised for maximum likelihood phylogenetic analyses, 
resulting in multiple sequence alignment consisting of 1496 positions. Models of 
nucleotide sequence evolution were evaluated using jModelTest2 v2.1.0 (313) 
under corrected Akaike Information Criterion (AICc) (314) and based on the results 
an appropriate model (GTR+G) was selected for phylogeny estimation. FastTree 
v2.1.9 with 1000 bootstrap iterations was used for phylogeny reconstruction (315). 
Scardovia inopinata JCM 12537T (=DSM 10107T) was used as an outgroup. 
Additionally, sequences for rpoB, rpoC, groL, dnaJ, clpC, dnaG and xpf genes were in 
silico extracted from all annotated genomes and concatenated for the purpose of 
multilocus sequence analysis. MAFFT v7.450 (316) was used to create the multiple 
sequence alignment, which was then subjected to quality trimming and model 
selection as above. GTR+G model was selected for the phylogenetic tree 
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reconstruction using FastTree v2.1.9 with 1000 bootstrap iterations. The tree was 
rooted using Scardovia inopinata JCM 12537T (=DSM 10107T). 
Furthermore, an alignment-free composition vector approach was used to 
reconstruct whole genome-based phylogeny from protein sequences employing a 
standalone version of CVTree v5.0 (317) with k-mer length of k=6. 
2.4.7 Pangenomics, phylogenomics and comparative analyses 
 
 Breast- and formula-fed infant study (B. longum) (Chapter 3) 
 
General feature format files of B. longum strains were inputted into the Roary pan-
genome pipeline v.3.12.0 to obtain core-genome data and the multiple sequence 
alignment (msa) of core genes (MAFFT v7.313) (318, 319). All SNP analyses of 
strains from individual infants were performed using Snippy v4.2.1 (320) and the 
resulting msa was passed to the recombination removal tool Gubbins (321). 
Alignments resulting from all previous steps were cleaned from poorly aligned 
positions using manual curation and Gblocks v0.9b where appropriate (322). The 
core-genome tree was generated using FastTree v2.1.9 using the GTR model with 
1000 bootstrap iterations. Snippy v4.2.1 with the “—ctgs” option, SNP-sites v2.3.3 
(323) and FastTree v2.1.9 (GTR model with 1000 bootstrap iterations) were used to 
generate the whole genome SNP tree. Snp-dists v0.2 was used to generate pairwise 
SNP distance matrix between strains within individual infants (324). Scoary v1.6.16 
with Benjamini Hochberg correction (325) was used on the output file from Roary 
to associate subsets of genes with specific traits – breast-fed, formula-fed,  
pre-weaning, weaning and post-weaning. The p-value cut-off was set to <1e-5, 
sensitivity cut-off to ≥70 % and specificity cut-off to ≥90 % to report the most 
overrepresented genes. 
 
 Wild mammal study (Chapter 4) 
 
Anvi’o version 6.1 (326) was used to generate pan-genomes and single copy core 
gene data for other analyses. Briefly, a text file was created containing required 
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information on the collection of genomes and this file was used to generate 
genomes storage database. Next, the pan-genome was computed using the script 
anvi-pan-genome with parameters “--minbit 0.5 --mcl-inflation 10 --use-ncbi-blast”. 
Single copy core genes were identified in the pan-genome and their aligned amino 
acid sequences recovered using anvi-get-sequences-for-gene-clusters with 
parameters “--min-num-genomes-gene-cluster-occurs”, “--max-num-genes-from-
each-genome”, “--concatenate-gene-clusters”. The resulting output was cleaned 
from poorly aligned positions using trimAl v1.4.1 (gaps in more than 50% of the 
genes) (312). IQ-TREE v1.6.1 (327) employing the ‘WAG’ general matrix model with 
1000 bootstrap iterations (328) was used to infer the maximum likelihood trees 
from protein sequences. Script anvi-import-misc-data was used to import the 
results into the anvi’o pan-genome database, and the output was visualised with 
anvi-display-pan.  
The host tree for co-phylogentic analysis for the wild mammal study was 
constructed using concatenated nucleotide sequences for 12S rRNA and partial cytb 
genes aligned using MAFFT v7.450, employing the ‘GTR’ model with 1000 bootstrap 
iterations. ParaFit (329) in the ‘ape’ package of R (329, 330) was used for topology-
based comparisons. 
 
 Captive animal study (Chapter 5) 
 
Sequences for rpoB, rpoC, groL, dnaJ, clpC and xpf genes were in silico extracted 
from annotated genomes of isolates belonging to potentially novel Bifidobacterium 
species, as well as the 87 recognised Bifidobacterium type strains, and 
concatenated for the purpose of multilocus sequence analysis. MAFFT v7.450 (316) 
was used to create the multiple sequence alignment, which was then subjected to 
quality trimming with trimAl v1.4.1 (gaps in more than 50% of the genes) (312) and 
tree generation using IQ-TREE v1.6.1 (327) employing the ‘GTR’ model with 1000 
bootstrap iterations (328). 
General feature format files of Bifidobacterium strains were inputted into the Roary 
pan-genome pipeline v.3.12.0 with the BLASTP threshold set to 50% to obtain core-
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genome data and the multiple sequence alignment (msa) of core genes (MAFFT 
v7.313) (318, 319). The resulting msa was processed as above, to generate the 
maximum likelihood core-genome tree. 
 
2.4.8 CAZyme analysis  
 
Functional categories (COG categories) were assigned to genes using EggNOG-
mapper v0.99.3, based on the EggNOG database (bacteria) (331) and the 
abundance of genes involved in carbohydrate metabolism was calculated. A 
standalone version of dbCAN2 (v2.0.1) was used for glycobiome annotation (332). 
Glycosyl hydrolase (GH) gain-loss events were predicted using Dollo parsimony 
implemented in Count v9.1106 (333).  
 
2.4.9 Screening for the presence of eps genes 
 
BLAST+ v2.9.0 (e-value of 1e-5 and 50% identity over 50% sequence coverage) (334) 
was used to screen B. castoris genomes for the presence of homologues of eps 
genes from B. animalis subsp. lactis Bl12 (accession number CP004053.1, eps3: 
Bl12_1287 – Bl12_1328) and B. pseudolongum subsp. globosum LMG 11569T 
(accession number JGZG01000015.1, eps4: BPSG_1548 – BPSG_1565).  
 
2.4.10 Horizontal gene transfer prediction 
 
SIGI-HMM (335) tool implemented in Islandviewer4 (336) was employed to predict 
HGT events. 
 
2.4.11 CRISPR-Cas prediction 
 
CRPSPRCasFinder v1.1.2 (337) was used to predict the presence of CRISPR-Cas loci. 
Sequences for CRISPR arrays were retrieved using CRISPRDetect v2.4 (338) and 




2.4.12 Prophage prediction 
 
Prediction of prophage sequences was made using VirSorter v1.0.6 (340). The 
software identifies viral regions in bacterial genomes and categorises them as 
follows: 1 and 4 (viral and lysogen, respectively) are “most confident” predictions 
similar to known viral references, categories 2 and 5 are “likely” predictions 
divergent from references, as well as partial sequences lacking viral hallmark genes 
which may include defective prophages, while categories 3 and 6 comprise 
sequences or regions with structure similar to viral genomes, but lacking similarity 
to known viruses or viromes. Sequences predicted to belong to categories 3 and 6 
were excluded from analyses. Prophage sequences were visualised using BRIG 
v0.95 (341). Whole predicted prophage sequences, as well as the sequence for 
phage signature portal protein were used to construct maximum likelihood 
phylogenetic trees in IQ-TREE v1.6.1 employing ‘GTR’ and ‘WAG’ models, 
respectively. BLAST+ v2.9.0 with options “-evalue 1 -gapopen 10 -gapextend 1” was 
used to screen spacers identified in strains with complete CRISPR-Cas systems 
against predicted prophage sequences and Bifidobacterium genomes. Only matches 
showing 100% identity and 100% coverage were retained. 
 
2.4.13 Nucleotide sequence accessions  
 
Genome assemblies for the breast- and formula-fed infant study (B. longum) 
(Chapter 3) have been deposited at the GOLD database (https://img.jgi.doe.gov) 
under the accession number Gs0145337.   
 
2.5 Experimental methods 
 
2.5.1 Carbohydrate utilisation assay 
 
Bifidobacterium (1%, v/v) was grown in modified (m)MRS (pH 6.8) supplemented 
with cysteine HCl at 0.05% and 2% (w/v) of selected carbohydrates as described 
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previously (162), except for pectin and mucin which were added at 1% (w/v). 
Growth was determined over a 48-h period using Tecan Infinite 50 microplate 
spectrophotometer at OD595. Experiments were performed in biologically 
independent triplicates, and the plate reader measurements were taken 
automatically every 15min following 60s of shaking at normal speed. Due to the 
drop in initial OD values (i.e. recorded between T0 and T1) growth data were 
expressed as mean of the replicates between T2 (30 min) and Tend (48-h). 
 
Table 2.8 Materials used in carbohydrate utilisation assays. 
 
2.5.2 High-performance anion-exchange chromatography (HPAEC) 
 
Mono-, di- and oligo- saccharides present in the spent media samples were 
analyzed on a Dionex ICS-5000 HPAEC system operated by the Chromeleon 
software version 7 (Dionex, Thermo Scientific). Samples were bound to a Dionex 
CarboPac PA1 (Thermo Scientific) analytical column (2 × 250 mm) in combination 
with a CarboPac PA1 guard column (2 × 50 mm), equilibrated with 0.1 M sodium 
hydroxide (NaOH). Carbohydrates were detected by pulsed amperometric 
detection (PAD). The system was run at a flow rate of 0.25 mL/min. The separation 
was done using a stepwise gradient going from 0.1 M NaOH to 0.1 M NaOH–0.1 M 
sodium acetate (NaOAc) over 10 min, 0.1 M NaOH–0.3 M NaOAc over 25 min 
Item Supplier
mMRS Tripticase peptone BD Biosciences, New Jersey, USA
Yeast extract Oxoid (Thermo Fisher Scientific), Loughborough, UK 
Tryptose BD Biosciences, New Jersey, USA
K2HPO4 Sigma-Aldrich, Dorset, UK 
KH2PO4 Sigma-Aldrich, Dorset, UK 
Ammonium citrate tribasic Sigma-Aldrich, Dorset, UK 
Pyruvic acid Sigma-Aldrich, Dorset, UK 
Cysteine HCl Sigma-Aldrich, Dorset, UK 
Tween 80 Sigma-Aldrich, Dorset, UK 
MgSO4 • 7H2O Sigma-Aldrich, Dorset, UK 
MnSO4 • 4H2O Sigma-Aldrich, Dorset, UK 
FeSO4 • 7H2O Sigma-Aldrich, Dorset, UK 
Carbon sources Lactose monohydrate Sigma-Aldrich, Dorset, UK 
D-(+)-Glucose Sigma-Aldrich, Dorset, UK 
D-(+)-Cellobiose Sigma-Aldrich, Dorset, UK 
D-(+)-Mannose Sigma-Aldrich, Dorset, UK 
Mucin from porcine stomach Sigma-Aldrich, Dorset, UK 
Pectin from apple Sigma-Aldrich, Dorset, UK 
L-Rhamnose monohydrate Sigma-Aldrich, Dorset, UK 
D-(+)-Xylose Sigma-Aldrich, Dorset, UK 
L-(+)-Arabinose Sigma-Aldrich, Dorset, UK 
(+)-Arabinogalactan Sigma-Aldrich, Dorset, UK 
Lacto-N-neotetraose Glycom, Hørsholm, Denmark
2'-fucosyllactose Glycom, Hørsholm, Denmark
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followed by a 5 min exponential gradient to 1 M NaOAc, before reconditioning with 
0.1 M NaOH for 10 min. Commercial glucose, cellobiose, fucose, lactose and lacto-
N-neotetraose (LNnT) were used as external standards. This experiment was 





B. longum subsp. longum strain 25 (B_25) was grown in triplicate in mMRS 
supplemented with L-cysteine HCl at 0.05% and 2% (w/v) glucose, cellobiose or 
LNnT as a sole carbon source. B. longum subsp. longum strain 71 (B_71) was grown 
in triplicate in mMRS supplemented with cysteine HCl at 0.05% and either 2% (w/v) 
glucose or 2’-FL as a sole carbon source. Cell pellets from 50 mL samples (at the 
mid-exponential growth phase) were collected by centrifugation (4500 × g, 10 min, 
4 °C) and washed three times with PBS pH7.4. Cells were resuspended in 50mM 
Tris-HCl pH8.4 and disrupted by bead-beating in three 60s cycles using a FastPrep24 
(MP Biomedicals, CA). Protein concentration was determined using a Bradford 
protein assay (Bio-Rad, Germany). Protein samples, containing 50μg total protein, 
were separated by SDS-PAGE with a 10% Mini-PROTEAN gel (Bio-Rad Laboratories, 
CA) and then stained with Coomassie brilliant blue R250. The gel was cut into five 
slices, after which proteins were reduced, alkylated, and in-gel digested as 
previously described (342). Peptides were dissolved in 2% acetonitrile containing 
0.1% trifluoroacetic acid and desalted using C18 ZipTips (Merck Millipore, 
Germany). Each sample was independently analysed on a Q-Exactive hybrid 
quadrupole-orbitrap mass spectrometer (Thermo Scientific) equipped with a nano-
electrospray ion source. MS and MS/MS data were acquired using Xcalibur (v2.2 
SP1). Spectra were analysed using MaxQuant v1.6.1.0 (343) and searched against a 
sample-specific database generated from the B_25 and B_71 genomes. Proteins 
were quantified using the MaxLFQ algorithm (344). The enzyme specificity was set 
to consider tryptic peptides and two missed cleavages were allowed. Oxidation of 
methionine, N-terminal acetylation and deamidation of asparagine and glutamine 
and formation of pyro-glutamic acid at N-terminal glutamines were used as variable 
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modifications, whereas carbamidomethylation of cysteine residues was used as a 
fixed modification. All identifications were filtered in order to achieve a protein 
false discovery rate (FDR) of 1% using the target-decoy strategy. A protein was 
considered confidently identified if it was detected in at least two of the three 
biological replicates in at least one glycan substrate. The MaxQuant output was 
further explored in Perseus v1.6.1.1 (345). The proteomics data have been 
deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 
with dataset identifier PXD017277. This experiment was performed in collaboration 
with Dr Sabina Leanti La Rosa, who also carried out the analysis of the proteomics 
data. 
 
2.6 Graphs and illustrations 
 
Phylogenetic trees were visualised using iTOL (346). RStudio v1.3.1093 was used for 
R programming (347). Figures were generated using R packages ‘gplots’ 
‘ComplexHeatmap’, ‘gggenes’ and GraphPad Prism v8.4.3 for MacOS, GraphPad 
Software, La Jolla California USA (www.graphpad.com). Inkscape v1.0.0beta for 
MacOS was used to edit figures.  
 
2.7 Statistical analyses  
 
For all statistical analyses, P values <0.05 were considered to be significant. 
2.7.1 Breast-fed and formula-fed infant study (B. longum) (Chapter 3) 
 
The T-test function implemented in Microsoft Excel v16.16.20 was used to calculate 
statistically significant differences between average numbers of GH genes 




2.7.2 Wild mammal study (Chapter 4) 
 
c2 function implemented in R was used to assess difference in prevalence of 
Bifidobacterium between wild mice and voles.  
2.7.3 Captive animal study (Chapter 5) 
 
Normality of data was assessed using Shapiro-Wilk normality test implemented in 
GraphPad Prism v8.4.3. To account for the non-normal data and non-equal sample 
sizes, the Kruskal-Wallis and the Dunn’s post hoc tests (GraphPad Prism) were used 
to compare genome size and GH abundance between Bifidobacterium isolates 
belonging to different host categories. The T-test (GraphPad Prism) was used for 
comparisons between infant and adult categories within the human host group 
(normal data distribution). ANOSIM function implemented in R was used to test 
whether the host categories were associated with phylogenetic relatedness of 
Bifidobacterium based on the distance matrix generated from the maximum 
likelihood core-genome tree using ‘cophenetic’ function in ‘ape’ package.  
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Chapter 3  
 
Succession of Bifidobacterium longum strains in response to 




Dr Anne McCartney performed DNA extraction and provided strain collection. 
DNA library preparation for WGS was done by sequencing teams at the Wellcome 
Sanger Institute (Hinxton, UK) and Quadram Institute Bioscience (Norwich, UK). 
I performed carbohydrate growth experiments and prepared selected samples for 
carbohydrate uptake assay (HPAEC) and proteomics. 
Carbohydrate uptake and proteomics were performed by both Dr Sabina Leanti La 
Rosa and myself. 
I performed all computational analyses, except for the analysis of the results from 
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Diet-microbe interactions at early life stages are crucial for infant development and 
microbiota modulation. The gut of breast-fed infants is primarily colonised by 
members of genus Bifidobacterium, with particularly high prevalence of strains 
belonging to B. longum subsp. longum (B. longum) and B. longum subsp. infantis  
(B. infantis). Although introduction of a more diversified diet later in infancy 
initiates a shift in microbiota from Bifidobacterium-dominated to a more complex 
one, specific strains of B. longum can persist long-term in individual hosts. This 
study aimed to investigate the adaptation of B. longum to the changing infant diet. 
Examination of the genomes of 75 strains isolated from nine infants in their first 18 
months (either exclusively breast- or formula-fed pre-weaning), indicated intra-
individual and subspecies-specific strain diversity with respect to glycosyl hydrolase 
families and enzymes, which corresponded to different dietary stages. Phenotypic 
growth studies revealed strain-specific differences in utilisation of human milk 
oligosaccharides and plant carbohydrates between and within individual infants. 
Furthermore, carbohydrate uptake assay and proteomic profiling identified active 
gene clusters involved in degradation of selected carbohydrates. The results 
indicate a strong link between infant diet and the genomic diversity of B. longum 
subspecies and strains reflected in their carbohydrate utilisation profiles, which is in 
line with changes to the nutritional environment: i.e. moving from breast milk to a 
more complex diet. These data provide additional insights into possible 
mechanisms behind the competitive advantage of B. longum and its long-term 
persistence in a single host and may contribute to rational development of new 





The mutualistic relationship between the host and its microbiota begins with 
microbial colonisation shortly after birth (70, 162, 348). Infant development is 
strongly linked to the early life microbiota, with its crucial role in modulating 
immune responses, providing resistance to pathogens, and digesting dietary 
components (59, 132, 153, 349-352). Indeed, interactions between host diet and 
gut microbes are suggested to play a central role during infancy, leading to health 
effects that may extend to later life stages (77-80, 83, 85). The microbiota of 
vaginally delivered full-term healthy infants is relatively simple and characterised by 
the dominance of the genus Bifidobacterium (353, 354). In contrast, disrupted 
transmission of maternal gastrointestinal bacteria, such as Bifidobacterium, in 
infants born through caesarean section results in high levels of opportunistic 
hospital-associated pathogens, which have been shown to account for more than 
65% of the total microbiota composition in the first 4 days after birth (354).  
Considered the gold nutritional standard for infants, breast milk is also an 
important dietary supplement for early life microbiota members, including 
Bifidobacterium. The strong association between infant diet and gut microbes has 
further been supported by reports of differences in microbiota composition 
between breast- and formula-fed infants, linking low abundance of Bifidobacterium 
to formula-feeding (92, 172). These microbiota differences have further been 
associated with differential health outcomes between the two groups, for example 
increased instances of asthma, allergy and obesity in formula-fed infants (174, 178-
180, 355). 
The presence of specific carbohydrate utilisation genes and gene clusters in 
genomes of Bifidobacterium, particularly the ones involved in the metabolism of 
breast milk-associated human milk oligosaccharides (HMOs), has been linked to 
high abundance of Bifidobacterium in breast-fed infants (59). These genes often 
display species- and strain-specificity, and their presence has been described in  
B. breve, B. bifidum, B. longum, B. infantis, and more rarely in  
B. pseudocatenulatum (59, 156-158). Additionally, co-existence of Bifidobacterium 
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species and strains in individual infant hosts, and resulting interactions and 
metabolic co-operation within a single (HMO-associated) ecosystem have been 
reported (38, 162). 
Transition from breast milk to a more complex diet, coupled with the introduction 
of solid foods, has been considered the first step in the development of an adult-
like microbiome, functionally more complex and harbouring genes responsible for 
degradation of plant-derived complex carbohydrates, starches, and xenobiotics, as 
well as production of vitamins (88, 241). Non-digestible complex carbohydrates, in 
particular, including arabinoxylans (AX), inulin-type fructans (ITF) or arabinoxylo-
oligosaccharides (AXOS) present in complementary foods have been suggested to 
potentially exert beneficial health effects on hosts via their bifidogenic and 
prebiotic properties and resulting modulation of the intestinal microbiota and 
metabolic end-products (55, 242-244).  
Specific strains of Bifidobacterium, and B. longum in particular, have previously 
been shown to persist in individual infant hosts long-term, despite changes in 
microbiota composition during weaning (356, 357). Currently, B. longum is 
recognised as four subspecies, with subspecies longum and infantis associated with 
the human gut microbiota, and subspecies suis and suillum isolated from animal 
hosts (358, 359). It is considered to be the most common and prevalent species in 
the human gut, with B. longum subsp. infantis associated with infants, and  
B. longum subsp. longum linked to both infants and adults (24, 72). The differences 
in prevalence between the two subspecies, and the ability of human host to acquire 
new B. longum strains at different life stages have been associated with particular 
bacterial carbohydrate utilisation capabilities and the overall composition of the 
resident microbiota (289, 360).  
Recently, several metagenomic studies have investigated the early life microbiota in 
breast- and formula-fed infants (296, 361-363). The investigation of the 
DIABIMMUNE cohort, employing strain-level metagenomics, provided insights into 
diet-related functional aspects of B. infantis in breast-fed infants (288). Although 
several longitudinal studies focused specifically on B. longum and reported 
intraspecies diversity, colonisation and long-term persistence (years) of this species 
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in hosts (289, 357, 364), investigations into diet-related functions at early life stages 
remain limited. The studies examining infant-associated B. longum strains in 
relation to diet have not been profiled over longitudinal and changing dietary 
periods (365). Hence, further detailed longitudinal studies are required to assess  
B. longum strains in single hosts over time, with a particular focus on changing 
dietary patterns. 
In this study, I investigated the adaptations of Bifidobacterium to the changing 
infant diet and examined a unique collection of B. longum strains isolated from nine 
either exclusively breast- or formula-fed infants across their first 18 months, 
encompassing pre-weaning, weaning and post-weaning dietary stages. I assessed 
the genomic and phenotypic carbohydrate metabolism similarities between 62  
B. longum strains and 13 B. infantis strains. The results indicate a strong association 
between host diet and Bifidobacterium species and strains, which seems to align 
with changes to the nutritional environment.  
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3.3 Hypothesis and aims 
 
Whole genome sequences of Bifidobacterium longum display particular genomic 
features related to carbohydrate metabolism. These features may play a role in the 
establishment and persistence of members of this species in individual hosts during 
infancy despite dietary changes associated with transition from breast milk to solid 
foods. 
Aims: 
1) Explore genomic features of B. longum strains isolated from breast- and 
formula-fed infants during the first 18 months of life, with particular focus 
on traits related to carbohydrate metabolism 
2) Perform phenotypic growth experiments to assess functional capabilities of 
representative B. longum isolates. Link genomic predictions to phenotypic 
data 
3) Perform further experimental characterisation of strains displaying 







Previously, studies examining B. longum across the human lifespan have reported a 
broad distribution of this species and have suggested their ability to persist within 
hosts for prolonged periods of time and through changing nutritional environment 
(356, 357). To better understand potential mechanisms facilitating these properties 
during the early life window, I sought to investigate the genotypic and phenotypic 
traits of B. longum strains within individual infants in relation to diet (i.e. breast milk 
vs formula) and dietary stages (i.e. pre-weaning, weaning and post-weaning), 
following up on a longitudinal study of the infant faecal microbiota published in 
2010 (296). Briefly, faecal samples from seven either exclusively breast- or formula-
fed infants were collected regularly from 1 month to 18 months of age (296). The 
number of samples obtained from the breast-fed infants during the pre-weaning 
period was higher than that obtained from the formula-fed group, which may 
correlate with the age at which the two groups started weaning (~20.6 vs. ~17 
weeks old).  
In the original study, quantitative analysis using fluorescence in situ hybridization 
(FISH) was performed on collected samples to enumerate the predominant bacterial 
groups (Table S3.1) (296). In addition, bacterial isolation was carried out on selected 
samples, and the isolated colonies identified using ribosomal intergenic spacer 
analysis (296).  
 
3.4.1 Quantitative analysis of microbial communities in breast- and formula-fed 
infants 
 
I first sought to provide context to the gastrointestinal environment B. longum 
strains selected for the present study were isolated from. For this purpose, I re-
analysed the data originally generated by FISH (Figure 3.1 & Table S3.1) (296)). 
Proportionally, bifidobacteria detected with probe Bif164 constituted the 
predominant group in samples from breast-fed infants during pre-weaning and 
weaning, with their levels fluctuating from 16.5% to 100% of the microbiota across 
these dietary stages. Proportions of bifidobacteria across all breast-fed samples 
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decreased considerably during post-weaning and ranged from 4.6% to 12.1%. The 
levels of bacteria detected by Erec482 (members of Clostridium cluster XIVa) started 
to increase during weaning in all samples and this trend continued until the end of 
the study (mean±sd 0.25±0.66%, 2.04±3.39% and 18.16±10.24 % for pre-weaning, 
weaning and post-weaning phases, respectively). Members of genus Bacteroides, 
Parabacteroides and Prevotella species, Paraprevotella, Xylanibacter, Barnesiella 
species and Odoribacter splanchnicus, detectable by probe Bac303, were identified 
in all samples throughout the study. This bacterial group showed extensive inter-
individual variation, with mean proportions of 3.29±6.53%, 4.9±10.35% and 
13.1±9.73% for pre-weaning, weaning and post-weaning phases. Other microbiota 
members were detected in breast-fed samples at lower levels, including members of 
family Coriobacteriia (Ato291, mean <2 % of microbiota), Escherichia coli (EC1531, 
<1 %), members of Clostridium clusters I and II (Chis150, <1 %) and lactic acid 
bacteria (Lab158, mean <1 %). 
 
 
Figure 3.1  Proportional representation of bacterial populations in the faecal microbiota of a) breast-
fed and b) formula-fed infants based on FISH analysis. 
Numbers are expressed as percentage of the total bacterial population obtained using DAPI. The 
vertical solid black lines mark the different dietary phases in each infant (pre-weaning, weaning and 
post-weaning). Oligonucleotide probes used to determine bacterial populations: Bif164 – most 
Bifidobacterium species and Parascardovia denticolens, Bac303 – most members of the genus 
Bacteroides, some Parabacteroides and Prevotella species, Paraprevotella, Xylanibacter, Barnesiella 
species and Odoribacter splanchnicus, Erec482 – most members of Clostridium cluster XIVa, Ato291 – 
Cryptobacterium curtum, Gordonibacter pamelaeae, Paraeggerthella hongkongensis, all Eggerthella, 
Collinsella, Olsenella and Atopobium species, Chis150 – most members of Clostridium cluster I, all 
members of Clostridium cluster II, EC1531 – Escherichia coli, Lab158 – all Oenococcus, Vagococcus, 
Melissococcus, Tetragenococcus, Enterococcus, Catellicoccus, Paralactobacillus, Pediococcus and 
Lactococcus species, most Lactobacillus, Weissella and Leuconostoc species. 
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In contrast to the breast-fed group, no drastic changes in bacterial populations were 
observed in formula-fed infants throughout the study. Overall, levels of 
bifidobacteria detected during pre-weaning and weaning in this group were lower 
and fluctuated from 0.0% to 73.3% of the microbiota at different time points. During 
post-weaning, proportions of Bifidobacterium decreased across all formula-fed 
samples and ranged from 6.5% to 12% at month 18, similar to the breast-fed group. 
The levels of bacteria detected by probe Erec482 were overall higher in formula-fed 
samples throughout the duration of the study, with mean proportions of 
19.96±17.41%, 25.39±14.63% and 30.6±15.92% for pre-weaning, weaning and post-
weaning phases. Similarly, proportions of bacteria belonging to bacteroides group 
(probe Bac303) were higher in the formula-fed group compared to the breast-fed 
group during all dietary phases, with mean proportions of 3.55±5.51%, 
13.25±13.78% and 25.73±19.04% for pre-weaning, weaning and post-weaning, 
respectively. In contrast to the breast-fed group, levels of bacteria belonging to 
Clostridium clusters I and II (probe Chis150) started to increase during weaning in 
the formula-fed group and continued to increase throughout the remainder of the 
study (1.23±1.28%, 7.03±9.18% and 21.72±11.47% for pre-weaning, weaning and 
post-weaning, respectively). Levels of bacteria identified by Ato291 and EC1531 in 
formula-fed samples were slightly higher than in the breast-fed group (means of 
<3.5% and <1.25%, respectively), while the mean proportion of lactic acid bacteria 
(Lab158) remained below <1%.   
Overall, these results are in line with previous reports of differences in faecal 
microbiota composition between breast- and formula-fed babies, in particular 
during the pre-weaning and weaning phases, and demonstrate the succession of 
bacterial species over time and in relation to diet, including Bifidobacterium.  
 
3.4.2 General features of B. longum genomes 
 
Based on the previously published results of bacterial culture and colony 
identification (for details, refer to (363)), I selected 88 isolates that were originally 
identified as Bifidobacterium for the present study. Forty-six strains were recovered 
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from five exclusively breast-fed infants (BF1-BF5, including identical twins BF3 and 
BF4) and further 42 from four exclusively formula-fed infants (FF1-FF3 and FF5). 
Following sequencing and based on the initial ANI analysis (Tables S3.2 & S3.3), 75 
strains were identified as B. longum spp. and included in further analyses, with 62 
strains identified as B. longum subsp. longum (B. longum) and 13 strains identified as 
B. longum subsp. infantis (B. infantis) (Figure 3.2). 
To determine potential genotypic factors facilitating establishment and persistence 
of B. longum in the changing early life environment, I sought to assess the genome 
diversity of the selected strains. Sequencing generated between 12 and 193 contigs 
for each B. longum strain, with 74 out of 75 genomes containing fewer than 70 
contigs, yielding a mean of 66.95-fold coverage (Table S3.2). The predicted genome 
size for strains identified as B. longum ranged from 2.21 Mb to 2.58 Mb, with an 
average G+C% content of 60.11%, an average predicted ORF number of 2,023 and 
number of tRNA genes ranging from 55-88. For strains identified as B. infantis, the 
predicted genome size ranged from 2.51 Mb to 2.75 Mb, with an average G+C% 
content of 59.69%, an average predicted ORF number of 2,280 and the number of 
tRNA genes ranging from 57 to 62. 
 
3.4.3 Comparative genomics 
 
To assess nucleotide-level genomic differences between B. longum strains, I 
performed ANI analysis. Results (Table S3.3) indicated higher levels of sequence 
identity between B. longum strains isolated from individual infant hosts than 
between those isolated from different hosts. For example, pairwise identity values 
for strains isolated from infant BF3 showed the narrowest range (average value of 
99.99±3.15e-5%), followed by infant FF2 strains (99.98±1.12e-4%), with infant BF2 





Figure 3.2 Identification and relatedness of B. longum strains.  
Sampling scheme and strain identification within individual breast-fed (BF1-BF5) and formula-fed 
(FF1-FF3 and FF5) infants based on average nucleotide identity values (ANI). The three levels of 
shading mark different dietary phases: pre-weaning, weaning, and post-weaning. B) Relatedness of B. 
longum strains based on core proteins. Coloured strips represent isolation period (pre-weaning, 
weaning and post-weaning) and isolation source (individual infants), respectively. 
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Next, I examined genetic diversity of newly sequenced B. longum strains and their 
relatedness to each other, alongside the B. longum type strains B. longum subsp. 
longum JCM 1217T, B. longum subsp. infantis ATCC 15697T and B. longum subsp. suis 
LMG 21814T. This analysis identified a total of 1002 core genes present in at least 
99% of the analysed B. longum subspecies genomes. Based on the 
absence/presence of specific genes, a clear distinction between B. longum 
subspecies (i.e. longum vs. infantis) could be made. (Table S3.4). Phylogenetic 
analysis revealed the clustering of the B. longum strains within each subspecies 
according to isolation source (i.e. individual infants), rather than dietary stage (i.e. 
pre-weaning, weaning and post-weaning) (Figure 3.2). Interestingly, strains isolated 
from formula-fed baby FF5 clustered into two separate clusters, irrespective of the 
isolation period, suggesting that two highly related B. longum groups are present 
within this infant. Moreover, strains isolated from identical twins BF3 and BF4 
clustered together, indicating their close relatedness. 
Based on the generated pan-genome data, I next sought to identify whether specific 
components of the B. longum subspecies genomes were enriched in infant hosts 
using Scoary. This software sequentially scores each candidate gene in the accessory 
genome according to its apparent correlation to predefined traits, in this case host 
diet (breast vs. formula) or dietary stage (pre-weaning, weaning and post-weaning). 
Based on the results of this analysis, a gene annotated as α-L-arabinofuranosidase, 
along with four other genes coding for hypothetical proteins, were predicted to be 
overrepresented in B. longum strains isolated from breast-fed infants. Alpha-L-
arabinofuranosidases catalyse hydrolysis of terminal non-reducing α-L-
arabinofuranoside residues in α-L-arabinosides and act on such carbohydrates as 
(arabino)xylans (366, 367). In addition, two genes encoding hypothetical proteins 
and a gene coding for Mobility protein A were overrepresented in strains isolated 
from formula-fed infants. Furthermore, no associations between genes and dietary 
stages in B. longum, nor any associations whatsoever in B. infantis were observed 
(Table S3.5).  
Given that B. longum strains were isolated from individual infants at different time 
points, I next sought to assess their intra-strain diversity. I used the first B. longum 
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isolate from each infant as the “reference” strain, to which all other strains from the 
same infant were compared (Figure 3.3). The lowest strain diversity was observed in 
infants BF1, BF3 and FF2, with respective mean pairwise SNP distances of 18.7±20.3 
SNPs (mean±sd), 10.3±5.0 SNPs and 13.3±5.3 SNPs. These results indicate that 
strains isolated from these infants may be clonal, suggesting long-term persistence 
despite dietary changes. Surprisingly, analysis of strains isolated from breast-fed 
identical twins BF3 and BF4 revealed higher strain diversity in baby BF4 
(1034.5±1327.1 SNPs), compared to the highly similar strains in infant BF3 (i.e. 
10.3±5.0 SNPs).  
 
Figure 3.3 Pairwise SNP distances between B. longum strains of the same subspecies within individual 
infants.  
Individual points show data distribution, diamonds indicate the group mean, box plots show group 
median and interquartile range. 
 
Based on these results, I conducted SNP analysis on B. longum strains isolated from 
both babies. The data indicated that out of 13 strains analysed (n=8 from BF3 and 
n=5 from BF4), 12 isolated during pre-weaning, weaning and post-weaning seemed 
to be clonal (with mean pairwise SNP distance of 10.0±5.5 SNPs) and one strain from 
baby BF4 isolated post-weaning was more distant, 2595.4±2.8 SNPs. This difference 
in strain diversity may possibly be explained by the fact that infant BF4 received a 
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course of antibiotics during pre-weaning (Figure 3.3, Tables S3.2 and S3.6) (296). 
Furthermore, the presence of clonal strains in both babies suggests vertical 
transmission of maternal B. longum strains to both infants, or potential horizontal 
strain transmission between babies, consistent with previous reports (146, 147, 289, 
368). B. infantis strains isolated from infant BF2 showed the highest strain diversity, 
with the mean pairwise distance of 9030.9±8036.6 SNPs. Seven strains isolated 
during both pre-weaning and weaning periods appeared to be clonal, 6.3±1.6 SNPs, 
while four strains isolated during weaning and post-weaning were more distant, 
with mean pairwise SNP distance of 14983.5±4658.3 SNPs (Table S3.6). 
 
3.4.4 Functional annotation of B. longum subspecies genomes – carbohydrate 
utilisation  
 
To investigate genomic differences between B. longum strains at a functional level, I 
next assigned functional categories to ORFs of each genome. This resulted in the 
identification of carbohydrate transport and metabolism as the second most 
abundant category (after unknown function), reflecting the saccharolytic lifestyle of 
Bifidobacterium (Figure S3.1) (38, 42). B. longum had a slightly higher proportion of 
carbohydrate metabolism and transport genes (11.39±0.31%) compared to  
B. infantis (10.20±0.60%), which is in line with previous reports (56, 369). B. longum 
strains isolated during pre-weaning had a similar proportion of carbohydrate 
metabolism genes in comparison with the strains isolated post-weaning: 
11.28±0.23% and 11.48±0.38%, respectively. Furthermore, comparison between  
B. longum strains isolated from breast- and formula-fed infants produced similar 
results, with respective values of 11.41±0.21% and 11.38±0.38%. In contrast,  
B. infantis strains isolated pre-weaning had a lower proportion of carbohydrate 
metabolism genes in their genomes compared to the ones isolated post-weaning: 
9.90±0.24% and 11.20±0.01%, respectively (Table S3.7).  
Glycosyl hydrolases (GH), which facilitate glycan metabolism in the gastrointestinal 
tract, are one of the major classes of carbohydrate-active enzymes. I thus sought to 
investigate and compare the repertoire of GHs in B. longum using dbCAN2. This 
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analysis resulted in the identification of a total of 36 different GH families in all 
Bifidobacterium strains. B. longum was predicted to contain 55 GH genes per 
genome on average (2.72 % of OFRs), while this number was lower for B. infantis 
strains, with an average of 37 GH genes per genome (1.62% of ORFs) (Figure 3.4 & 
Table S3.8).  
The predominant GH family within the B. longum group was GH43, whose members 
include enzymes involved in metabolism of complex plant carbohydrates such as 
(arabino)xylans (370), followed by GH13 (starch), GH51 (hemicelluloses) and GH3 
(plant glycans) (33, 38). Strains isolated during pre-weaning had a slightly lower 
mean number of GH genes compared to strains isolated post-weaning (54.46±2.81 
vs. 56.85±2.77). In addition, strains isolated from breast-fed babies contained an 
average of 53.96±3.82 GH genes per genome, while this number was slightly higher 
for strains isolated from formula-fed infants; 56.47±2.96. Further analysis revealed 
that these differences appeared to be intra-host-specific and related to diet. For 
example, strains isolated from breast-fed twins BF3 and BF4 pre-weaning were 
predicted to harbour 11 GH43 genes per genome, while the pre-weaning strain from 
formula-fed baby FF3 had 13 GH genes per genome predicted to belong to this GH 
family. Similarly, strains isolated from babies BF3 and BF4 post-weaning had 11 
predicted GH43 genes, while the three strains isolated from infant FF3 were 
predicted to contain 16, 16 and 18 GH43 genes per genome, respectively (Table 
S3.8). 
Next, I sought to determine whether observed differences in GH gene numbers 
statistically correlated with breast- and formula-fed groups (Table S3.8). The results 
of the t-test suggested significant differences (P < 0.05) between mean numbers of 
GH genes belonging to the predominant GH families (GH43 – higher abundance in FF 
babies, GH13 – higher abundance in BF babies, and GH51 – higher abundance in FF 
babies), and several other GH families, including GH5 (cellulases), GH38 
(mannosylglycerate hydrolases) and GH36 (α-galactosidases), all more abundant in 
BF babies. Further analysis, with the focus on dietary phases, suggested significant 
differences in mean numbers of GH genes between breast- and formula-fed groups 
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during pre-weaning (e.g. families GH43, GH13, GH5, GH38), but not in the post-
weaning phase (Table S3.8).  
Given that glycosyl hydrolases belonging to distinct GH families may have similar 
catalytic properties, I next grouped the GH genes for which the predicted enzyme 
class annotation was available and investigated their abundance (Table S3.9). The 
predominant enzyme classes in B. longum strains were non-reducing end α-L-
arabinofuranosidases belonging to GH43 and GH51, followed by β-galactosidases 
(GH2 and GH42), oligo-1,6-glucosidases (GH13) and β-N-acetylhexosaminidases 
(GH3 and GH20). As mentioned above, arabinofuranosidases (EC 3.2.1.55) hydrolyse 
a-1,2-, a-1,3-, a-1,5-L arabinofuranosidic bonds in arabinoxylan and L-arabinan and 
are accessory enzymes involved in the degradation of plant cell wall polysaccharides 
(371). The enzymatic activity of beta-galactosidases (EC 3.2.1.23) ranges from 
lactose present in breast milk to galacto-oligosaccharides and galactans found in 
plant cell walls (372, 373), while oligo-1,6-glucosidases (3.2.1.10) are debranching 
enzymes which act on oligosaccharides containing a-1,6 linkages to produce  
a-glucose (374). Beta-N-acetylhexosaminidases (EC 3.2.1.52) remove non-reducing 
terminal β-1,4 linked N-acetylglucosamine (GlcNAc) or β-N-acetylgalactosamine 
(GalNAc) residues of oligosaccharides and their conjugates (375). 
The results of the analysis of mean numbers of enzyme classes between breast- and 
formula-fed babies suggested significant differences (P < 0.05) in the top three 
above-mentioned predominant enzyme classes as well as several other less 
abundant ones, including non-reducing end β-L-arabinofuranosidases (GH127 and 
GH146 – higher abundance in BF babies), α-galactosidases (GH36 – higher 
abundance in BF babies), and endo-1,5-α-L-arabinases (GH43 – higher abundance in 
FF babies). Additional analysis focusing on dietary phases suggested significant 
differences between breast- and formula fed groups during pre-weaning (e.g. non-
reducing end α-L-arabinofuranosidases, β-galactosidases, oligo-1,6-glucosidases as 
well as α-galactosidases), but not during post-weaning (Table S3.9). 
Next, I sought to examine the predicted glycosyl hydrolase repertoire of B. infantis 
strains, with the caveat that the majority of the strains belonging to this subspecies 
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were isolated from a single infant. The most abundant GH family in B. infantis was 
GH13 (starch), followed by GH42, GH20 and GH38 (Table S3.8), contrastingly to the 
B. longum group. B. infantis strains also harboured genes predicted to encode 
members of the GH33 family, which contains exo-sialidases (38). Strains isolated 
pre-weaning were predicted to contain an average of 34.83±0.4 GH genes per 
genome, while this number was higher for the strains isolated post-weaning (i.e. 
43.00±0.00 GH genes). B. infantis strains isolated post-weaning contained families 
GH1 and GH43 that were absent in the strains isolated pre-weaning. The GH1 family 
contains enzymes such as β-glucosidases, β-galactosidases and β-D-fucosidases 
active on a wide variety of (phosphorylated) disaccharides, oligosaccharides, and 
sugar–aromatic conjugates (376).  
The analysis of enzyme classes in the B. infantis strains suggested that  
β-galactosidases (GH2 and GH42) were predominant in this group, followed by  
β-N-actetylhexaminidases (GH3 and GH20), 4-α-glucanotransferases (GH77) and 
oligo-1,6-glucosidases (GH13) (Table S3.9). The enzyme 4-α-glucanotransferase  
(EC 2.4.1.25) has been reported to play a role in metabolism of maltose and 
maltodextrin by removing the reducing end glucosyl units from α-1,4-glucan and 
transfers the non-reducing dextrinyl moiety onto glucose or another α-1,4-glucan 
(377).  
Genomes of members of the genus Bifidobacterium have previously been shown to 
contain GH genes involved in metabolism of various HMOs present in breast milk 
(158, 378). Genes belonging to GH29 and GH95 (α-L-fucosidases found active on 
fucosylated HMOs (158, 379)) were identified in all  B. infantis strains, as well as four 
B. longum strains isolated from formula-fed baby FF3. Furthermore, all B. infantis 
and B. longum strains were predicted to harbour GH20 and GH112 genes (lacto-N-
biosidases and galacto-N-biose/lacto-N-biose phosphorylases shown to be involved 
in degradation of isomeric lacto-N-tetraose (LNT) (380)) (Table S3.8). 
Overall, these findings suggest differences in general carbohydrate utilisation 
between B. longum and B. infantis at different stages suggesting adaptation of 
Bifidobacterium to a changing early life diet, which may be a factor facilitating 




3.4.5 Prediction of gain and loss of GH families in B. longum  
 
Given the differences in the carbohydrate utilisation profiles between B. longum and 
B. infantis, I next sought to investigate the acquisition and loss of GH families using 
Count software. For this purpose, I additionally predicted the presence of GH 
families in type strains B. longum subsp. longum JCM 1217T, B. longum subsp. 
infantis ATCC 15697T and B. longum subsp. suis LMG 21814T with dbCAN2 and 
generated a whole genome SNP tree to reflect gene loss/gain events more 
accurately (Figure 3.4 & Table S3.10). Both B. longum and B. infantis lineages appear 
to have acquired GH families (when compared to the common ancestor of the 
phylogenetic group), with the B. longum lineage gaining two GH families (GH121 and 
GH146) and the B. infantis lineage one GH family (GH33). Within the B. infantis 
lineage, which also contains the B. suis type strain, the B. infantis taxon has further 
acquired two and lost five GH families. These findings suggest that the two human-
related subspecies have followed different evolutionary paths, which is in line with 
previous observation of differences between B. longum and B. infantis resulting 
from phylogenomic analyses (365). Interestingly, strain adaptation to the changing 
nutritional environment (i.e. individual infant gut) seems to be driven by loss of 
specific GH families (Figure 3.4). For example, B. infantis strains isolated during pre-
weaning and weaning from baby BF2 appear to be missing up to three GH families 
(GH1, GH43 and GH109) present in strains isolated post-weaning. Lack of family 
GH43 associated with enzymes acting on plant-derived polysaccharides in early life 
B. infantis strains may explain nutritional preference of this subspecies for an HMO-
rich diet.  
Similarly, I observed differential gene loss events in B. longum strains from individual 
hosts. For example, all strains isolated from baby BF5 appear to lack GH families 
GH1, GH29 and GH95. However, strains isolated pre-weaning additionally lacked 




Figure 3.4 Gene-loss events and abundance of GH families within B. longum subspecies.  
Pie charts superimposed on the whole genome SNP tree represent predicted GH family gain-loss 
events within B. longum and B. infantis lineages. Due to the size of the tree, examples of detailed gain 
loss events have been provided for main lineages, as well as baby BF2 (strains highlighted with light 
blue) and BF5 (strains highlighted with light purple). Heatmap represents abundance of specific GH 
families predicted in analysed B. longum strains. 
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galactotriose from type I arabinogalactans in B. longum (381). In contrast, strain 
B_38 isolated from this infant (BF5) post-weaning appears to have lost families 
GH136 and GH146. Interestingly, enzymes belonging to family GH136 are lacto-N-
biosidases responsible for liberating lacto-N-biose I from LNT, an abundant HMO 
unique to human milk (155), while family GH146 contains b-L-arabinofuranosidases 
displaying exo-activity on β-linked arabinofuranosyl groups.  
These events may possibly be explained by withdrawal of breast milk and/or 
changes in the composition of the microbiota post-weaning. Only one B. longum 
strain was isolated post-weaning from this baby, however FISH analysis (Figure 3.1 & 
Table S3.1) revealed an increase in the bacteroides group, which might explain the 
loss of family GH146 by strain B_38. The founding member of GH146 family,  
b-L-arabinofuranosidase, was first characterised in Bacteroides thetaiotaomicron 
(382). Overall, the presence of intra-individual and strain-specific GH family 
repertoires in B. longum suggests their adaptation to host-specific diet. The 
presence of strains with different GH content at different dietary stages further 
indicates potential acquisition of new Bifidobacterium strains with nutrient-specific 
adaptations in response to the changing infant diet. 
 
3.4.6 Prediction of single nucleotide polymorphisms (SNPs) in glycosyl 
hydrolases 
 
Given the intra-strain diversity in the nine babies and the differences in GH 
repertoires between B. longum and B. infantis, I next sought to assess nucleotide-
level differences in glycosyl hydrolase genes between strains in individual infants 
(Table S3.11). Unsurprisingly, I did not identify any significant SNPs that may lead to 
functional changes in GH genes in infants that had the lowest strain diversity (infants 
BF1, BF3 and FF2) (Table S3.6). The highest number of GH genes with predicted 
variants was recorded for B. infantis strains from baby BF2. In total, 52 synonymous 
variants and 29 missense variants were predicted at 81 different positions in 12 GH 
genes across strains that showed the highest diversity from the first “reference” 
isolate, namely one strain isolated during weaning and the three strains isolated 
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post-weaning. A number of missense variants, both complex and single, were 
recorded at several positions in the predominant enzyme classes, i.e.  
β-galactosidases (EC 3.2.1.23) and β-N-hexosaminidases (EC 3.2.1.52).  
Similarly, both synonymous and missense variants were predicted in B. longum 
strains less closely related to “reference” strains from breast-fed (BF4 and BF5) and 
formula-fed (FF1, FF3 and FF5) babies. I did not observe any trend in the distribution 
of SNPs across GH genes in B. longum strains. The number of predicted variants, the 
number of GH genes with identified mutations and their enzyme classification 
differed between individual infants. For example, in baby BF4 9 out of 10 predicted 
variants (4 synonymous and 5 missense) were identified in an α-xylosidase in a strain 
isolated post-weaning, while in baby FF5 14 synonymous and 10 missense variants 
were predicted at 24 positions in 7 different GH genes across strains isolated during 
weaning and post-weaning. Some missense changes do not compromise normal 
protein function, while others can change essential aspects of protein maturation, 
activity or stability (383). The presence of missense variants in GH genes of  
B. longum strains may indicate potential functional differences and provide 
additional explanation to intra-strain and intra-individual carbohydrate metabolism 
profiles of these bacteria, however experimental evidence would be essential to 
confirm the importance of these predictions. 
 
3.4.7 Phenotypic characterisation of carbohydrate utilisation 
 
B. longum strains have previously been shown to be able to utilise a range of 
carbohydrates, including dietary and host-derived glycans (195, 365). Given the 
predicted differences in carbohydrate metabolism profiles, and to determine strain-
specific nutrient preferences, I next sought to assess their glycan utilisation 
capabilities. I performed growth assays on 49 representative strains from all nine 
infants, cultured in modified MRS supplemented with selected carbohydrates as the 
sole carbon source. I chose both plant- and host-derived glycans that I would expect 
to constitute components of the early life infant diet (384). All B. longum strains 
were able to grow on simple carbohydrates (i.e. glucose and lactose). In terms of 
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growth on more complex carbohydrates, I observed subspecies-specific preferences, 
consistent with bioinformatic predictions (Figure 3.5).  
I selected 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT) as examples of 
HMOs found in breast milk, to represent host-derived carbohydrates. Out of the 
tested isolates, all B. infantis strains as well as three B. longum strains isolated from 
a formula-fed baby FF3 during weaning and post-weaning were able to utilise 2’-FL 
(Figure 3.5). These observations were in line with the results of in silico analysis and 
the prediction of genes potentially involved in degradation of fucosylated 
carbohydrates in the genomes of these isolates (GH29 and GH95).  
 
 
Figure 3.5 Growth performance of B. longum strains isolated from individual infants on different 
carbon sources.  
The coloured bars above the heatmap represent the classification of the isolates into the 
Bifidobacterium longum subspecies: B. longum – blue, B. infantis – yellow. The heatmap displays the 
difference in average growth of triplicates between T2 (30 min) and Tend (48 hours). Moderate growth 
is considered above 0.15 difference in OD from time T2, high growth above 0.25 difference in OD from 
time T2. Asterisks represent strains for which inconsistent growth was recorded (difference in OD of at 
least 0.15 between any of the duplicates in the triplicate experiment).  
 
Bioinformatic analysis predicted the presence of genes involved in metabolism of 
isomeric LNT in all B. longum strains (GH20 and GH112). However, the ability of  
B. infantis to utilise LNnT was strain-specific, with most strains showing what  
I considered moderate (above 0.15 difference in OD from time T2) to high growth 
rates (above 0.25 difference in OD from time T2), and two strains displaying 
inconsistent growth (Table S3.12). Out of B. longum strains, B_24 and B_25 (isolated 
during weaning from breast-fed baby BF3) also grew on LNnT, albeit this was 
inconsistent. In contrast to all other B. longum strains, strain B_25 was not able to 
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metabolise plant-derived arabinose and xylose despite the predicted presence of 
genes involved in metabolism of monosaccharides (GH43, GH31, GH2). However, it 
was one of the two strains (out of 49 tested) that showed growth on cellobiose in 
two out of the three performed experiments; the other one being the B. infantis 
strain B_19 isolated from baby BF2 post-weaning. Given these interesting results,  
I performed additional experiments using cellobiose as the sole carbon source over 
72h, in which the B. longum strain B_25 showed high growth rate (above 0.25 
difference in OD from time T2), while the B. infantis B_19 strain did not grow at all 
(Table S3.12). Furthermore, both B. longum and B. infantis strains showed varying 
degrees of growth performance on mannose, even when analysing the same strain, 
while none of the tested strains were able to grow on arabinogalactan, pectin or 
rhamnose (Figure 3.5). 
To further probe strains identified above for putative carbohydrate degradation 
genes and gene clusters, I collaborated with Dr Sabina Leanti La Rosa to receive 
training and perform carbohydrate uptake analysis and proteomics. For these 
experiments, I chose the breast-fed B. longum strain B_25 that showed growth on 
LNnT and cellobiose, and the formula-fed strain B_71 which was able to grow on 
2’-FL. Initially, supernatant from these cultures was analysed using high-
performance anion-exchange chromatography (HPAEC) to determine the 
carbohydrate-depletion profiles (Figure 3.6). In all three cases, the chromatograms 
showed complete utilisation of the tested carbohydrates and absence of any 
respective degradation products in the stationary phase culture.  
Both cellobiose and 2’-FL were depleted in the early exponential phase by B_25 and 
by B_71, respectively. LNnT was still detected in the culture supernatant until the 
late exponential growth phase, which indicated more efficient internalisation of 
cellobiose and 2’-FL, compared to LNnT. Next, the proteome of B_25 and B_71 when 
growing on cellobiose, LNnT and 2’-FL compared to glucose was determined  
(Figure 3.6 a-c & Table S3.13). The top 10 most abundant proteins in the cellobiose 
proteome of B_25 included three β-glucosidases belonging to GH3 family, as well as 
a homologue of transport gene cluster previously shown to be upregulated in  
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B. animalis subsp. lactis Bl-04 during growth on this carbohydrate (Figure 3.6 a & 




Figure 3.6 HPAEC-PAD traces showing mono-, di- and oligo-saccharides detected in the supernatant of 
either B_25 or B_71 single cultures during growth in mMRS supplemented with (a) cellobiose; (b) 
LNnT; (c) 2’-FL.  
The data are representative of biological triplicates. Abbreviations: LNnT, Lacto-N-neotetraose; Glc, 
glucose; Glc2, cellobiose; 2’-FL, 2ʹ-fucosyllactose. Panel on the right shows (a) cellobiose; (b) LNnT; (c) 
2’-FL utilization clusters in B_25 and B_71 and proteomic detection of the corresponding proteins 
during growth on HMOs. Heat maps above genes show the LFQ detection levels for the corresponding 
proteins in triplicates grown on glucose (G); cellobiose (C); LNnT (L); and 2’-FL (F). Numbers between 
genes indicate percent identity between corresponding genes in homologous PULs relative to strains 
B_25 and B_71. Numbers below each gene show the locus tag in the corresponding genome. Locus 
tag numbers are abbreviated with the last numbers after the second hyphen (for example 
B_25_XXXXX). The locus tag prefix for each strain is indicated in parenthesis beside the organism 
name. 
 
Among the three β-glucosidases, B_25_00240 showed 98% sequence identity to the 
structurally characterized BlBG3 from B. longum, which has been shown to be 
involved in metabolism of the natural glycosides saponins (386). B_25_01763 and 
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B_25_00262 showed 46% identity to the β-glucosidase Bgl3B from Thermotoga 
neapolitana (387) and 83% identity to BaBgl3 from B. adolescentis ATCC 15703T 
(388), respectively, two enzymes previously shown to hydrolyse cello-
oligosaccharides. With respect to LNnT degradation by the same strain, the most 
abundant proteins were encoded by genes located in two gene clusters 
(B_25_00111-00117 and B_25_00130-00133) with functions compatible with LNnT 
import, degradation to monosaccharides and further metabolism. The identified 
gene clusters contain the components of an ABC-transporter (B_25_00111-00113), a 
predicted intracellular GH112 lacto-N-biose phosphorylase (B_25_00114), an  
N-acetylhexosamine 1-kinase (B_25_00115) and enzymes involved in the Leloir 
pathway. All these proteins were close homologues to proteins previously 
implicated in the degradation of LNT/LNnT by type strain B. infantis ATCC 15697T 
(291) (Figure 3.6 b & Table S3.14). Interestingly, based on the results of 
bioinformatic predictions, all clonal strains isolated from twin babies BF3 and BF4 
contained close homologues of all the above-mentioned genes in their genomes (in 
some cases identical to those determined in B_25), however, only strain B_25 was 
able to grow on cellobiose and LNnT. Growth of B_71 on 2’-FL corresponded to 
increased abundance of proteins encoded by the gene cluster B_71_00973-00983. 
These proteins showed close homology to proteins described for B. longum SC596 
and included genes for import of fucosylated oligosaccharides, fucose metabolism 
and two α-fucosidases belonging to the families GH29 and GH95 (Figure 3.6c & 




There is a strong link between high abundance of Bifidobacterium, particularly  
B. longum, in early infancy and nutrient availability. The dominance of this species in 
breast-fed infants has been correlated with enrichment of genes required for the 
degradation of HMOs present in breast milk, while the transition to solid foods 
during weaning has been linked to genes involved in degradation of complex plant-
derived carbohydrates (70, 88, 155). The aim of this study was to investigate the 
adaptations of B. longum to the changing infant diet during the early life 
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developmental window. I examined wider microbiota composition based on FISH 
data originally generated by Roger and McCartney (296) and assessed the intra-
subspecies genomic diversity of 75 B. longum strains isolated from nine individual 
infants at different dietary stages, i.e. pre-weaning, weaning and post-weaning, 
focussing on their potential carbohydrate utilisation capabilities. In addition,  
I determined growth performance of representative strains on selected 
carbohydrates as sole carbon sources. The results suggest intra-individual and diet-
related differences in genomic content of analysed strains, which links to their ability 
to metabolise specific dietary components.  
The FISH results are in line with findings from previous studies investigating the 
infant gut microbiota. I observed inter-individual variability during pre-weaning and 
weaning, with a shift towards a more adult-like faecal microbiota linked to more 
complex diet at post-weaning across all samples (88, 241). During pre-weaning and 
weaning, Bifidobacterium constituted the predominant group in breast-fed infants, 
while the composition of microbiota in the formula-fed group during these stages 
showed higher complexity. 
In line with previous reports (289, 356), the results of comparative genomic analysis 
suggest that despite significant changes in diet during weaning, clonal strains of  
B. longum can persist in individuals through infancy, for at least 18 months. At the 
same time new strains displaying different genomic content and potential 
carbohydrate metabolism capabilities can be acquired, possibly in response to the 
changing nutritional environment. Strain shift related to withdrawal of breast milk 
has previously been suggested for B. infantis by Vatanen et al. (288) based on a 
strain-level metagenomic approach. Similarly, work of Asnicar et al. (389) indicated 
that strains of B. longum acquired at birth can be replaced at later life stages. Initial 
vertical acquisition of maternal Bifidobacterium strains by newborn babies has been 
well documented (146, 368, 389, 390); however, details of strain acquisition and 
transmission later in life are currently unclear. Work of Odamaki et al. (289) 
suggested person-to-person horizontal transmission of a particular B. longum strain 
within one family, with direct transfer, common dietary sources or environmental 
reservoirs, such as family homes (391), as potential transmission vehicles and 
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routes. In this study, I observed the presence of clonal strains in identical twins BF3 
and BF4, which may have resulted from a maternal transfer event. However, 
potential strain transmission between these infants living in the same environment 
may also occur. Wider studies involving both mothers and twin babies (and other 
siblings) could provide details on the extent, timing and location of transmission 
events between members of the same household.  
Prediction of genes belonging to GH families was another aspect of performed 
comparative genomic analysis. The results were in line with previous findings and 
suggested genome flexibility within B. longum, with strains belonging to the same 
subspecies displaying differences in GH family content. B. infantis was found to be 
predominantly enriched in GH families implicated in the metabolism of host-derived 
breast milk-associated components like HMOs, while B. longum predominantly 
contained GH families involved in the degradation of plant-derived substrates (33, 
38). Previously, Vatanen et al. (288) suggested that the presence of the HMO gene 
cluster allowing for intracellular HMO utilisation in B. infantis strains confers a 
particular competitive advantage for this subspecies, leading to its higher relative 
abundance in the early life microbiota. The results of the analysis of B. infantis group 
indicated the presence of glycosyl hydrolases associated with HMO metabolism in all 
isolates and revealed subspecies-specific differences in GH content between pre- 
and post-weaning strains. Furthermore, the data suggested that there are 
differences in the number of genes belonging to the most abundant GH families  
(e.g. GH43) between breast-fed and formula-fed strains at different dietary stages, 
which can be linked to nutrient availability. Surprisingly, both computational and 
phenotypic approaches identified closely related weaning and post-weaning  
B. longum strains capable of metabolising HMOs (i.e. 2’-FL) in a formula-fed baby 
that only received standard formula not supplemented with any prebiotics or 
synthetic HMOs. Moreover, the prediction of SNP variants in genes identified as 
glycosyl hydrolases indicated the presence of missense mutations in both B. longum 
and B. infantis strains. Since some missense variants can compromise protein 
function (383), these results indicate potential functional differences that could 
further explain intra-strain and intra-individual carbohydrate utilisation properties of 
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B. longum. However, experimental validation would be essential to confirm the 
importance of variant predictions. 
Recorded phenotypic growth data complemented the results of genomic analyses 
and further highlighted differences in carbohydrate metabolism profiles between 
and within B. longum and B. infantis. As suggested above, the ability of B. infantis to 
utilise different types of HMOs may facilitate their establishment in early life. 
Similarly, the preference of B. longum for plant-based nutrients may be one of the 
factors influencing their ability to persist within individual hosts through significant 
dietary changes. The differences in growth of genotypically similar B. longum strains 
on various carbohydrate sources and the ability of formula-fed strains to metabolise 
selected HMOs suggest that Bifidobacterium possess an overall very broad 
repertoire of carbohydrate utilisation genes that may be differentially switched on 
and off in response to the presence of specific dietary components (392, 393). 
Potential influence of the intra-individual environment on epigenetic mechanisms in 
these bacteria may provide another explanation for these results. One potential 
factor involved in this process may be strain cooperation supported by cross-feeding 
activities among Bifidobacterium, or between Bifidobacterium and other members 
of the microbiota, e.g. Bacteroides and Eubacterium species (38, 162, 394, 395). 
Indeed, the FISH results revealed the presence of members of these groups, Bac303 
(bacteroides) and Erec482 (eubacterium), in faecal samples of both breast- and 
formula-fed infants, with intra-individual variation at different dietary stages.  
Glycan uptake analysis and proteomics resulted in the determination of the 
mechanisms employed by selected B. longum strains to metabolise different 
carbohydrates. The predicted activity of the most abundant proteins detected 
during growth on cellobiose, LNnT and 2’-FL, indicated that all these carbohydrates 
were imported intracellularly and “selfishly” degraded, therefore limiting release of 
degradation products that could allow cross-feeding by other gut bacteria. These 
results corroborated the findings from the carbohydrate uptake analysis, where no 
peak for cellobiose, LNnT and 2’-FL degradation products could be detected. The 
uptake of cellobiose in B_25 appears to occur via a mechanism similar to that of  
B. animalis subsp. lactis Bl-04 (385), with cellobiose hydrolysis mediated by the 
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activity of three intracellular β-glucosidases; however, further confirmatory 
biochemical characterization of these enzyme is required. B_25 was observed to 
utilise LNnT using a pathway similar to that previously described in B. longum subsp. 
infantis, whereby LNnT is internalized via an ABC-transporter (B_25_00111-00113) 
followed by intracellular degradation into constituent monosaccharides by a GH112 
(B_25_00114) and an N-acetylhexosamine 1-kinase (B_25_00115). LNnT degradation 
products are further metabolized to fructose-6-phosphate by activities that include 
B_25_00116-00117 (galactose-1-phosphate urydyltranferase, UDP-glucose 4-
epimerase, involved in the Leloir pathway) and B_25_01030-01033 (for metabolism 
of N-acetylgalactosamine) prior to entering the Bifidobacterium genus-specific 
fructose-6-phosphate phosphoketolase (F6PPK) pathway (291). Strain B_71 was 
predicted to deploy an ABC-transporter (B_71_00974-00976) that allows uptake of 
intact 2’-FL that is subsequently hydrolysed to L-fucose and lactose by the two 
predicted intracellular α-fucosidases GH29 (B_71_00982) and GH95 (B_71_00983). 
L-fucose is further metabolized to L-lactate and pyruvate, via a pathway of non-
phosphorylated intermediates that include activities of L-fucose mutarotase 
(B_71_00981), L-fucose dehydrogenase (B_71_00978), L-fuconate hydrolase 
(B_71_00977) as previously described for B. longum subsp. longum SC596 (158). 
Given that the proteins encoded by the aforementioned genes are located in the 
cellobiose, LNnT and 2’-FL gene clusters that share high similarity and similar 
organization with those found in equivalent systems in other B. longum and  
B. animalis, it is reasonable to suggest that the gene clusters are related and may be 
the results of horizontal gene transfer events. Collectively, these data reflect inter- 
and intra-host phenotypic diversity of B. longum strains in terms of their 
carbohydrate degradation capabilities and suggest that intra-individual environment 
may influence epigenetic mechanisms in Bifidobacterium, resulting in differential 
growth on carbohydrate substrates.  
In conclusion, this study provides new insights into distinct genomic and phenotypic 
abilities of B. longum species and strains isolated from the same individuals during 
the early life developmental window by demonstrating that subspecies- and strain-
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specific differences between members of B. longum spp. in infant hosts can be 
correlated to their adaptation at specific age and diet stages. 
 
3.6 Future work 
 
Through the combination of bioinformatic approaches with experimental 
techniques, this study provided additional insights into genomic and phenotypic 
features of B. longum species and strains isolated from individual infant hosts during 
the early life developmental window. However, one important limitation was the 
small number of B. infantis strains (n=13) available for analysis, coupled with the fact 
that the majority of these strains (n=11) were isolated from a single breast-fed baby. 
Although the investigation of these strains provides important insight into the 
properties of this subspecies during the transition from breast milk to more 
diversified diet, it is difficult to assess how representative these results are of the 
wider population. Furthermore, only one B. infantis strain was available from a 
formula-fed baby, making it impossible to examine properties of members of this 
subspecies within this dietary group and make comparisons with breast-fed strains. 
Moreover, only one bacterial strain per time point was available for analysis. 
Inclusion of additional strains would contribute further observations on inter-
individual diversity and functional properties of Bifidobacterium in infant hosts.  
To assess bacterial communities in faecal samples, I re-analysed the data originally 
generated using FISH. With detection limit of ∼106 bacterial cells (wet weight 
faeces)−1 (296), this technique allows investigation of important bacterial groups, 
but faecal samples may contain a number of organisms at levels below the 
methodological detection threshold. Furthermore, this technique does not allow for 
tracking of microbial populations at species level. The use of comprehensive 
sequencing methods, such as shotgun metagenomics, combined with advanced 
computational methods to achieve strain-level resolution would allow more detailed 
examination of bacterial communities in individual hosts.  
Phenotypic experiments revealed inconsistencies in growth of individual B. longum 
strains on such carbohydrates as LNnT, cellobiose and mannose. Previously, 
variability in growth of B. longum on mannose, even when analysing the same strain 
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(Bifidobacterium longum NCC2705) has been reported (396, 397). Additional 
carbohydrate metabolism experiments would help determine whether inconsistency 
in growth on specific carbohydrate sources is inherent to particular Bifidobacterium 
strain. Furthermore, although B. infantis is primarily associated with the degradation 
of HMOs, I recorded growth of one of the B. infantis strains from formula-fed baby 
FF1 on xylose, albeit with inconsistent outcomes between experiments. Further 
growth assays would help assess the ability of B. longum subsp. infantis strains to 
degrade a wider range of non-HMO carbohydrates in early life. 
Finally, no metadata on complementary foods during weaning and infant diet post-
weaning were available for this study. This information would allow bioinformatic 
predictions to be related to carbohydrate degradation properties of B. longum and 
the specific dietary components present in weaning infant foods. Future longitudinal 
studies could be designed to include these data. 
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Chapter 4  
 
Wild mice are enriched in Bifidobacterium castoris strains 
that circulate within populations and geographical regions 
and encode specialised genomic signatures related to 
carbohydrate metabolism and host modulation. 
 
 
Faecal samples were collected by Dr Sarah Knowles, Miss Aura Raulo and Dr Laima 
Baltrūnaitė between December 2015 and December 2018. 
I carried out all bacterial isolations, DNA extractions and processing for initial 
identification of the isolates based on the 16S rRNA gene sequences, as well as later 
WGS sequencing of those isolates initially identified as Bifidobacterium spp.  
DNA library preparation for WGS was done by sequencing teams at the Wellcome 
Sanger Institute (Hinxton, UK) and Quadram Institute Bioscience (Norwich, UK). 
Biochemical characterisation of strain LH_867 was performed by DSMZ 
Identification Services (Braunschweig, Germany), except for growth in different pH 
values, which was carried out by myself. 









Members of the gut microbiota genus Bifidobacterium are widely distributed in the 
animal kingdom and are believed to exert beneficial effects on their hosts via a 
variety of mechanisms. In comparison to human-associated strains, in-depth 
genomic analyses of animal-associated Bifidobacterium species and strains are 
somewhat lacking, particularly in wild animal populations. In this study, I isolated 
Bifidobacterium strains from faecal samples obtained from wild small mammals 
from two distinct geographical regions in Europe (UK and Lithuania), and performed 
whole genome sequencing and bioinformatic analysis. The Bifidobacterium strains 
identified (belonging to the species Bifidobacterium castoris, B. animalis and  
B. pseudolongum) were only found in wild mice (Apodemus sylvaticus, Apodemus 
agrarius and Apodemus flavicollis) but not voles. Further analysis focusing on the 
most commonly isolated species (B. castoris, 80% isolates) revealed three major 
mouse-associated clades. These clades were not location- or host species-specific, 
and their distribution across the host phylogeny was consistent with regular host 
shifts rather than host-microbe co-speciation. At a finer within-clade level, most  
B. castoris strains were only detected in a single population, but populations 
frequently harboured multiple co-circulating strains.  Functional level analysis 
indicated that B. castoris strains encoded an extensive arsenal of carbohydrate-
active enzymes, and a range of glycoside hydrolases including putative novel 
enzymes such as chitosanases, that may act on chitin-derived substrates such as 
mushrooms or insects. Gene loss/gain analysis suggested that the B. castoris 
species has acquired the GH49 family, whereas at the strain level, those colonising 
mice showed mostly glycoside hydrolase gene losses rather than gain events. Other 
key genomic features uncovered include the presence of putative 
exopolysaccharides, known to modulate host immune responses, which may have 
been acquired (alongside carbohydrate metabolism genes) via horizontal gene 






Species and strains belonging to the bacterial genus Bifidobacterium are prominent 
members of the gut microbiota in many animals, and are universally distributed 
among animals exhibiting parental care, including humans and non-human 
mammals, birds and social insects (6). Bifidobacterium species that colonise the 
human gut, especially those associated with early life stages, have received much 
attention in recent years due to their ability to confer positive health benefits on 
their host, including supporting development of the wider gut microbial ecosystem, 
colonisation resistance against pathogens and immune modulation. These 
beneficial properties have been linked to their carbohydrate metabolism and 
exopolysaccharide (EPS) biosynthesis capabilities (48, 398). 
Next-generation DNA sequencing, together with comparative and functional 
genomics, have been shown to be particularly useful in exploring the diversity of 
Bifidobacterium and the genetic basis for their beneficial properties and adaptation 
to the specific nutritional environment (i.e. host gut). Currently, over 80 
Bifidobacterium species and subspecies have been identified in multiple animal 
hosts, with around 2,100 genome assemblies available on the NCBI Genome 
database (July 2020) (5). However, the majority of available genome sequences 
come from human-associated bifidobacteria (B. longum, B. breve, B. bifidum,  
B. pseudocatenulatum). Consequently, it is mainly these taxa, as well as type strains 
of the genus Bifidobacterium, that have been subjected to in-depth genomic 
analysis (6, 27, 28, 33, 36, 38, 61).  
Recently, work by Lugli et al. (292, 293) provided insights into genotypic and 
phenotypic properties of animal-associated B. animalis and B. pseudolongum taxa. 
These species were found in multiple animal hosts, including mammals and birds, 
and thus appear to be generalists. However, information relating to other animal-
associated Bifidobacterium species at the genetic variant or strain level is limited, 
therefore further studies are required to determine if this generalism holds true at 
higher taxonomic resolution, or whether there is strain-specific host specialisation. 
This is particularly important when exploring adaption of bacterial symbionts to the 
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host gut environment in wild populations (rather than model organisms and captive 
animals). 
Recent reports have proposed that the gut microbiota of animals can affect host 
phenotype in several ways, including through traits related to digestion and energy 
acquisition and immune development (399, 400). These findings suggest that 
differences in the composition of symbiotic microbial communities may play an 
important role in host ecology and evolution, and understanding the related 
distribution and diversification of key bacterial species may provide important 
insights into microbe-host interactions, particularly in wild populations (401). This 
knowledge may also be important from an animal conservation and management 
perspective, for example for the maintenance of natural microbiota diversity 
through conspecific co-habitation or bioaugumentation through microbiota 
transplantation (402), and for determining the potential for animal populations to 
respond to environmental (e.g. climate) change, especially in non-captive 
populations in their natural environment (403). 
Recent reports of congruent phylogenies between mammals and gut commensal 
taxa have suggested that animal hosts and their symbionts may evolve and speciate 
together (404-407). Amplicon-based approaches identified hundreds of bacterial 
clades whose approximate divergence times are consistent with those of mammals 
(405). For example, parallel subclade speciation was suggested for members of 
Bifidobacteriaceae, based on their topological and temporal congruency with the 
phylogenetic tree of four primate species (Homo sapiens, Pan troglodytes, Pan 
paniscus, and Gorilla gorilla) (404). These patterns have been linked to convergent 
acquisition of function by different bacterial phylogenetic clades, with horizontal 
gene transfer and gene loss proposed as potential mechanisms involved in the 
process (408, 409). 
It remains unclear, which processes govern the evolution of mammalian gut 
microbial symbionts (410, 411). Recently, Groussin et al. (412) argued that 
reciprocal and specific functional dependencies between mammalian hosts and 
single bacterial clades are not strong enough for co-evolution to occur and result in 
co-speciation events. Instead, the authors proposed that allopatric speciation, 
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which implies geographic isolation of the host species and subsequent limited 
symbiont dispersal and diversification, may lead to host-symbiont co-speciation. 
According to this model, host adaptation to new conditions following an allopatric 
event results in an altered intestinal environment, to which symbiotic bacteria can 
quickly adapt (e.g. different glycan composition of plant-derives substrates in 
herbivore hosts) (412). While studies using methods of broad taxonomic resolution 
(e.g. down to genus or species-level) provide some information on evolutionary 
relationships between hosts and their gut microbes, higher (strain-level) resolution 
studies in natural systems remain scarce, yet may reveal cryptic diversity and 
patterns of host-specificity and host-microbe evolution not previously appreciated.   
Wild small mammals provide an ideal study system in which to explore host- gut 
microbe relationships in more detail, as they are geographically widespread, 
diverse, easily trapped and possess a rich gut microbiota that, in the case of rodents 
and especially mice, can be relatively well-understood from studies of laboratory 
mice. Therefore, wild rodents were chosen as a target host group in which to 
profile patterns of Bifidobacterium diversity, and determine strain-level and 
functional adaptation to different host species and geographical regions. To this 
end, I performed Bifidobacterium isolation screens in wild mice and voles from 
multiple populations in two geographically distinct parts of Europe and 
subsequently investigated a collection of the identified Bifidobacterium genomes.  
Phylogenomic and functional genomic analysis indicated enrichment for B. castoris 





4.3 Hypothesis and aims 
 
Whole genome sequences of Bifidobacterium isolated from small mammals display 
particular genomic features related to carbohydrate metabolism, host modulation 
and defence mechanisms. 
Aims: 
1) Isolate Bifidobacterium from wild small mammal populations, sequence 
their genomes and select particularly interesting strains for in-depth 
genomic analysis 
2) Determine genomic features of selected strains, with particular focus on 
traits directly and indirectly linked to carbohydrate metabolism  
3) Further explore genomes of selected strains for other interesting properties, 






4.4.1 Isolation of Bifidobacterium from small mammal faecal samples  
 
Through collaboration with Dr Sarah Knowles and Dr Laima Baltrūnaitė, between 
April 2017 and December 2018, I obtained and processed a total of 220 faecal 
samples from 9 species of small mammals (mice, voles and shrews) caught at 14 
sites across two European countries – Lithuania and the UK. In the UK, samples 
were collected from two mouse species (Apodemus sylvaticus and Apodemus 
flavicollis) in both Wytham Woods (Oxfordshire, n=78) and Silwood Park (Berkshire, 
n=14). In Lithuania, 54 samples from mice (Apodemus agrarius, A. flavicollis),  
61 samples from voles (Microtus agrestis, Microtus arvalis, Microtus oeconomus, 
Myodes glareolus) and 13 samples from shrews (Sorex araneus, Sorex minutus, 
Neomys fodiens) were obtained across 12 trapping sites (Table S4.1).  
Typically, de Man, Rogosa and Sharpe (MRS) agar supplemented with mupirocin 
(50mg/l) and L-cysteine (50mg/l) (MRSCM) has been used for Bifidobacterium 
recovery from faeces. However, previous isolation efforts in the lab using this 
medium produced a number of “false positive” results from animal samples, 
relating to the fact that different bacterial species displayed colony morphology 
similar to that of Bifidobacterium. Based on these observations and given the fact 
that only small amounts of faecal material were available from small mammals 
(~50mg), I decided to carry out isolations using an alternative medium composed of 
BHI agar supplemented with mupirocin (50mg/l), L-cysteine (50mg/l) and sodium 
iodoacetate (7.5mg/l) (please also see Chapter 5.4.1 Notes on the isolation of 
bifidobacterial species from animal gut microbiota). 
The isolation experiments resulted in the recovery of 51 Bifidobacterium strains 
from a total of 32 individuals spanning three wild mice species – A. flavicollis,  
A. sylvaticus, and A. agrarius, which corresponded to 21.9% of mouse samples 
screened, including 27.02% A. flavicollis samples, 26.31% A. sylvaticus samples and 
6.9% A. agrarius samples, respectively. No Bifidobacterium strains were isolated 
from voles or shrews. The probability of isolating Bifidobacterium varied strongly 
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across host families (Pearson’s c2(df=2) = 18.98, P < 0.001). Whole genome 
sequencing of recovered strains yielded a mean of 265-fold coverage for strains 
sequenced on HiSeq (minimum 172-fold, maximum 300-fold) and 225-fold for 
samples sequenced on MiSeq (minimum 130-fold, maximum 325-fold). One 
sequence did not assemble correctly and was removed from the dataset. The initial 
ANI analysis led to the exclusion of further 17 duplicate genomes representing 
strains from the same individuals sequenced multiple times. In total, I identified 26 
strains as a novel Bifidobacterium species, 4 strains as B. animalis and a further 3 
strains as B. pseudolongum (Table S4.1). 
Given that strains belonging to the novel species constituted the majority of all 
recovered Bifidobacterium strains and were present in individuals from both 
geographical regions, I selected one strain for characterisation as a type strain and 
proceeded with the analysis of whole genome sequences (with the plan to publish 
results in International Journal of Systematic and Evolutionary Microbiology). 
However, these efforts were stopped following a recent publication that described 
five novel bifidobacterial species (413). My subsequent ANI re-analysis indicated 
close relatedness (above 95%) between the 26 wild mice strains and the newly 
characterised type strain B. castoris 2020BT isolated from a captive beaver (Castor 
fiber), ultimately classifying them as B. castoris.  
 
4.4.2 Characterisation of strain LH_867 and comparison with type strain 
 B. castoris 2020BT 
 
Initially, prior to the publication of the description of type strain B. castoris 2020BT 
(413), ANI analysis showed that wild mice isolates, representing the putative novel 
species, displayed sequence identities below 94% to the type strain B. italicum 
Rab10AT. Based on these results, I decided to proceed with the genome analysis 
and biochemical characterisation of strain LH_867 isolated from A. sylvaticus from 
Wytham Woods, UK. In order to evaluate the phylogenetic relationship between 
strain LH_867 and other (at that time, April 2019) recognised Bifidobacterium 
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species and subspecies, I used 16S rRNA, rpoB, rpoC, groL, dnaJ, clpC, dnaB and xpf 
genes, as well as whole genome sequences.  
Following isolation, all newly recovered isolates were routinely subjected to 
molecular typing based on the partial 16S rRNA gene sequence and initially 
identified using the BLASTN algorithm with default settings against the NCBI 16S 
ribosomal RNA sequence (Bacteria and Archaea) database (334). This approach 
yielded a partial 16S rRNA gene sequence of 987 bp for LH_867, which 
subsequently showed similarity of 99.80% (over 100% sequence length) with that of 
B. choerinum Su 806 (Figure 4.1).  
 
 
Figure 4.1 Results of the BLASTN similarity search performed for the amplified partial LH_867 16S 
rRNA gene sequence against the NCBI 16S rRNA gene sequences database, showing similarity over 
99% to the 16S rRNA gene of B. choerinum Su 806. 
 
Given that experimental 16S rRNA gene amplification did not yield whole sequence 
length, the location of 16S rRNA genes was also predicted in the whole genome 
sequence of strain LH_867 as well as the genomes of type strains and extracted  
in silico. In case of Bifidobacterium simiarum TRI 7T the 16S rRNA gene sequence 
could not have been predicted, and as it is not available for download from public 
databases, this strain was excluded from the 16S rRNA gene analysis.  
Strain LH_867 showed the highest 16S rRNA gene similarity values with 
Bifidobacterium choerinum LMG 10510T with 99.41% similarity and Bifidobacterium 
italicum Rab10AT with 99.12% similarity, respectively (Table 4.1). This result was 
consistent with the maximum likelihood analysis which indicated phylogenetic 




Figure 4.2 Phylogenetic tree based on 16S rRNA gene sequences (1,496 positions) showing 
relationship of strain LH_867 to type strains of recognised 69 Bifidobacterium species. 
The tree was reconstructed using the maximum likelihood method with 1000 bootstrap iterations 
and rooted with Scardovia inopinata JCM 12537T (=DSM 10107T). Bootstrap values above 70% are 
marked on the tree branches. 
Previously, multilocus sequence analysis has been proposed as an alternative and 
robust method for identification and classification of bacterial isolates. Additionally, 
sequences for housekeeping genes rpoB, rpoC, groL, dnaJ, clpC, dnaB and xpf genes 
were in silico extracted from all annotated genomes and concatenated for the 
purpose of multilocus sequence analysis. The resulting multiple sequence 
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alignment yielded 16,588 positions and was used for the phylogenetic tree 
reconstruction employing the maximum likelihood method. Based on this analysis, 
strain LH_867 was found phylogenetically related to B. italicum Rab10AT (Figure 
4.3) 
 
Figure 4.3 Phylogenetic tree based on concatenated housekeeping gene sequences for rpoB, rpoC, 
groL, dnaJ, clpC, dnaB and xpf genes (16,588 nt) showing relationship of strain LH_867 to type strains 
of recognised 70 Bifidobacterium species.  
The tree was reconstructed using the maximum likelihood method with 1000 bootstrap iterations 
and the sequence of Scardovia inopinata JCM 12537T (=DSM 10107T) was used as an outgroup. 




Furthermore, alignment-free composition vector approach was used to reconstruct 
whole genome-based phylogeny from protein sequences with k-mer length of k=6. 
The results of this analysis were consistent with the multilocus sequence analysis 
and indicated phylogenetic relatedness of LH_867 to B. italicum Rab10AT  
(Figure 4.4 A). Additionally, ANI analysis showed that LH_867 displayed the highest 







Figure 4.4 Relatedness of LH_867 to type strains of recognised 70 Bifidobacterium species based on 
whole genome sequences.  
(A) Alignment-free whole genome sequence phylogeny constructed based on amino acid sequences 
with k-mer length of k=6. The sequence of Scardovia inopinata JCM 12537T (=DSM 10107T) was used 
as an outgroup; (B) Average Nucleotide Identity values between LH_867 and genomes of type strain 
Bifidobacterium. The diagram shows values between 70-100%, values above 95% are marked in red. 
 
Upon publication of the description of several novel Bifidobacterium species (413), 
ANI re-analysis revealed the identity value of 98.69% between the type strain  
B. castoris 2020BT and strain LH_867. Similar results were obtained for the 
 
 120 
remaining 25 wild mice isolates, subsequently resulting in their classification as 
members of this species (Table S4.1). The comparison between B. castoris 2020BT 
and LH_867 indicated strain specific differences in genomic and phenotypic 
features, including genome size, number of ORFs and tRNAs, growth conditions and 
fermentation profiles (Table 4.1 & Table 4.2). 
 
 B. castoris 2020BT LH_867 
Biological origin Castor fiber Apodemus sylvaticus 
Geographical location Italy (captive) United Kingdom (wild) 
Average coverage 195 286 
No of contigs 22 15 
Genome length 2496067 2280630 
Average GC % 65.41 65.48 
No of ORFs 2053 1840 
tRNA 55 53 
16S rRNA gene similarity 98.76% B. choerinum 99.41% B. choerinum 
ANI value 93.8% B. italicum 92.98% B. italicum 
Table 4.1 General genomic features of B. castoris 2020BT and LH_867. 
 
Optimal growth conditions of both B. castoris 2020BT and LH_867 were determined 
in MRS after incubation at different temperatures and at different pH in anaerobic 
conditions for 48 hours. B. castoris 2020BT was reported to grow at the 
temperature range between 25 to 40 oC, but not below or above these values (413). 
In contrast, data for LH_867 showed a wider growth temperature range, from 20 to 
45 oC. In terms of growth at different pH, B. castoris 2020BT was shown to grow at 
pH 5-6, however growth at higher pH values was not tested. I observed growth of 
strain LH_867 at pH ranging from 5 to 8. With regard to enzymatic activity, both 
strains are catalase and gelatinase negative. Fermentation profiles of B. castoris 
2020BT and LH_867 revealed that the strains are able to digest a wide range of 
simple and complex carbohydrates, and that their carbohydrate metabolism 
profiles are strain-specific, with recorded differences in growth on substrates 
including D-ribose, D-galactose, D-mannose, cellobiose, sucrose, raffinose and L-
fucose (Table 4.2). 
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Members of Bifidobacterium and related bacterial genera can convert 
monosaccharides resulting from the degradation of complex carbohydrates to 
intermediates of a particular hexose fermentation pathway, the ‘‘bifid shunt’’, and 
ultimately produce SCFAs, e.g. acetate, formate, and other organic compounds 
(4, 42, 48). The key enzyme in the “bifid shunt” is fructose-6-phosphate 
phosphoketolase (EC 4.1.2.2), considered a taxonomic marker for identification of 
Bifidobacteriaceae (49). The results of the prediction of the “bifid shunt” in the 
genome of strain LH_867 were in line with those reported for B. castoris 2020BT 




Characteristic B. castoris 2020BT LH_867 
Carbohydrate metabolism: 1% of substrate in mMRS  API 50 CHL 
Glycerol n/a - 
Erithritol n/a - 
D-Arabinose - - 
L-Arabinose n/a W 
D-Ribose + W 
D-Xylose W W 
L-Xylose n/a - 
D-Adonitol n/a - 
Methyl α-D-xylopyranoside n/a - 
D-Galactose + W 
D-Glucose + ? 
F-Fructose - - 
D-Mannose + - 
L-Sorbose n/a - 
L-Rhamnose - - 
Dulcitol n/a - 
Inositol n/a - 
D-Mannitol - - 
D-Sorbitol W - 
Methyl α-D-
mannopyranoside n/a - 
Methyl α-D-
glucopyranoside n/a - 
N-acetylglucosamine W - 
Amygdalin n/a - 
Arbutin n/a - 
Aesculin ferric citrate n/a - 
Salicin n/a - 
Cellobiose + - 
Maltose n/a ? 
 
 122 
Lactose (bovine origin) n/a ? 
Melibiose W W 
Sucrose + W 
Trehalose W - 
Inulin W - 
Melezitose n/a - 
Raffinose + W 
Starch W W 
Glycogen n/a W 
Xylitol n/a - 
Gentiobiose n/a W 
Turanose n/a - 
D-Lyxose n/a - 
D-Tagatose n/a - 
D-Fucose n/a - 
L-Fucose W - 
D-Arabitol n/a - 
L-Arabitol n/a - 
Potassium gluconate n/a - 
Potassium 2-ketogluconate n/a - 
Potassium 5-ketogluconate n/a W 
   
Enzymatic activities:   
Catalase - - 
Oxidase n/a - 
Haemolysis n/a - 
Gelatinase - - 
   
Temperature for growth (°C) 
range 
25-40 oC 20-45 oC 
pH for growth range 5-6 (tested up to pH 6) 5-8 (tested up to pH 8) 
DNA G+C% content 65.41 mol% (in silico 
prediction) 
65.0 mol% 
Peptidoglycan type n/a L-Lys(L-Orn)-L-Ala(L-Ser)-L-Ala2 
   
Table 4.2 Differential phenotypic characteristics of type strain B. castoris 2020BT and LH_867.  
Values for B. castoris 2020BT adapted from Duranti et al. (2019) (413).  
 
The estimation of G+C% content of LH_867 DNA was performed by the DSMZ 
Identification Service, Braunschweig, Germany using the Agilent 1260 Infinity II 
HPLC system. Strain LH_867 had a DNA G+C% content of 65.0 mol%. This value is 
similar to that reported for strain B. castoris 2020BT (in silico prediction) and within 
the range reported for the genus Bifidobacterium: 52–67 mol% (1). 
The peptidoglycan composition of strain LH_867 was examined by the DSMZ 
according to protocol used in Schumann, 2011 (414). The total hydrolysate (4N HCl, 
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16h, 100 °C) of the peptidoglycan contained muramic acid (Mur) and the amino 
acids alanine (Ala), serine (Ser), ornithine (Orn), lysine (Lys) and glutamic acid (Glu) 
in the following molar ratio: 3.4 Ala, 0.3 Ser, 0.2 Orn, 0.7 Lys, 1.0 Glu and 1.7 Mur. 
Enantiomeric analysis of the peptidoglycan amino acids revealed the presence of  
D-Ala and L-Ala in a ratio of 1:3.9. The partial hydrolysate (4N HCl, 0.75h, 100°C) of 
the peptidoglycan contained (in addition to the amino acids) the peptides Lys-Ala, 
Lys-(Ala)2 (3 isomers), Lys-(Ala)3 (4 isomers), Orn-Ser, Lys-(Ala)4, Lys-(Ala)4-Lys,  
M-Ala, Ala-Glu. Based on these results, it was concluded that strain LH_867 
represents the peptidoglycan type A3α L-Lys(L-Orn)-L-Ala(L-Ser)-L-Ala2 (type A11.21 
according to www.peptidoglycan-types.info). The peptidoglycan composition of 
strain B. castoris 2020BT was not reported. 
 
4.4.3 Genomic characterisation of B. castoris taxon 
 
Following the classification of the mice strains as B. castoris, I performed genomic 
re-analysis of the entire dataset with strain B. castoris 2020BT included as reference 
(Table S4.1). The assembled draft genome sizes for the mouse-associated B. 
castoris isolates ranged from 2.27 Mb to 2.39 MB, possessing an average G+C% 
content of 65.53% and a number of contigs ranging from 9 to 56. The number of 
predicted ORFs in each genome ranged from 1,832 to 1,980. Genome sizes and 
gene numbers were therefore lower in comparison to the type strain B. castoris 
2020BT, whose genome size is 2.50 Mb, with 2,053 ORFs and an average G+C% 
content of 65.41% (Table 4.1) (413). The sizes of draft genomes for B. animalis and 
B. pseudolongum ranged from 2.15 Mb to 2.19 Mb (1,808 to 1,849 ORFs) and 2.03 
Mb to 2.06 Mb (1,705 to 1,725 ORFs), respectively. B. animalis strains had an 
average G+C% content of 60.00%, while this value was at 63.34% for B. 
pseudolongum. These findings are in line with previous reports for members of 
these species isolated from rodents (292, 293). 
In terms of Bifidobacterium distribution across the host species, A. sylvaticus (n= 19, 
UK) was found to harbour B. castoris and B. animalis strains. A. flavicollis in the UK 
(n=2) only harboured B. animalis strains, whereas the same host species in 
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Lithuania (n=8) harboured both B. castoris and B. pseudolongum strains. A. agrarius 
(n=2, Lithuania) was found to only harbour B. castoris strains. With strains 
displaying ANI value above 99.9% considered identical (309), 5 B. castoris and  
2 B. animalis strains were identified in A. sylvaticus population, 5 B. castoris,  
2 B. animalis and 3 B. pseudolongum strains were found in A. flavicollis, while  
2 B. castoris strains were present in A. agrarius. On average, I recovered one 
unduplicated Bifidobacterium strain per individual, except for one A. sylvaticus 
individual from Wytham (X0418EBC072), who was found to have harboured both  
B. castoris and B. animalis.  
Interestingly, all newly isolated strains belonged to the previously established  
B. pseudolongum phylogenetic group (286). Recent taxonomic analyses of genus 
Bifidobacterium indicated that this phylogenetic group was the most diverse in 
terms of ecological niches represented by host species, and encompassed strains 
isolated from animals such as chickens, geese, dogs, oxen, pigs, rabbits, hamsters 
and rats (286). Since the relatedness of organisms can effectively be predicted 
based on their shared gene content (415, 416), I constructed a maximum-likelihood 
phylogenetic tree using single copy core genes to assess relationships between the 
wild mice strains and the representative members of the B. pseudolongum group 
(n=112), with particular interest in strains isolated from rodents (Figure 4.5). 
Despite a limited number of rodent-associated Bifidobacterium genomes available 
for this analysis (n=18), the results show that while there is some clustering of 
strains according to the host phylogeny, this is far from perfect. For example, while 
B. animalis strains isolated from mice tend to cluster separately from those from 
rats, the type strain of B. castoris from a beaver falls in the middle of a clade 
otherwise comprised entirely of mouse-isolated strains. This observation is in line 
with previous analysis of animal-associated B. pseudolongum strains, which 
indicated that different animal hosts may harbour specific clusters of members of 





Figure 4.5 Cladogram of Bifidobacterium pseudolongum phylogenetic group, including 112 publicly 
available representative strains and the 33 strains recovered in this study.  
Maximum likelihood phylogeny was based on single copy core genes, employing the ‘WAG’ general 
matrix model with 1000 bootstrap iterations. Bootstrap values above 70% are displayed on tree 
branches. Strains isolated from rodent hosts are marked with coloured background. Coloured 
symbols on the branches depict respective host species (square) and trapping sites (circle) for strains 
recovered in this study. 
 
Since B. castoris constituted 78% of all recovered Bifidobacterium strains recovered 
in this study and this species is the least well-characterised, I focused further 
analyses on this species. The pangenomic analysis of 27 strains of B. castoris  
(Figure 4.6) revealed a total of 2,897 gene clusters. Based on the distribution of 
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gene clusters in the pan-genome, I identified 1,412 gene clusters that constituted 
the core genome shared by all strains (48.7% of all clusters), while 438 clusters 
(15.1% of all clusters) were unique genes (Table S4.4). Using protein sequences for 
single copy genes of the pan-genome, I constructed a B. castoris phylogeny based 
on maximum likelihood estimation (Figure 4.6 and Figure 4.7 A). 
 
Figure 4.6 Pan-genomic analysis of 27 genomes of B. castoris.  
The results revealed 1,412 (48.7% of all clusters) core gene clusters, and 438 (15.1%) strain-specific 
unique gene clusters among 2,897 total gene clusters. The heatmap represents average nucleotide 
identities between genomes (ANI > 95%). 
 
Examination of the B. castoris phylogenetic tree (Figure 4.7 A), indicated the 
presence of three major mouse-associated B. castoris clusters. One cluster is more 
distant from the other two and contains strains from both A. sylvaticus and A. 
flavicollis. The second cluster seems to be A. sylvaticus-specific and appear to 
contain 2 main strains, while the third main cluster contains strains isolated from all 
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three Apodemus species, including one A. sylvaticus-specific subclade, and another 




Figure 4.7 Phylogeny of 27 Bifidobacterium castoris strains (A) and their rodent hosts (B).  
Maximum likelihood trees were constructed using single copy core genes employing WAG model and 
1000 bootstrap iterations for B. castoris and concatenated 12S rRNA and partial cytochrome b genes 
employing ‘GTR’ model with 1000 bootstrap iterations for host species. Bootstrap values above 70% 
are displayed on tree branches. 
 
Overall, these observations are not consistent with a strong pattern of co-
speciation. Therefore, I sought to test for co-phylogenetic signal between the host 
and Bifidobacterium by performing a topology-based comparison (329). The host 
tree was constructed using concatenated sequences for part of the cytochrome b 
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(cytb) gene and the mitochondrial 12S rRNA gene (Figure 4.7 B) (417). Co-phylogeny 
was first tested using the global ParaFit statistic (H0: the hosts and B. castoris have 
independent phylogenetic structure). The result (permutational P = 0.3588 after 
9999 permutations) was not significant, falling to reject the null hypothesis, 
providing no evidence that the phylogeny of B. castoris and its hosts are correlated. 
Further test of individual host-Bifidobacterium associations did not reveal any 




Table 4.3 Results of co-phylogenetic analysis using the ParaFit statistic with 9999 permutations. 
 
Next, I sought to determine how many different strains circulate in each host 
population and country. Average identity value for the two strains isolated from  
Global test:  ParaFitGlobal = 8.835461e-05 , p-value = 0.3588 (9999 permutations) 
 
Test of individual links ( 9999 permutations) 
Link Host B. castoris  strain F1 stat F1 p-value F2 stat F2 p-value
[26,] A. agrarius LH_967 2.66E-05 0.3085 9.07E-03 0.3081
[27,] A. agrarius LH_971 2.66E-05 0.3054 9.08E-03 0.3051
[21,] A. flavicollis LH_980 -6.22E-07 0.7777 -2.12E-04 0.7777
[22,] A. flavicollis LH_976 -1.76E-05 0.8014 -5.99E-03 0.8032
[23,] A. flavicollis LH_973 -1.52E-05 0.7789 -5.17E-03 0.7811
[24,] A. flavicollis LH_977 -2.70E-08 0.5797 -9.20E-06 0.5797
[25,] A. flavicollis LH_979 7.89E-09 0.5611 2.69E-06 0.5611
[10,] A. sylvaticus LH_946 6.99E-06 0.2167 2.38E-03 0.2168
[11,] A. sylvaticus LH_949 6.99E-06 0.2119 2.38E-03 0.2127
[12,] A. sylvaticus LH_961 6.99E-06 0.2195 2.38E-03 0.2193
[13,] A. sylvaticus LH_956 6.99E-06 0.2128 2.38E-03 0.2128
[14,] A. sylvaticus LH_951 6.99E-06 0.2175 2.38E-03 0.2168
[15,] A. sylvaticus LH_874 7.00E-06 0.2117 2.39E-03 0.2115
[16,] A. sylvaticus LH_912 6.99E-06 0.2173 2.38E-03 0.2177
[17,] A. sylvaticus LH_917 7.21E-06 0.2087 2.46E-03 0.2092
[18,] A. sylvaticus LH_921 7.21E-06 0.2158 2.46E-03 0.2157
[19,] A. sylvaticus LH_955 3.41E-06 0.4103 1.16E-03 0.4083
[2,] A. sylvaticus LH_775 1.14E-06 0.4466 3.90E-04 0.4461
[20,] A. sylvaticus LH_964 3.41E-06 0.4081 1.16E-03 0.4067
[3,] A. sylvaticus LH_799 1.14E-06 0.4403 3.90E-04 0.4386
[4,] A. sylvaticus LH_950 -3.04E-06 0.839 -1.04E-03 0.8392
[5,] A. sylvaticus LH_805 6.00E-06 0.279 2.04E-03 0.2777
[6,] A. sylvaticus LH_867 6.98E-06 0.2161 2.38E-03 0.2169
[7,] A. sylvaticus LH_872 6.99E-06 0.2179 2.38E-03 0.2188
[8,] A. sylvaticus LH_876 6.98E-06 0.218 2.38E-03 0.2175
[9,] A. sylvaticus LH_911 6.99E-06 0.2135 2.38E-03 0.2135
[1,] B. castoris B_castoris_2020B 2.75E-06 0.3883 9.36E-04 0.3854
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A. agrarius trapped at two different sites in Lithuania (LH_967 and LH_971) was 
99.88% (Table S4.5). Overall, strains isolated from A. flavicollis had the broadest 
identity value range (97.07±0.01% mean±sd), suggesting that they are less closely 
related to each other than strains isolated from A. agrarius, as well as A. sylvaticus 
in the UK (99.11±0.01%, mean±sd). Based on identity values between individual 
isolates in the latter population, and with the majority of strains at Wytham being 
identical (ANI values > 99.99%, it appears that a total of 5 B. castoris strains 
circulate across the two UK sites: two strains at Silwood, and three at Wytham (with 
one strain being more common than the others).  
 
4.4.4 Glycobiome of B. castoris  
 
To determine functional differences between B. castoris strains, I next assigned 
functional categories to ORFs of each genome. This analysis reflected the 
saccharolytic lifestyle of this species, with carbohydrate transport and metabolism 
identified as second most abundant COG category (after unknown function) 
constituting 9.98% of its pan-genome (Table S4.6). This value is slightly higher 
compared to previous findings for the pan-genome of the animal-associated B. 
pseudolongum taxon (9%) and within the range reported for other bifidobacteria 
(162, 293). Members of Bifidobacterium have been shown to synthesize and digest 
a wide range of carbohydrates through an extensive arsenal of carbohydrate-active 
enzymes (CAZymes)(42, 258). I thus sought to investigate the genetic repertoire 
predicted to be involved in carbohydrate metabolism and biosynthesis in B. 
castoris. In silico analyses performed using dbCAN2 identified three classes of 
enzymes, namely glycoside hydrolases (GHs), glycoside transferases (GTs) and 
carbohydrate esterases (CEs), as well as enzyme-associated carbohydrate-binding 
modules (CBMs) (Figure 4.8 & Table S4.7). On average, B. castoris genomes 
harboured 87.52±3.15 CAZymes. Previous reports on CAZyme abundances in strains 
isolated from different hosts and environments showed that, on average, 
Bifidobacterium isolated from rodents had less than 50 CAZyme genes in their 
genomes, a number comparable with strains isolated from dairy and wastewater 
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(31). Interestingly, the abundance of CAZymes similar to that of B. castoris was 
reported for strains isolated from non-human primates (84±10 CAZymes) (31). 
Glycosyl hydrolases are key enzymes in carbohydrate metabolism that catalyse the 
hydrolysis of glycosidic bonds between two or more carbohydrates or between a 
carbohydrate and non-carbohydrate moiety (418). I identified a total of 25 different 
GH families in B. castoris strains containing an average of 50.48±1.99 GH genes per 
genome (2.67%±0.16 of ORFs and 57.68±0.01% of predicted glycobiome). The 
predominant GH family, with 15.15±1.29 GH genes per genome (mean±sd), was 
GH13, whose members include enzymes acting on a very wide range of 
carbohydrates containing a-glucoside linkages, e.g. starches and related substrates, 
trehalose, raffinose, stachyose and melibiose (38, 42, 419). This was followed by 
families GH31 (a diverse group of enzymes with α-glucosidase and α-xylosidase 
activities) and GH36 (enzymes metabolising α-galacto-oligosaccharides present in 
various plants, i.e. melibiose, raffinose, stachyose) (420, 421), with 3.63±0.68 and 
3.18±0.39 GH genes per genome, respectively.  
Strain-specific predictions of GH repertoires in B. castoris seem to mostly support 
previous observations on strains circulating in Apodemus populations. In contrast 
with the majority of strains isolated from A. sylvaticus in the UK, strains from A. 
flavicollis in Lithuania displayed individual differences in GH profiles, with a subset 
harbouring genes predicted to encode members of GH46 containing chitosanases 
acting on chitin-derived substrates (i.e. mushrooms, fungi and insects), and GH127 
encompassing enzymes with b-L-arabinofuranosidase activity (Figure 4.8 & Table 
S4.7) (422, 423). In the UK, 13 out of 16 isolates from A. sylvaticus from Wytham 
appeared to have identical numbers of genes belonging to specific GH families, 
while the remaining 3 isolates displayed different GH profiles. These results support 
previous findings that there appear to be 4 strains circulating in the A. sylvaticus 
population at this location. However, I did not observe this consistency with isolates 
from A. sylvaticus from Silwood. The two isolates which showed ANI value of 
99.99% (LH_775 and LH_799) displayed differences in the number of predicted 
GH13 genes (14 vs 16), with identical values for the other identified GH families. 
This result may possibly be explained by the gene calling process during the 
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annotation of draft assemblies and the resulting differences in the number of 
predicted ORFs (1,942 for LH_775 vs 1,933 for LH_799, Table_S4.1).  
 
 
Figure 4.8 Glycosyl hydrolase (GH) family gain-loss events in B. castoris and the type strains 
representative of the B. pseudolongum phylogenetic group (A), and the abundance of carbohydrate-
active enzymes (CAZymes) in B. castoris (B) .  
(A) Maximum likelihood phylogeny reconstruction was based on single copy core genes of the B. 
castoris pan-genome, employing the ‘WAG’ general matrix model with 1000 bootstrap iterations. 
Dollo parsimony was used to predict GH family gain-loss events. 
(B) The coloured strips represent isolation period geographical locations and host species, 
respectively. The bar plot shows proportional representation of four CAZyme classes constituting 
the predicted B. castoris glycobiome. The two heatmaps present abundances of genes predicted 
to belong to specific glycosyl hydrolase (GH) and glycosyl transferase (GT) families. 
 
Glycosyl transferase class of enzymes catalyse the formation of glycosides involved 
in the biosynthesis of oligosaccharides, polysaccharides and glycoconjugates (424) 
and have previously been associated with production of exopolysaccharide (EPS) in 
different bacterial species (425). A total of 8 GT families were predicted in the  
B. castoris genomes, with 18.70±1.61 GT genes on average (21.41±0.02% of 
predicted glycobiome). GT2 family was predominant in all analysed strains, with an 
average of 8.15±0.53 GT genes per genome. Carbohydrate esterases, whose 
function is to release acyl or alkyl groups attached by ester linkage to carbohydrates 
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(426), and carbohydrate-binding modules, which have no hydrolytic activity, but 
bind to carbohydrate ligands and enhance the catalytic efficiency of carbohydrate 
active enzymes (426), constituted 10.66±0.01% and 10.24±0.02% of predicted 
glycobiome, with 9.33±1.00 and 9.00±1.75 genes per genome, respectively  
(Figure 4.8 & Table S4.7). Overall, these findings highlight a predominance of genes 
encoding GH families predicted to be responsible for the breakdown of plant-
derived polysaccharides in the genomes of B. castoris species. 
 
4.4.5 Glycosyl hydrolase gene gain and loss in B. castoris 
 
Given the differences in glycosyl hydrolase repertoires among B. castoris strains, I 
next investigated the acquisition and loss of GH families within this species based 
on the predictions from dbCAN2 (Figure 4.8). Results suggest that during the course 
of evolution B. castoris, as well as its closest relative B. italicum, acquired three GH 
families (GH20, GH33 and GH95). These three families contain enzymes previously 
associated with degradation of host-derived carbohydrates in human-associated 
Bifidobacterium: lacto-N-biosidases, exo-sialidases and α-L-fucosidases, reported to 
be involved in metabolism of specific oligosaccharides, including HMOs present in 
maternal breast milk and intestinal glycoconjugates (63, 158, 379, 380). 
Furthermore, B. castoris alone, appears to have acquired GH49 family, which 
contains dextranases acting on dextran and pullulan (427). Within the B. castoris 
taxon, strain adaptation to the wild murine gut environment (as opposed to the 
beaver) appears to be driven by gene loss rather than gene gain events. The 
majority of strains isolated from hosts across all trapping sites appear to be lacking 
families GH51 and GH127, which predominantly contain a- and b-L-
arabinofuranosidases that hydrolyse the glycosidic bond between 
L-arabinofuranoside side chains of hemicelluloses such as arabinoxylan, 
arabinogalactan, and L-arabinan (423, 428). The exception are 4 strains isolated 
from A. agrarius and A. flavicollis from site1 and site2 in Lithuania, 3 out of which 
appear to additionally have acquired GH46 chitosanases and lost GH20, GH33 and 
GH95. Overall, these observations shed light on potential evolutionary adaptations 
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of B. castoris strains to the host diet, however with only one non-mouse strain 
available for the analysis, the results are very speculative. 
4.4.6 Identification of eps genes in B. castoris 
 
Given the prediction of glycosyl transferase genes in the B. castoris glycobiome, I 
next examined the collection of genomes for the presence of genes potentially 
involved in exopolysaccharide (EPS) biosynthesis, as previous studies have indicated 
that EPS may support gut colonisation and stimulate host immune responses (398). 
Recently, relatively conserved genomic regions predicted to contain genes involved 
in EPS production have been identified in Bifidobacterium type strains, including 
members of B. pseudolongum phylogenetic group (gene clusters eps3 and eps4). 
For this search, I selected amino acid sequences of eps gene clusters from  
B. animalis subsp. lactis Bl12 (eps3: Bl12_1287 – Bl12_1328) and B. pseudolongum 
subsp. globosum LMG 11569T (eps4: BPSG_1548 – BPSG_1565) as references (398). 
This analysis identified homologues of several conserved eps-key genes in  
B. castoris genomes (Figure 4.9 & Table S4.7). All analysed strains had homologues 
of the eps3 cluster gene predicted to encode the priming glycosyl transferase 
(pGTF), which catalyses the first step in EPS biosynthesis. Moreover, I identified 
genes predicted to encode enzymes involved in rhamnose biosynthesis, showing 
high amino acid identity (over 80% in all cases) with glucose-1-phosphate 
thymidylyltransferase, dTDP-4-dehydrorhamnose 3,5-epimerase and dTDP-glucose 
4,6-dehydratase from B. animalis subsp. lactis Bl12 in the collection of strains. The 
presence of rare carbohydrates in the EPS, including rhamnose and fucose, have 
been associated with additional biological properties of these polymers, including 
differential modulation of the immune system (429, 430). 
Transport of the formed EPS-unit across the cytoplasmic membrane has previously 
been suggested to be carried out by either an ABC-type transporter or by a 
“flippase”-like protein (425). All analysed B. castoris genomes harboured 
homologues of an ABC-type transporter and I identified “flippase”-like transport 






Figure 4.9 Identification of homologues of eps-key genes in B. castoris.  
Sequences of B. animalis subsp. lactis Bl12 (accession number CP004053.1, eps3: Bl12_1287 – 
Bl12_1328) and B. pseudolongum subsp. globosum LMG 11569T (accession number JGZG01000015.1, 




Similarly, I identified homologues of conserved genes from B. pseudolongum subsp. 
globosum LMG 11569T eps4 cluster in my collection of genomes, including glycosyl 
transferases and ABC-type transporters (Figure 4.9 & Table S4.7). These results 
confirm that B. castoris strains harbour putative eps-key genes and suggest 
potential ability for this species to produce EPS. 
 
4.4.7 Horizontal gene transfer in B. castoris 
 
Given the identification of putative eps-key genes in the collection of genomes, and 
that potential horizontal transfer of eps clusters in Bifidobacterium has previously 
been suggested, I next sought to determine the role horizontal gene transfer (HGT) 
has played in the evolution of B. castoris strains. For this purpose, I used the  
SIGI-HMM tool implemented in the software IslandViewer4. This analysis revealed 
that on average, 3.14±0.50 % of ORFs in B. castoris genomes were predicted to be 
horizontally acquired (range 31 to 74 genes per genome) (Figure 4.10 &Table S4.8). 
The highest proportion of horizontally acquired genes in each genome were those 
of unknown function (1.20±0.20% of ORFs and 38.46±4.36% of the predicted 
acquired genes on average), followed by genes involved in replication, 
recombination and repair (averaging 0.60±0.15% of ORFs and 19.25±4.43% of 
predicted acquired genes). This group, among others, encompassed genes 
associated with Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR). Further analysis of the HGT predictions revealed that genes involved in 
the cell wall/membrane/envelope biosynthesis constituted 11.35±4.35% of all 
predicted acquired genes per genome. This group contained genes neighbouring 
those identified by the BLAST+ analysis as putative eps genes, suggesting they might 





Figure 4.10 Functional classification of proteins predicted to be horizontally acquired by B. castoris 
strains based on COG categories.  
Summary of predicted COG categories:[C] Energy production and conversion; [D] Cell cycle control, 
cell division, chromosome partitioning; [E] Amino acid transport and metabolism; [F] Nucleotide 
transport and metabolism; [G] Carbohydrate transport and metabolism; [I] Lipid transport and 
metabolism; [J] Translation, ribosomal structure and biogenesis; [K] Transcription; [L] Replication, 
recombination and repair; [M] Cell wall/membrane/envelope biogenesis; [O] Post-translational 
modification, protein turnover, and chaperones; [P] Inorganic ion transport and metabolism; 
[S] Function unknown; [T] Signal transduction mechanisms; [U] Intracellular trafficking, secretion, 
and vesicular transport; [V] Defence mechanisms. 
 
Moreover, genes identified as involved in carbohydrate transport and metabolism 
constituted on average 3.34±2.10% of all predicted HGT genes per genome. Further 
analysis of the results for this group revealed that 6 strains isolated from across all 
locations (all strains from Silwood Park, one strain from Wytham Woods (LH_950) 
and two strains from Lithuania (LH_973 and LH_980)) might have acquired a GH43 
family member annotated as α-L-arabinofuranosidase through an HGT event. 
Additionally, strains LH_955 and LH_964 from Wytham Woods, as well as strains 
LH_973 and LH_979 from Lithuania were predicted to horizontally acquire a GH36 
family a-galactosidase (Table S4.8). Overall, these results suggest that HGT may 
have contributed to the evolution of B. castoris strains and their glycobiome, 
however experimental validation through carbohydrate metabolism experiments 
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and enzyme characterisation would be essential to confirm the functional 
importance of these events. 
 
4.4.8 CRISPR-Cas systems of B. castoris 
 
Given the predicted acquisition of CRISPR-associated genes through HGT events, I 
next sought to investigate the occurrence and diversity of CRISPR-Cas systems in  
B. castoris genomes. Their presence or absence was determined using 
CRISPRCasFinder based on the database of known Cas protein sequences and 
models of CRISPR-Cas systems architecture. These systems are heritable adaptive 
immune mechanisms in bacteria and archaea, which originate through selection 
and integration of foreign nucleic acids into the genome in the form of CRISPR 
arrays to provide memory of infection (431). 
Initially, I examined the occurrence of a universal core protein Cas1, required for 
spacer acquisition and characteristic of the CRISPR-Cas systems subtypes (432). 
Eighty five percent of B. castoris isolates contained cas1 genes in their genome. This 
proportion was higher than previously estimated for bacteria (46%) (433), genus 
Bifidobacterium (up to 77%) (434), and specific Bifidobacterium species, namely  
B. longum (38%) (435) and B. pseudocatenulatum (62%) (436). A total of 4 isolates, 
three from Silwood Park and one from Lithuania, were found to encode two cas1 
genes in different regions of their genomes, suggesting the presence of two CRISPR 
loci (Table 4.4). This feature has previously been reported for other strains of 
Bifidobacterium, e.g. B. dentium LMG 11045 (434), B. longum 1-6B, 2-2B, 44B and  







Table 4.4 CRISPR-Cas systems in Bifidobacterium castoris isolates.  
Isolates harbouring complete CRISPR-Cas systems are marked in grey. Nucleotide polymorphisms 
between repeats in complete subtype I-E systems are marked in red. 
 
Overall, 27 CRISPR loci were predicted in 23 B. castoris isolates. The designation of 
predicted loci into CRISPR subtypes was performed based on the system 
architecture and presence of signature cas genes - cas3 characteristic of Type I 
systems and cas9 distinctive of Type II systems. This approach resulted in the 
classification of 23 loci as Type I-E system and 4 loci as Type II-C system. Previous 
examinations of CRISPR-Cas systems in B. longum and B. pseudocatenulatum 
showed higher diversity of Type I subtypes in these species: in both cases subtypes 
I-C, I-E and I-U were identified, with subtype I-C being the most prevalent (435, 
436). With regard to Type II systems, the presence of subtypes II-A, II-B, and II-C 
was previously reported for Bifidobacterium (434), however neither subtype II-A 
nor II-B were predicted in B. castoris. Phylogenetic analysis based on the amino acid 
sequence of the Cas1 protein further supported these results and showed the 
divergence of the two different CRISPR subtypes grouped in two distinct branches 
(Figure 4.11).  
Strain Geographical origin Type-subtype Repeat sequence Repeat length No of repeats cas1 cas3 cas9
B_castoris_2020B Italy No cas
LH_775 1st locus Silwood Park I-E GTGTTCCCCGCAAGTGCGGGGATGATCCC 29 51 Y
LH_775 2nd locus Silwood Park II-C CAAGTCTATCAGGAAGGGAAGAAGCTAATTTCCAGC 36 18 Y Y
LH_799 1st locus Silwood Park I-E GTGTTCCCCGCAAGTGCGGGGATGATCCC 29 51 Y
LH_799 2nd locus Silwood Park II-C CAAGTCTATCAGGAAGGGAAGAAGCTAATTTCCAGC 36 22 Y Y
LH_805 1st locus Silwood Park I-E GTGTTCCCCGCAAGTGCGGGGATGATCCC 29 37 Y Y
LH_805 2nd locus Silwood Park II-C CAAGTCTATCAGGAAGGGAAGAAGCTAATTTCCAGC 36 13 Y Y
LH_867 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_872 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_874 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_876 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_911 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_912 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_917 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_921 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_946 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_949 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_950 Wytham Woods No cas
LH_951 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_955 Wytham Woods I-E GTGCTCCCCGCAAGCGCGGGGATGATCCC 29 98 Y Y
LH_956 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_961 Wytham Woods I-E CGGATCATCCCCGCGTGTGCGGGGCAAAC 29 16 Y Y
LH_964 Wytham Woods I-E GTGCTCCCCGCAAGCGCGGGGATGATCCC 29 98 Y Y
LH_967 Lithuania I-E GTCTGCCCCGCACACGCGGGGATGATCCG 29 45 Y Y
LH_971 1st locus Lithuania I-E GTCTGCCCCGCACACGCGGGGATGATCCG 29 47 Y Y
LH_971 2nd locus Lithuania II-C CAAGTCTATCAGGAAGGGAAGAAGCTAATTTCCAGC 36 24 Y Y
LH_973 Lithuania I-E GTCTGCCCCGCACACGCGGGGATGATCCG 29 83 Y Y
LH_976 Lithuania I-E GTCTGCCCCGCACACGCGGGGATGATCCG 29 51 Y Y
LH_977 Lithuania I-E GTGCTCCCCGCAAGCGCGGGGATGATCCC 29 61 Y Y
LH_979 Lithuania No cas
LH_980 Lithuania No cas
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Figure 4.11 Phylogenetic tree based on the amino acid sequences of Cas1 protein in B. castoris.  
The tree was reconstructed using the maximum likelihood method (WAG model) with 1000 bootstrap 
iterations. Bootstrap values above 70 are marked on the nodes. 
 
The 27 CRISPR loci detected in B. castoris isolates were next annotated with the 
purpose to assess their architecture (Figure 4.12). Only three strains harboured 
complete CRISPR-Cas systems, with strains LH_955 and LH_977 possessing subtype 
I-E, and strain LH_971 harbouring both subtype I-E and subtype II-C. With regard to 
subtype I-E, the majority of isolates (n=18) were missing cas2 gene from the system 
architecture. The product of this gene, the Cas2 protein, cooperates with Cas1 in 





Figure 4.12 Schematic representation of CRISPR-Cas systems in B. castoris isolates. 
CRISPR repeats are represented as black lines on the right side of each locus (spacers are not 
represented). 
 
Furthermore, 2 isolates lacked the flag subtype I-E cas3 gene and only harboured a 
partial effector complex which was missing cas7 gene. Despite the absence of the 
signature cas3 gene from these CRISPR loci, they were correctly assigned to their 
respective system based on other distinct proteins, namely Cas1. Out of the 4 
isolates predicted to additionally possess the subtype II-C system, three showed an 
incomplete subtype architecture missing the cas2 gene. The presence of these 
incomplete CRISPR loci in B. castoris genomes might result either from genetic 
reorganization, the loss of activity toward the acquisition of the other CRISPR loci, 
or incomplete genome assemblies (435). In terms of the size of CRISPR-Cas loci, the 
length of complete subtype I-E systems ranged from 12 to over 15Kb due to their 
multi-gene architecture and high number of repeats (47-98), while the subtype II-C 
was shorter and encompassed lower number of accessory cas genes and repeats 
(24) (Figure 4.12). Consistent with previous reports (435), the length of the repeats 
was 29 for subtype I-E and 36 for subtype II-C. The consensus repeat sequence for 
complete I-E subtype in strain LH_971 showed 6 nucleotide polymorphisms in 
comparison to repeats from strains LH_955 and LH_977 (Table 4.4).  
The CRISPR-spacer content (Figure 4.13) showed diversity across isolates consistent 
with the results of phylogenomic analysis (Figure 4.8) and phylogenetic 
investigation of the Cas1 protein (Figure 4.11) and provided additional support for 







Figure 4.13 Comparison of CRISPR spacers in B. castoris.  
Squares represent spacers and each unique spacer sequence is marked with unique colour and 
geometric figure. The last spacer acquired is represented on the left side while the first spacer is on 
the right side. The isolates possessing the complete CRISPR-Cas systems are marked in red. 
 
4.4.9 Association between CPISPR-Cas and prophages in B. castoris  
 
Given that spacers in CRISPR arrays originate from invading foreign elements, e.g. 
bacteriophages or invasive plasmids, I next sought to identify putative prophages in 
B. castoris genomes using VirSorter. This software detects viral sequences that are 
integrated into the bacterial chromosome (categories 4 to 6), as well as lytic and 
lysogenic prophages existing as an extrachromosomal plasmid (categories 1 to 3). 
Categories 1 and 4 contain the most confident predictions, while those belonging to 
categories 3 and 6 are the least certain (436). Here, I defined categories 1, 2, 4, and 
5 as “high-confidence” and only retained predictions belonging to these categories 
for analysis. Additionally, I decided to refer to prophage sequences belonging to 
categories 1 and 2 as “unintegrated” and categories 4 and 5 as “integrated”.  
The results of this analysis predicted the presence of a total of 33 viral regions in 23 
out of 27 analysed isolates (Figure 4.14 & Table S4.9). Seven category 2 
“unintegrated” predictions and 26 category 5 “integrated” predictions, with no 
predictions belonging to the highest confidence level categories (category 1 
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“unintegrated” and category 4 “integrated”) were made in B. castoris isolates. 
Interestingly, this approach did not identify prophages in the four Lithuanian strains 
from site1 and site2 forming the distinct phylogenetic cluster in the B. castoris 
phylogenetic tree (LH_967, LH_971, LH_973 and LH_976) (Figure 4.7 A), which all 
harboured CRISPR-Cas loci. This observation suggested that the defence systems in 
these strains may be functional. This result may also be explained by the fact that 
only viral predictions classified into the “high-confidence” prediction categories in 
VirSorter were retained. 
The size of predicted prophage sequences ranged from 16.6 to 121.3 Kb, with G+C% 
content between 59.42% and 67.43%. Previous findings on Bifidobacterium-
associated prophages reported prophage sizes up to 60 Kb, with similar G+C% 
content (436, 437). Eight isolates (34.8%) had more than one prophage associated 
with their genome. The BLASTN comparison between predicted viral signals, with 
that of LH_799 prophage 1 (the longest identified) selected as “reference”  
(Figure 4.14A), indicated diversity among B. castoris prophages. To better 
understand their evolutionary trajectory, I constructed phylogenetic trees using 
whole predicted sequences, as well as the sequence for phage signature portal 
protein, which was identified in all prophages. In addition to the B. castoris 
prophages, whole genome sequences of two Bifidobacterium-associated phages 
Bbif-1 (GCA_002633625.1) and PMBT6 (GCA_006529735.1) were included in this 





Figure 4.14 Identification of viral signal in B. castoris (A) and phylogenetic trees of B. castoris 
prophage elements built based on whole genome sequences (left) and portal protein (right) (B).  
(A) The representation of all identified sequences belonged to VirSorter categories 2 or 5, which 
encompass sequences divergent from references and partial sequences lacking viral hallmark genes 
which may include defective prophage, respectively. The map represents BLASTN comparisons of 
viral regions predicted for B. castoris genomes to that of an unintegrated LH_799 prophage_1. (B) 
Phylogenetic trees were reconstructed using the maximum likelihood method with 1000 bootstrap 
iterations, employing ‘GTR’ and ‘WAG’ models for whole genome sequences and portal protein, 







Examination of the phylogenetic tree based on whole genome sequences indicated 
the presence of three main prophage clusters, while this distinction was not as 
clear in the topology of the tree built using the portal protein. However, there were 
similarities in the clustering of prophages between the two trees that were also 
consistent with previous findings resulting from phylogenomic analyses of the  
B. castoris taxon. Sequences of strains LH_775 and LH_779 from A. sylvaticus from 
Silwood Park, LH_977 and LH_979 from A. flavicollis from Lithuania, LH_955 and 
LH_964 from A. sylvaticus from Wytham Woods clustered together, indicating their 
close relatedness. Similarly, the clustering of the 13 prophage sequences from  
B. castoris isolates from A. sylvaticus from Wytham was consistent across the 
constructed phylogenies, supporting the previous observation on high prevalence 
of one particular strain in this population. 
Based on the output from VirSorter, a total of 2,105 ORFs were identified in the 33 
prophage sequences (Table S4.10). Out of those, the function for 1,359 (64.6%) 
could not be predicted (hypothetical proteins), indicating there is a vast scope for 
further studies. Only 203 genes (9.64%) were clearly annotated with phage-
associated functions. Using previous work of Botstein (438) as basis, I categorised 
genes with predicted functions into five functional modules, namely lysogeny, DNA 
replication, DNA packaging, head and tail morphogenesis, and lysis (Figure 4.15). 
The gene encoding portal protein belonging to the DNA packaging module was the 
only one consistently identified in all prophages, however, this module was not very 
well preserved across the analysed sequences. The only other gene associated with 
DNA assembly was capsid protein identified in 33% of prophage sequences. 
Integrase-encoding gene was the second most preserved, identified in 87% of 
sequences, followed by genes encoding single stranded DNA binding protein and 
endodeoxyribonuclease, both present in 73% of B. castoris prophages and 
belonging to the DNA replication module. The lysis module was the least well 
represented, with lysin identified in 30% of sequences and only one prophage from 




Figure 4.15 Classification of prophage genes into functional modules.  
Coloured squares represent the presence of genes predicted to encode particular functional proteins 
in the identified prophage sequences.  
 
Following identification of viral signals in B. castoris, I next sought to investigate the 
association between identified CRISPR-Cas systems and prophage sequences in 
Bifidobacterium. For this purpose, I screened spacers from the three B. castoris 
strains possessing the complete CRISPR-Cas systems against prophages identified in 
B. castoris, as well as the custom database of 2,030 publicly available 
Bifidobacterium genomes (downloaded from NCBI on August 6, 2020) (Figure 4.16). 
This investigation revealed homology between spacers from both subtype I-E and 
subtype II-C systems and prophage elements in B. castoris (Figure 4.16 A), as well as 
members of 7 other Bifidobacterium species (Figure 4.16 B). Overall, sequences 
from strain B. castoris 2020BT, and in particular the integrated prophage_2, 
represented the most targeted prophages with matches from both subsystem I-E 
and II-C spacers. Further, both prophage sequences identified in the Wytham 
LH_950 strain were targeted by subsystem I-E spacers from strains LH_955 and 







Figure 4.16 B. castoris CRISPR spacers targeting prophages in B. castoris genomes (A) and other 
Bifidobacterium species (B).  
The vertical axis represents the prophage sequences identified in B. castoris genomes (A) and the 
genomes of Bifidobacterium strains that harbour prophages targeted by B. castoris CRISPR spacers 
(B). The horizontal axis represents CRISPR-Cas spacers from strains with complete CRISPR-Cas 
systems. The colour scales represents the number of targeting events.  
 
With regard to the wider Bifidobacterium screen, apart from targeting prophages in 
type strain B. castoris 2020BT, spacers from the subtype I system also targeted 
strains belonging to B. choerinum, B. cuniculi, B. italicum, B. criceti, Bifidobacterium 
anseris, B. animalis and B. pseudolongum species. Spacers from strain LH_955 had 
the widest range, targeting prophages in all abovementioned Bifidobacterium 
species, while spacers from LH_977 only showed homology to viral signals in  
B. castoris 2020BT and B. pseudolongum. Spacers from the subtype II system only 
showed homology to prophage elements in B. pseudolongum strains. Given that  
B. castoris spacers seem to only target sequences in Bifidobacterium species 
belonging to the B. pseudolongum phylogenetic group (Figure 4.5) (286), it is 
reasonable to suggest that B. castoris strains acquired immunity against prophages 






This work is the first to describe the results of Bifidobacterium screens in wild 
rodent populations and key aspects of the pan-genome of Bifidobacterium castoris 
species. I recovered Bifidobacterium castoris, Bifidobacterium animalis and 
Bifidobacterium pseudolongum from three species of wild mouse (Apodemus 
sylvaticus, Apodemus flavicollis and Apodemus agrarius) from two European 
countries, UK and Lithuania. The species B. animalis and B. pseudolongum had 
previously been isolated from a number of animal hosts and at the species-level are 
considered host generalist (292, 293). B. castoris had previously only been isolated 
from beavers, but here I show it also colonises mice. Some species of 
Bifidobacterium show higher host specificity than others, e.g. Bifidobacterium 
tissieri has only been associated with primates to date (294). While the results 
suggest B. castoris strains might be able to infect a broad range of rodents (beavers 
and mice so far), additional isolation efforts would be required to confirm its true 
host range. Interestingly, despite testing roughly equal numbers of mouse and vole 
faecal samples collected at trapping sites in Lithuania, I did not manage to isolate 
Bifidobacterium from voles. This could reflect either its absence in voles or 
presence at low abundance. 
The genomic data generated in this work provided additional insight into the 
phylogeny and genomic features of B. castoris, using 26 isolates newly isolated here 
and the previously described type strain B. castoris 2020BT, recovered from a 
captive European beaver (Castor fiber) in Italy. Previous research has shown strong 
patterns of co-phylogeny between some mammalian hosts and Bifidobacteriaceae. 
Moeller et al. (404) showed tight congruence between the phylogenies of 
Bifidobacteriaceae and their hominid hosts, providing support for co-diversification. 
In this work I tested whether a similar pattern holds in a different mammalian 
order, using a much higher (genome-level) resolution analysis of strains from a 
single Bifidobacterium species (B. castoris) and their mouse hosts. In contrast to 
previous work (404), I found no statistical congruence between the B. castoris and 
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host phylogenies. B. castoris strains did not show clear phylogenetic clustering by 
host species nor geographic region. All B. castoris strains identified were only found 
in a single mouse species, suggesting strains may be host-species specific, though 
more extensive sampling would be needed to test this definitively. The results are 
more consistent with regular host shifts among B. castoris strains than  
co-diversification, and if co-diversification did in fact occur, its signature has by now 
been eroded by subsequent host shifts. An interesting question is what might drive 
the contrasting host-Bifidobacterium evolutionary patterns in hominids and mice.  
I speculate that differences in host evolutionary history and ecology may be 
important here. One theoretical possibility is that speciation may have been 
allopatric in hominids but sympatric for Apodemus mice, but the literature indicates 
that allopatric speciation is likely in Apodemus (439, 440). A more plausible 
explanation might be that allopatry did not persist among nascent Apodemus 
species for very long, and that since they speciated, contact among species in this 
genus has been more extensive than in hominids, allowing more frequent  
B. castoris transfer and host shifts. Hominid species show very strongly bounded 
present-day geographical ranges (441), whereas Apodemus species in Europe have 
very broad overlapping ranges, and different species (e.g. A. flavicollis and  
A. agrarius at the Lithuanian sites) can often be caught in adjacent traps. Thus, 
earlier and more extensive contact between Apodemus mouse species may have 
allowed more cross-species transmission and host shifts of B. castoris strains over 
evolutionary time than could have taken place among hominid species. Future work 
testing the generality of co-diversification across hosts groups with different 
speciation patterns would be highly informative to understand how the 
biogeographic and temporal patterns of speciation may affect evolutionary 
patterns in host-symbiont relationships (412). Another possibility is that 
behavioural differences have contributed to the contrasting host-Bifidobacterium 
evolutionary patterns between hominids and mice. For example, the practice of 
coprophagy, common to rodents, has been shown to affect the composition and 
abundance of the intestinal microbiota within mouse litters (442). 
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The identification of the B. castoris glycobiome provided insight into the strain-
specific genetic repertoire predicted to be involved in carbohydrate metabolism 
and synthesis. The data indicated that B. castoris is predominantly enriched in GH 
families implicated in the degradation of plant-derived carbohydrates. Consistent 
with previous studies (33, 38), analysis of CAZymes identified family GH13 as 
predominant in all B. castoris genomes, constituting on average 29.98±1.88% of 
their GH repertoire. This finding is consistent with the largely plant-based 
(granivorous) diet of Apodemus mice, including as found at several of the sites in UK 
and Lithuania (443-446).  
The predicted acquisition of family GH49 by B. castoris taxon is especially 
interesting. To my knowledge, this is the first report identifying the putative 
presence of enzymes belonging to this family in Bifidobacterium. Most known GH49 
dextranases have been discovered in fungi, with only 7 listed as characterised in 
bacteria to date (based on CAZy database, July 2020). Overall, members of this 
family are not very well characterised in prokaryotes (427). A recent study using a 
recombinant dextranase from the marine bacterium Arthrobacter oxydans KQ11 
reported positive effects of its product – an isomalto-oligosaccharide – on the 
growth of beneficial human-associated Lactobacillus and Bifidobacterium, and the 
inhibition of pathogenic E. coli and S. aureus in vitro (427). 
 
Previously, several bifidobacterial arabinofuranosidases that belong to families 
GH43 and GH51 and act on arabinose-substituted polysaccharides have been 
identified in Bifidobacterium (261, 447, 448). The analysis of the GH gain loss events 
in B. castoris suggested that most strains isolated from mouse hosts lack family 
GH51 and GH127. The data indicated that all B. castoris genomes harbour 2-3 
copies of GH43 arabinofuranosidases and that, interestingly, some of these copies 
seemed to have been acquired via an HGT event. These findings suggest there 
might be an evolutionary advantage for B. castoris in possessing GH43 
arabinofuranosidases over those belonging to families GH51 and GH127, which may 
be linked to the composition of the host diet. However, it is difficult to speculate on 
biological significance of these results without the supporting experimental data. It 
has previously been shown that arabinofuranosidases characterised in  
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B. adolescentis belonging to different families display variation in substrate 
specificity; AbfA belonging to family GH43 removed arabinose on position C(O)2 
and C(O)3 of monosubstituted xylose residues and had larger hydrolytic activity 
towards substrates with a low amount of arabinose substitutions, while AbfB from 
GH51 only hydrolysed arabinoses from the C(O)3 position of disubstituted xyloses 
(261).  
Interestingly, three Lithuanian strains isolated from A. agrarius and A. flavicollis 
from two distinct trapping sites (site1 and site2) seemed to have acquired 
chitosanases (GH46). The presence of such genes may reflect nutrient availability or 
dietary preferences of their animal hosts, though no data on the diet of mice 
analysed in this study were available. Nonetheless, stomach contents analysis has 
previously detected fungi as a dietary item of Apodemus flavicollis in Lithuania at 
sites close to those studied here (443), as well as in one of the UK sampling sites. 
(444). Moreover, spores of putatively edible fungi (with macroscopic fruiting 
bodies) were frequently detected in the faeces Apodemus spp. in other parts of 
Lithuania (449), suggesting that mycophagy in Apodemus spp. may not be 
uncommon. Further information on the specific food items eaten by Apodemus 
could allow bioinformatic predictions of carbohydrate degradation properties of  
B. castoris strains, based on specific dietary components found in host diet. The 
presence of predicted GH46 in genomes of B. castoris is very interesting and has 
not been previously reported, to my knowledge. The potential of Bifidobacterium to 
degrade chitin-derived substrates is currently not very well understood. Previously, 
studies looking into functional effects of chito-oligosaccharides (COS) on gut 
microbiota members produced inconsistent results. Lee et al. (450) showed 
increased growth of B. bifidum in pure cultures supplemented with COS. Contrary 
to this, Vernazza et al. (451) did not observe any positive effects of COS on growth 
of human-associated bifidobacteria from faecal inocula. Furthermore, Yang et al. 
(452) reported an increase in the population of Bifidobacterium upon dietary 
supplementation of weaning pigs with COS, however a recent study using both in 
vitro fermentation and in vivo mouse model indicated that Bifidobacterium growth 
was significantly inhibited in mice fed with COS, leading to the conclusion that 
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these oligosaccharides should not be considered preferred prebiotic substrates 
(453). 
These same Lithuanian strains, unlike all the remaining B. castoris strains, also 
appear to be lacking GH families containing enzymes previously associated with 
degradation of specific fucosylated and sialylated milk oligosaccharides and 
intestinal glycoconjugates in Bifidobacterium isolated from human hosts (GH20, 
GH33, GH95). The structure and composition of the milk oligosaccharides differ 
greatly between mammalian species. According to Prieto et al. (454) human milk 
contains the most complex mixture of reducing oligosaccharides, many of which 
include fucose and determinants for human blood groups, e.g. the ABO and Lewis 
system. Compared to human breast milk, composition of oligosaccharides in mouse 
milk is mainly limited to sialyllactoses with minuscule amounts of fucosylated 
lactose (3’-fucosyllactose) (454). The fact that I identified enzymes belonging to 
families GH20, GH33 and GH95 in B. castoris strains indicate that members of this 
species may have the ability to metabolise specific host-derived oligosaccharides, 
including milk oligosaccharides, however experimental evaluation of substrate 
specificity of these enzymes is required.  
The identification of genes predicted to encode GTs in genomes of B. castoris 
prompted questions about potential ability of members of this species to produce 
EPS. Recent genomic studies have described high levels of inter-species variation 
with respect to the number, function and organisation of genes in Bifidobacterium 
eps clusters (398, 425). However, a set of conserved eps-key genes has been 
proposed as universal markers, including genes predicted to encode the priming 
glycosyl transferase (pGTF), other glycosyl transferases (GTs), transporter enzymes 
(either “flippases” or ABC transporters) and various carbohydrate precursor 
biosynthesis or modification enzymes (425, 455). The results of the BLAST+ search 
for the homologues of these eps-key genes previously identified in type strains 
most closely related to B. castoris 2020BT revealed their presence in all B. castoris 
strains, suggesting this species may be able to synthesize EPS. Furthermore, the 
analysis of predicted HGT events identified additional genes of unknown function 
neighbouring the eps-key genes that may be part of a distinct B. castoris eps cluster. 
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These findings support previous suggestions on a possible role of HGT in acquisition 
of complete or partial eps clusters by Bifidobacterium (398), however additional 
studies are required to assess the functionality of the putative EPS biosynthesis 
machinery in B. castoris species. Previous analyses of the genomes of 
Bifidobacterium type strains reported that each taxon, except for B. bifidum, 
possess at least one eps cluster (398). In line with these observations, I identified 
homologues of protein members of clusters eps3 and eps4 in B. castoris, including 
enzymes involved in rhamnose biosynthesis in cluster eps3. These results may 
suggest that EPS polymers encoded by different clusters may exert different effects 
on the gut environment. Previous studies showed that rhamnose-rich EPS from 
Lactobacillus paracasei DG displayed particular immunostimulatory properties by 
enhancing the gene expression of the proinflammatory cytokines in the human 
monocytes (430), while polymers mainly composed of glucose and galactose have 
been associated with modulation of gut microbial structure and metabolism by 
acting as dietary components (456, 457).  
CRISPR-Cas systems provide bacteria with an evolutionary advantage, acting as 
defence mechanisms against invasion from either prophages or other types of 
foreign DNA. The analysis of CRISPR-Cas systems in B. castoris revealed the 
presence of two different subtypes belonging to Type I and Type II systems. 
Previous investigations of CRISPR-Cas systems in human-associated B. longum and 
B. pseudocatenulatum reported higher diversity of subtypes, with Type I systems 
represented by I-C, I-U and I-E subtypes in both species and Type II systems 
represented by subtypes II-A and II-C in B. pseudocatenulatum and B. longum, 
respectively (435, 436). The majority of B. castoris isolates were found to harbour 
subtype I-E, while subtype II-C was detected in 4 strains, with only one strain 
possessing a complete locus. Among CRISPR-Cas types, Type I-E was previously 
reported as the most prevalent in genus Bifidobacterium based on the analysis of 
48 type strains (434). Type II systems, however, have been found to be the least 
common in nature (458), and in genus Bifidobacterium (434). In line with these 
findings, the presence of Type II systems in B. castoris is uncommon and seems to 
be a strain-specific characteristic rather than a general feature.   
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Given that CRISPR arrays are hypervariable, yet conserved genomic regions, their 
use as an additional tool for strain genotyping and evolutionary studies has 
previously been postulated (434, 435). Indeed, the analysis of CRISPR spacers 
showed diversity across B. castoris that was in line with the results of phylogenomic 
analysis and further supported identification of strains circulating within Apodemus 
populations. Further, spacer diversity indicated that these elements seemed to 
have originated from various sources, suggesting that the Apodemus gut is a phage-
rich environment. The spacers from strains harbouring the complete CRISPR-Cas 
systems were predicted to target prophages present not only in B. castoris, but also 
in 7 other Bifidobacterium species. Interestingly, all targeted strains belong to  
B. pseudolongum phylogenetic group, which indicates they may share the same 
ecological niche in their respective hosts that is also rich in phages. 
Efforts to identify prophages in B. castoris resulted in the detection of viral signals 
in 80% of analysed isolates. All identified prophage sequences were categorised as 
either divergent from viral references or partial and potentially lacking viral key 
genes. Indeed, sequence analysis indicated the presence of some of the phage-
associated signature genes in predicted prophages, including portal protein, 
integrase and genes involved in DNA replication. Lysis was the least preserved 
functional module in identified prophages, suggesting they may not be able to 
enter into the lytic cycle (459). However, many of the well-established hallmark 
genes, e.g. those encoding head protein, terminase or tape measure protein, could 
not be identified based on available annotation, suggesting that B. castoris 
prophages may be defective. Prophage degeneration has previously been shown to 
be a common process under purifying selection (460-462). Previous studies on E. 
coli indicated that despite undergoing inactivation followed by much slower 
degradation after being incorporated into bacterial genomes, defective prophages 
can still have adaptive functions, such as production of non-infective particles (e.g. 
bacteriocins) (462). Further bioinformatic analyses incorporating data from several 
software for better gene annotation combined with experimental approaches 




4.6 Future work 
 
Although it is now well established that members of Bifidobacterium have a wide 
host range, studies focusing on members of this genus in animals remain lacking. 
This work has laid the foundations for further examinations of Bifidobacterium 
communities in wild host populations. Additional screening of other wild host 
populations across different geographical locations for the presence of 
Bifidobacterium would help assess the distribution and prevalence of members of 
this genus, and perhaps lead to the discovery of new species. With regard to  
B. castoris specifically, such efforts would help establish whether this species is 
restricted to rodent hosts. This could be achieved in the laboratory setting by 
further isolation experiments. In addition, generation of metagenomic data using 
shotgun metagenomic sequencing and the use of genome reconstruction methods 
would complement laboratory approach. These data would also allow examination 
of prokaryotic and viral communities in wild host populations.   
The prediction of glycosyl hydrolase families GH46 and GH49 in B. castoris – 
previously unreported for members of Bifidobacterium – presents potential for 
further investigation. Carbohydrate metabolism experiments using chitosan and 
dextran as carbon sources would complement the results of bioinformatic analysis, 
and if the functionality is confirmed, further transcriptomic and proteomic analysis 
would allow to determine genes and gene clusters involved in the utilisation of 
specific carbohydrates. Bacterial co-culture experiments would allow to assess the 
effect of the degradation products on other members of the gut bacterial 
community. Additionally, characterisation of catalytic activity of recombinant 
glycosyl hydrolases could reveal potential industrial applications for these enzymes 
(e.g. in the prebiotic industry). 
Similarly, experimental procedures would confirm the functionality of predicted eps 
clusters. Phenotypic characterisation of strains producing surface-associated EPS 
could be performed using ruthenium red-milk medium. Furthermore, 
transcriptomics of strains cultured in mono- or multi-association in different types 
of media (e.g. faecal-based vs. non-faecal based) would allow to assess how  
 
 155 
co-culture and medium type stimulate the transcription of genes involved in EPS 
production. Additionally, the functional effects of EPS-producing strains, as well as 
extracted EPS, on the cells of the immune system and the intestinal epithelium 
could be investigated experimentally, e.g. measurement of cytokine responses in 
stimulated immune cells or adhesion studies using fluorescent probes. 
Potentially, Type II CRISPR-Cas systems can be exploited to create new tools for 
genome editing and engineering. The characterisation of the complete Type II 
CRISPR-Cas system in this study would be complemented with the bioinformatic 
analysis of protospacer adjacent motifs (PAMs) essential for Cas9 target 
recognition. Experimental approaches using transcriptomics and associated 
bioinformatic analysis could be used to investigate whether the identified CRISPR-
Cas systems are actively transcribed and protect against invasive DNA, e.g. 
prophages. 
The investigation of prophages in B. castoris genomes would be further expanded 
by integration of data from other available software to improve the identification of 
prophage-associated genes. These data could then be used to assess whether 
experimental prophage induction using Mitomycin C is possible, and if successful, 
electron microscopy could be used to confirm the structure of isolated phages. 
Whole genome sequencing of phage DNA would significantly expand the currently 




Chapter 5  
 
Genomic signatures of animal-derived Bifidobacterium are 
associated with their isolation sources. 
 
 
Animal faecal samples were obtained through collaboration with Ms Sarah 
Goatcher at Banham Zoo and Africa Alive (Norfolk, UK) in years 2014 - 2017. 
Between June 2014 and October 2016, bacterial isolations and associated DNA 
extractions and processing for the purpose of initial identification based on 16S 
rRNA gene and whole genome sequencing of isolates initially identified as 
Bifidobacterium sp. were carried out by Ms Jennifer Ketskemety and Ms Charlotte 
Leclaire. I continued this work as part of my PhD.  
DNA library preparation for WGS was done by sequencing team at the Wellcome 
Sanger Institute (Hinxton, UK). 





The widespread distribution of Bifidobacterium in the animal kingdom is well 
documented. However, compared to human-derived strains, animal-associated 
isolates are significantly underrepresented in databases. In this study, we isolated 
Bifidobacterium from faecal samples of captive animals obtained in collaboration 
with the Banham Zoo and Africa Alive (Norfolk, UK), and performed whole genome 
sequencing and bioinformatics analysis. Experimental efforts resulted in the 
recovery of a substantial number of Bifidobacterium isolates from a wide range of 
hosts, including a subset of strains identified to belong to putative novel species. 
Bioinformatic analyses indicated an “open” pan-genome of the genus, suggesting 
more novel genes to be discovered. In addition, Bifidobacterium isolated from 
different hosts and environments displayed differences in genomic signatures such 







In recent years, the importance of next-generation sequencing for studying 
bacterial diversity has increased significantly. This approach allows for next stage 
genomic, phylogenomic and evolutionary analyses that facilitate taxonomic 
classification of bacterial isolates and provide insights into the mechanisms 
underlying colonisation and establishment of a particular organism within a more 
complex microbial community. However, the selection of organisms for sequencing 
has largely been guided by their public health or applied industrial relevance (463). 
In case of members of the genus Bifidobacterium, human-associated strains, in 
particular, have received much attention in recent years due to their probiotic 
properties. 
Since the publication of the first genomic sequence of Bifidobacterium in 2002  
(B. longum subsp. longum NCC2705) (44), the number of available bifidobacterial 
genomes has been growing rapidly. However, although over 80 Bifidobacterium 
species have currently been identified, sufficient genomic information for the 
majority of representative taxa is lacking. Overall, human-derived species are 
overrepresented in databases, in particular those associated with infant hosts and 
thought to exhibit health-promoting effects (e.g. B. longum), while those associated 
with animals are in the minority despite recent additions of newly characterised 
Bifidobacterium species and strains (292, 293, 413, 464, 465). As a consequence, 
broad information on the intra-species genomic variation is mainly available for 
those overrepresented Bifidobacterium species (36, 61, 466).  In addition, studies 
that correlate Bifidobacterium genomes to the host or environment from which the 
sequenced isolates were recovered, and assess whether these genomes display 
particular environmentally relevant features or signatures of host specialisation, are 
limited (31, 463).  
A more robust representation of animal-associated Bifidobacterium strains and 
species would improve the analytical power of genomic methods, and facilitate the 
understanding of specific genomic patterns across different species, as well as 
particular habitat-specific drivers behind  genome evolution (463). In addition, this 
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extra genomic information would help assess the true extent of diversity within the 
genus (463). For this purpose, as many Bifidobacterium genomes as possible should 
be sequenced and annotated, across a wide host range. 
To date, a number of studies have sought to determine Bifidobacterium diversity  
(25, 27-31). However, the majority of these studies have either focused on a subset 
of human-associated isolates or examined single type strains as representatives of 
species, and in consequence included a limited number of the isolates from 
different habitats. Interestingly, all studies suggest an “open” Bifidobacterium  
pan-genome (25, 27-31). However, since the number of genomes included in the 
pangenomic approach may affect the accuracy of prediction (467), it is important to 
re-assess the pan-genome of the genus Bifidobacterium, and explore their intra- 
and inter-species diversity using a higher number of available genome sequences. 
This work sought to provide new insights into the diversity of animal-associated 
Bifidobacterium. I undertook isolation of new species and strains of Bifidobacterium 
from a wide range of hosts, covering mammals, birds, reptiles and insects. This 
effort resulted in the recovery of over 100 unduplicated isolates, including strains 
representative of 19 putative novel Bifidobacterium species. Preliminary analysis of 
the associated genomic data indicated an open nature of the pan-genome of the 
genus and suggested the presence of significant differences in genomic signatures 




5.3 Hypothesis and aims 
 
The diversity of Bifidobacterium in animal hosts is not fully explored. Experimental 
and computational methods (bacterial isolation and genomic analysis, respectively) 
contribute to the discovery of true diversity within the genus. Whole genome 
sequences of animal-associated isolates display particular traits related to their 
isolation source and functional capabilities, e.g. degradation of carbohydrates.  
 
Aims: 
1) Isolate Bifidobacterium from faecal samples of captive animals and 
sequence their genomes 
2) Define and create the genomic dataset composed of unduplicated newly 
sequenced genomes as well as publicly available sequences, with particular 
focus on animal-associated isolates 
3) Determine genomic features of isolates in the dataset, with particular focus 
on traits directly and indirectly linked to carbohydrate metabolism  






5.4.1 Notes on the isolation of bifidobacterial species from animal gut microbiota 
samples 
 
At the start of my PhD, the zoo animal microbiome project was already in progress, 
with 240 faecal samples from 116 species of mammals, birds, reptiles and insects 
processed for bacterial isolation by former lab members between June 2014 and 
October 2016. The isolation protocol for the culture of bacterial isolates from faecal 
samples involved the use of MRS agar supplemented with mupirocin (50mg/l) and 
cysteine (50mg/l) as selective medium (MRSCM). This medium, officially termed 
bifidobacterial selective medium, was developed by Leuschner et al. (468) for the 
enumeration of bifidobacterial species from animal feed. It has been shown to 
inhibit growth of Lactobacillus, Streptococcus and Bacillus strains, and reduce the 
colony size of Pediococcus, Enterococcus and Propionibacterium, allowing these 
species to be visually distinguished from Bifidobacterium. 
However, previous experiments conducted by my colleagues, in which MRSCM was 
used for the isolation of Bifidobacterium from animal faecal samples, produced a 
number of “false positive” results. Several bacterial species have previously been 
observed by lab members to have similar morphology to that of bifidobacteria, 
including clostridia at early growth phases and enterococci, when grown on this 
selective medium. Consistent with this observation, I identified 44 isolates out of 66 
available for DNA extraction at the start of my PhD as bacteria other than 
bifidobacteria (66%), out of which 27 belonged to the class Clostridia, and 8 were 
enterococci (Table S5.1). Thus, I decided to introduce an additional selective agent, 
sodium iodoacetate, into the isolation procedure, with the aim of increasing the 
selectivity for bifidobacteria. 
Sodium iodoacetate contains one iodine atom attached to its methyl group and is a 
potent inhibitor of the glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Previous studies in lactic acid bacteria showed that 
inhibition of GAPDH activity with iodoacetate caused a shift towards homolactic 
fermentation in a mixed-acid-producing strains (298, 299). Bifidobacterium, being 
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heterolactic, do not have an obligate requirement for GAPDH activity in their 
carbohydrate metabolism pathway (37). Thus, sodium iodoacetate has been used in 
a number of selective media formulations, developed for isolation and enumeration 
of bifidobacterial species (469, 470). 
To test if different media types with/without sodium iodoacetate could provide 
increased selectivity for Bifidobacterium, I cultured three animal faecal samples on 
BHI, MRS and RCA supplemented with, and without this selective agent (Figure 5.1). 
Sample Z200 was recovered from the lab isolate archive and had previously been 
confirmed to contain bifidobacteria, whereas samples Z241a and Z243 were more 
recently obtained from the Banham Zoo and were due to be processed.  
BHI and RCM are very rich media, and visibly supported growth of a variety of 
bacterial species, regardless of whether sodium iodoacetate was added to the 
medium or not (Figure 5.1). Most of the BHI- and RCA-based plates contained 
bacterial species with distinguishably different colony morphologies, including ones 
with colony morphology consistent with that of Bifidobacterium. Similar 
observations were made for MRSCM medium. MRSCM+I medium, however, was 
observed to either support growth of bacteria with colony morphology consistent 
with that of bifidobacteria, but significantly smaller in size (Z200 and Z241a), or did 
not support bacterial growth at all (Z243).  
Although media containing sodium iodoacetate have widely been used for isolation 
of bifidobacteria, a number of research groups have reported selective 
bifidobacterial growth inhibition linked to iodoacetate concentration. Silvi et al. 
(471) compared three selective bifidobacterial media, and found that BIM-25 based 
on RCM and containing sodium iodoacetate at 25mg/l inhibited growth of  
B. longum, and failed to recover bifidobacterial species from human and rat faecal 
samples. Similarly, Munoa and Pares (469) found that this medium inhibited  
B. adolescentis strains. Other groups reported that bifidobacterial growth was 




Figure 5.1 Growth of bacteria from three animal faecal samples (Z200, Z241a and Z243) on RCM 
agar, MRS agar and BHI agar with the addition of cysteine (C ) 50mg/l and mupirocin (M) 50mg/l 
(labelled RCACM, MRSCM and BHICM, respectively) and additionally supplemented with sodium 
iodoacetate (+I) at 25mg/ (labelled RCACM+I, MRCSM+I and BHICM+I). 
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Thus, I decided to screen the Bifidobacterium library available in the lab for growth 
inhibition on MRSCM and BHICM with addition of sodium iodoacetate at 3 different 
concentrations (25mg/l, 15mg/l and 7.5mg/l). These media were selected based on 
the isolation results obtained in the lab prior to the start of my PhD, where distinct 
bifidobacterial species were recovered from both human and animal samples using 
MRSCM (at least 15 distinct bifidobacterial species), as well as on the results of my 
own experiments with different media types (Figure 5.2). 
 
A) MRSCM+I 7.5mg/l B) MRSCM+I 15mg/l C) MRSCM+I 25mg/l D) RCACM (control) 
    
E) BHICM+I 7.5mg/l F) BHICM +I 15mg/l G) BHICM +I 25mg/l  
   
 
Figure 5.2 Growth of different species and strains of Bifidobacterium on MRS agar (top panel, A-C) 
and BHI agar (bottom panel, E-G) supplemented with cysteine 50mg/l (C ), mupirocin 50mg/l (M) and 
sodium iodoacetate (+I) at three different concentrations: 7.5mg/l, 15mg/l and 25mg/l (marked on 
the figure, respectively). RCM agar (RCA) (top panel, D) with the addition of cysteine (C ) 50mg/ and 
mupirocin (M) 50mg/l was used as control. 
 
From the results shown in Figure 5.2 A-C, the combination of MRS agar with 
mupirocin (50mg/l), cysteine (50mg/l) and sodium iodoacetate, regardless of the 
concentration of the latter, seemed to selectively inhibit the growth of a significant 
number of Bifidobacterium strains isolated both from human and animal hosts 
(compared to control, Figure 5.2 D). Bifidobacterial capacity to grow on MRS with 
sodium iodoacetate appears to be largely strain specific. Interestingly, none of the 
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human-associated isolates identified with BLAST as B. pseudocatenulatum grew on 
any of the plates containing MRSCM+I (e.g. row H, wells 3-6 and 10-12). 
Similarly, strain-specific growth was observed when the library was grown on the 
medium composed of BHI agar supplemented with mupirocin (50mg/l), cysteine 
(50mg/l) and different concentrations of sodium iodoacetate, however the overall 
inhibitory effects of these medium formulations on bacterial growth were weaker 
(compared to MRSCM+I) (Figure 5.2 E-G). The isolates showed identical growth 
profiles regardless of the concentration of sodium iodoacetate. Based on the results 
of this experiment I concluded that BHI- but not MRS-based medium supplemented 
with sodium iodoacetate could potentially be used in future isolation experiments 
that pose particular difficulties in terms of Bifidobacterium recovery, with the 
caveat that the diversity of the recovered strains and species may be affected.  
 
5.4.2 Defining the study population 
 
Prior to the start of my PhD, 60 isolates recovered from 20 animal species were 
identified as Bifidobacterium spp. based on partial 16S rRNA gene and subsequently 
subjected to whole genome sequencing. A further 66 isolates were available for 
DNA extraction and initial identification. I carried out these experiments shortly 
after starting my PhD. Preliminary analysis of partial 16S rRNA gene sequences 
using the BLAST algorithm identified 18 out of the 66 sequences (27%, from 13 
animal species) as bifidobacteria and one insect-derived sequence inconclusively as 
either Neoscardovia arbecensis or B. breve. N. arbecensis has been proposed as the 
only representative of new genus Neoscardovia in the family Bifidobacteriaceae in 
2012 based on the analysis of 16S rRNA gene and hsp60(groL) gene sequences, with 
a maximum identity of 94% to its closest relatives, including bifidobacterial species, 
namely B. indicum JCM 1302T and B. breve DSM 20213T  (473). Due to the close 
relationship between the two species, I decided to treat inconclusive BLAST results 
as potential Bifidobacterium isolates to be validated by whole genome sequencing. 
Between October 2016 and November 2017, I received and processed a further 109 
faecal samples from 98 animal species. These efforts resulted in the preliminary 
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identification of an additional 88 isolates from 17 animal species, putatively 
identified as Bifidobacterium strains. In total, 167 samples from 51 animal hosts 
were subjected to whole genome sequencing within this project. Additionally, 33 
human-associated isolates and one isolate from a probiotic formulation were added 
to this collection, bringing the total number of sequenced samples to 201. 
Following sequencing, contamination check and the initial ANI analysis, I excluded 
81 samples, as either contaminated or duplicate sequences (ANI > 99.99%, isolated 
from the same faecal sample), with 120 genomes from 40 host species retained for 
further analysis (Table S5.2). The assembled draft genome sizes for newly 
sequenced isolates ranged from 1.85 Mb to 3.27 Mb, with G+C% content between 
54.83% and 65.88%. These values are in line with previous reports for members of 
genus Bifidobacterium (27). 
Additionally, 281 publicly available Bifidobacterium genome assemblies were 
downloaded from NCBI and included in the dataset, together with the B. castoris 
data generated for the wild mammal study (Chapter 4). The vast majority of 
genomes available in the NCBI database represent human isolates, and in many 
cases there is very limited metadata available (e.g. information on host age and 
environmental background of the sample (e.g. faeces, milk, oral cavity, urogenital, 
etc.)). Since the primary focus of this project was on animal-associated 
Bifidobacterium, I decided to select 5 representative publicly available sequences 
from each human-associated Bifidobacterium species and subspecies, and tried to 
include both adult and infant isolates where possible. The final dataset 
encompassed 433 genomes representing isolates obtained from a wide range of 
hosts, both animal (n=350) and human (n=68), as well as loosely defined 
“environmental” sources (anaerobic digester, dairy, probiotic formulation and 
sewage) (n=13) (Figure 5.3). The majority of genome assemblies included in the 




Figure 5.3 Statistics of genomes included in the analysis.  
(A) Number of contigs in the assemblies. (B) Isolate categories according to 
animal/human/environmental sources. (C) Isolate categories according to host/environment groups. 
 
Animal- and human-associated Bifidobacterium genomes were assigned to arbitrary 
host categories at the intersection of taxonomic classification and diet. Non-human 
mammalian isolates, which constituted the majority of the dataset, were split into 
groups based on the type of diet i.e. omnivore, carnivore, herbivore (ruminant and 
non-ruminant). Taxonomic grouping was employed where a considerable number 
of isolates representing animals at a specific taxonomic level were available  
(e.g. primate n=106, rodent n=66, pig n=29, rabbit n=8). Human-associated isolates 
for which the corresponding metadata were available were grouped into adult and 
infant categories (Figure 5.3). 
 
5.4.3 Preliminary analysis of potential new Bifidobacterium species 
 
Comparison of ANI values between 120 isolates and 87 Bifidobacterium type strains 
allowed taxonomic assignment of 76 genomes (63.33%) to 31 Bifidobacterium 
species and subspecies (ANI > 95%) (Table S5.3). The predominant species and 
subspecies identified through this analysis included animal-associated 
Bifidobacterium pseudolongum subsp. globosum (7 isolates, 9.21% of assigned 
genomes), Bifidobacterium reuteri (also 7 isolates, 9.21% of assigned genomes) and 
Bifidobacterium animalis subsp. animalis (5 isolates, 6.58% of assigned genomes). 
Surprisingly, genomes of 44 isolates (36.67% of sequenced samples) showed ANI 
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values below 95% to the known Bifidobacterium type strains, suggesting they may 
represent putative novel species. These isolates were recovered from 21 animal 
hosts, with those obtained from primates constituting the highest proportion 
(52.3% of putative novel isolates). Other hosts harbouring potential novel 
Bifidobacterium species included a South American species of rodent – Azara’s 
agouti (18.2% of isolates), various species of birds (13.6%), a cockroach (9.1%) and 
two species of tortoises (6.8%). Interestingly, a number of isolates within this 
group, both from the same and different hosts, displayed ANI values above 95% 
between each other (Figure 5.4). Further analysis of these data revealed that the 44 
isolates appeared to belong to 19 putative novel Bifidobacterium species. 
 
 
Figure 5.4 ANI analysis between the type strains of the recognised 87 species of Bifidobacterium and 
the isolates predicted to belong to putative novel Bifidobacterium species. The diagram shows values 
between 70-100%, values above 95% are marked in red. 
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Based on these findings, I sought to conduct a preliminary analysis of these putative 
novel species using additional in silico methods. For this purpose, I predicted their 
16S rRNA gene sequences and performed a screen against the SILVA 16S rRNA gene 
sequences database (v.138, 16 December 2019) (Table 5.1).  
 
  
Table 5.1 Summary of the results of the ANI analysis and the screen of the 16S rRNA gene sequences 
predicted from the genomes of isolates identified to belong to putative novel Bifidobacterium species 
against SILVA 16S rRNA gene sequences database (v.138, 16 December 2019).  
Strains displaying ANI values above 95% to each other were assigned to the same putative novel 
species.  
 
Overall, the isolates predicted to belong to the same putative novel species showed 
highest 16S rRNA gene similarity values with a particular Bifidobacterium species, 
e.g. isolates predicted to belong to novel species ‘2’ displayed highest 16S rRNA 
gene similarity values (above 97%) with strains of B. longum. Some exceptions to 
this observation included isolates predicted to belong to putative novel species ‘4’ 
and ‘6’. For example, the majority of isolates assigned to species ‘4’ showed highest 
16S rRNA gene similarity to B. choerinum, with an exception of one tortoise-
associated isolate which displayed highest 16S rRNA gene similarity to B. breve, 
with 94% similarity value. Overall, members of this group showed low predicted 
16S rRNA gene sequence similarities (below 96%) to known Bifidobacterium 
species. These observations suggest that these isolates may be representative of a 
Isolate Host Group Host ID ANI value type 
strain (>95%)
ANI type strain Same species 
(ANI > 95%)
16S rRNA species (SILVA database) 16S rRNA identity 
(%)
16S rRNA coverage 
(%)
LH 230 Cotton top tamarin Primate n/a Potential novel 1 FNSE01000001.1499458.1500992_Bifidobacterium_dentium_JCM_1195 94.792 100
LH 274 Cotton top tamarin Primate n/a Potential novel 2 FTRS01000105.3844.5341_Bifidobacterium_longum 98.675 100
LH 312 Emporer tamarin Primate n/a Potential novel 2 FNRW01000001.379172.380700_Bifidobacterium_longum 98.317 100
LH 384 Emporer tamarin Primate n/a Potential novel 2 FNRW01000001.379172.380700_Bifidobacterium_longum 98.317 100
LH 416 Cotton top tamarin Primate n/a Potential novel 2 FNRW01000001.379172.380700_Bifidobacterium_longum 97.253 100
LH 457 Emporer tamarin Primate n/a Potential novel 2 JRWN01000007.321.1855_Bifidobacterium_longum 97.706 100
LH 725 Goeldi's marmoset Primate Z245 n/a Potential novel 2 FNRW01000001.379172.380700_Bifidobacterium_longum 97.705 100
LH 389 Geoffroy's marmoset Primate n/a Potential novel 3 AP012331.721637.723165_Bifidobacterium_scardovii_JCM_12489 95.176 100
LH 410 Red footed tortoise Reptile n/a Potential novel 4 AWFT01000016.15.1546_Bifidobacterium_breve_MCC_1340 94.01 100
LH 418 Azara's agouti Rodent n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 94.444 100
LH 450 White-faced saki monkey Primate n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 94.444 100
LH 470 Azara's agouti Rodent Z241a n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 94.972 100
LH 521 Azara's agouti Rodent Z241a n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 95.531 99
LH 524 Azara's agouti Rodent Z241a n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 95.531 100
LH 605 Azara's agouti Rodent Z211 n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 95.531 100
LH 716 Azara's agouti Rodent Z241b n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 93.738 100
LH 717 Azara's agouti Rodent Z241b n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 94.186 100
LH 718 Azara's agouti Rodent Z241b n/a Potential novel 4 CP018044.576115.577667_Bifidobacterium_choerinum 93.996 100
LH 413 Cotton top tamarin Primate n/a Potential novel 5 16S sequence too short
LH 419 Golden-headed lion tamarin Primate n/a Potential novel 5 AP012331.721637.723165_Bifidobacterium_scardovii_JCM_12489 97.065 100
LH 424 Golden lion tamarin Primate n/a Potential novel 5 AP012331.3080655.3082183_Bifidobacterium_scardovii_JCM_12489 96.924 100
LH 426 Goeldi's marmoset Primate n/a Potential novel 5 AP012331.721637.723165_Bifidobacterium_scardovii_JCM_12489 96.464 100
LH 456 Emporer tamarin Primate n/a Potential novel 5 AP012331.3080655.3082183_Bifidobacterium_scardovii_JCM_12489 96.924 100
LH 417 Cotton top tamarin Primate n/a Potential novel 6 AP012331.721637.723165_Bifidobacterium_scardovii_JCM_12489 96.369 100
LH 421 Golden-headed lion tamarin Primate n/a Potential novel 6 JGZP01000012.99390.100910_Bifidobacterium_stellenboschense 97.321 99
LH 423 Golden lion tamarin Primate n/a Potential novel 7 AWFT01000016.15.1546_Bifidobacterium_breve_MCC_1340 97.186 100
LH 449 Scarlet ibis Bird n/a Potential novel 8 CP007456.2269054.2270590_Bifidobacterium_kashiwanohense_PV20-2 95.901 100
LH 454 Geoffroy's marmoset Primate n/a Potential novel 9 LKUR01000021.717.2255_Bifidobacterium_bifidum 95.416 100
LH 458 Emporer tamarin Primate n/a Potential novel 10 CP001361.2165007.2166538_Bifidobacterium_bifidum_BGN4 95.366 100
LH 461 Pygmy marmoset Primate n/a Potential novel 11 KC807989.1.1421_Bifidobacterium_aesculapii 99.502 99
LH 491 East African grey crowned crane Bird n/a Potential novel 12 JGZJ01000010.292735.294257_Bifidobacterium_pullorum 96.595 99
LH 512 Abyssinian blue winged goose Bird n/a Potential novel 13 CP021386.2234963.2236497_Bifidobacterium_breve 96.034 100
LH 558 Black lemur Primate Z174 n/a Potential novel 14 JGZJ01000010.292735.294257_Bifidobacterium_pullorum 96.525 100
LH 560 Madagascan hissing cockroach Insect Z185 n/a Potential novel 15 16S sequence too short
LH 700 Madagascan hissing cockroach Insect Z271 n/a Potential novel 15 AP012327.1791544.1793074_Bifidobacterium_kashiwanohense_JCM_15439 93.717 100
LH 702 Madagascan hissing cockroach Insect Z271 n/a Potential novel 15 AP012327.1791544.1793074_Bifidobacterium_kashiwanohense_JCM_15439 93.717 100
LH 709 Madagascan hissing cockroach Insect Z271 n/a Potential novel 15 AP012327.1791544.1793074_Bifidobacterium_kashiwanohense_JCM_15439 93.848 100
LH 687 Leopard tortoise Reptile Z267 n/a Potential novel 16 KP718951.1.1509_Bifidobacterium_tissieri 94.685 99
LH 692 Leopard tortoise Reptile Z267 n/a Potential novel 16 KP718951.1.1509_Bifidobacterium_tissieri 94.184 99
LH 838 White-faced duck Bird Z278 n/a Potential novel 16 KP718951.1.1509_Bifidobacterium_tissieri 94.184 99
LH 935 Spoonbills Bird Z55/Z88 n/a Potential novel 16 KP718951.1.1509_Bifidobacterium_tissieri 94.184 99
LH 730 Senegal bushbaby Primate Z260 n/a Potential novel 17 AP010889.960839.962368_Bifidobacterium_infantis_ATCC_15697 96.141 100
LH 743 Golden-bellied mangabey Primate Z265 n/a Potential novel 18 CP028341.2009205.2010740_Bifidobacterium_adolescentis 98.786 100
LH 898 White-faced owl Bird Z311 n/a Potential novel 19 CP017696.1972737.1974271_Bifidobacterium_asteroides_DSM_20089 99.278 100
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new clade of Bifidobacterium. Another potential explanation of these findings may 
be the fact that the SILVA database does not yet contain sequences of most 
recently characterised animal-associated Bifidobacterium species that may be more 
closely related to putative novel isolates identified in this study. 
To expand on the results of the 16S rRNA gene analysis, sequences for marker 
genes rpoB, rpoC, groL, dnaJ, clpC and xpf (26) were in silico extracted from 
annotated genomes of 87 Bifidobacterium type strains and the putative novel 
isolates, and concatenated for the purpose of multilocus sequence analysis. The 
quality trimmed multiple sequence alignment yielded 15,712 positions and was 
used for the phylogenetic tree reconstruction employing the maximum likelihood 
method (Figure 5.5).  
The inclusion of genes from recently characterised Bifidobacterium species 
provided additional resolution for findings resulting from 16S rRNA gene analysis. 
Several of the isolates predicted to be sole representatives of putative novel species 
appeared to be more closely related to recently described Bifidobacterium species 
(e.g. LH_558 isolated from a lemur clustered with Bifidobacterium lemurum and 
Bifidobacterium eulemuris also derived from lemurs). Further assessment of 
phylogenetic relatedness between known members of the genus Bifidobacterium 
and the putative novel species indicated that a number of putative novel species 
comprising several isolates (e.g. species ‘2’, ‘4’, ‘15’ and ‘16’) may be representative 
of new clades. Notably, there appears to be a tendency for isolates obtained from 
the same host or environment to cluster by clade, but this clustering is not 
complete. Broadly, isolates recovered from primates seem to cluster with those 
obtained from humans, while insect-associated isolates appear to be more closely 







Figure 5.5 Phylogenetic tree based on concatenated housekeeping gene sequences for rpoB, rpoC, 
groL, dnaJ, clpC and xpf genes (15,712 nt).  
The tree shows relationship between strains identified to belong to putative novel Bifidobacterium 
species and the type strains of currently recognised 87 Bifidobacterium species. The tree was 
reconstructed using the maximum likelihood method with 1000 bootstrap iterations and the 
sequences of Alloscardovia omnicolens DSM 21503T, Alloscardovia omnicolens F0580 and 
Gardnerella vaginalis JCM 11026T were used as an outgroup. Bootstrap values above 70% are 
marked on the tree branches. Coloured squares denote isolate distribution within putative novel 
Bifidobacterium species. 
 
5.4.4 Genomic features 
 
Previous studies suggested association between genomic signatures, e.g. genome 
size or specific genomic traits, and different bacterial habitats and lifestyles (463, 
474, 475). To assess differences between Bifidobacterium isolates grouped within 
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host/environment categories, I examined their general genomic features and 
specific traits linked to their carbohydrate metabolism capabilities. For the isolates 
recovered from different hosts and environments, the range of genome sizes was 
from 1.63 Mb (B. commune) to 3.27 Mb (B. myosotis), corresponding to 1,357 and 
2,628 protein-coding open reading frames, respectively. The genome sizes of 
human isolates ranged from 1.92 Mb to 3.16 Mb and corresponded to 1,606 and 
2,593 ORFs, respectively. These values fall within the range for previously reported 
animal- and human-associated Bifidobacterium species (33).  
 
Figure 5.6 Genome sizes of Bifidobacterium isolates derived from (A) multiple hosts and 
environments and (B) humans.  
The crosses represent the mean of each boxplot. The letters above each boxplot in the multiple host 
comparison diagram (A) represent the post hoc comparisons using Dunn’s test, with groups sharing a 
letter not significantly different.  
 
Comparison of genome sizes between groups indicated that isolates obtained from 
different hosts showed different trends with regard to genomes size (Kruskal-Wallis 
c2 = 186.06, P < 0.001, df = 13). Primate-associated Bifidobacterium isolates had the 
highest genome size (2.71 ± 0.30 Mb (mean ± sd)), while those obtained from 
insects displayed the lowest genome size (1.99 ± 0.18 Mb). These findings are in 
line with the results of the recent analysis of 129 publicly available Bifidobacterium 
strains (31). Similarly, the average genome size of isolates recovered from human 
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adults and infants displayed a significant difference (unpaired two-sample t-test,  
P < 0.05) (Figure 5.6).  
To further assess the diversity among Bifidobacterium, I next sought to construct 
the pan-genome of 433 isolates and investigate phylogenetic relationships between 
them. To establish an informed gene identity threshold accounting for inter-species 
diversity, I first screened predicted proteomes of the isolates for the presence of 
marker genes based on the database of 105 conserved single copy genes defined by 
Dupont et al. (476). This analysis identified 72 marker genes shared by all 
Bifidobacterium isolates. The results of all-vs-all protein search of the custom 
database created from a subset of 10 identified marker gene sequences indicated 
relatively high diversity within the genus. For example, the minimum identity value 
for the marker gene rnc encoding ribonuclease III was 54.8% recorded between 
human-associated B. animalis subsp. lactis S7 and LH_439_A isolated from a 
probiotic formulation (Table 5.2). Based on these findings, I set the protein search 
threshold for pan-genome construction at 50%.  
 
 
Table 5.2 Minimum identity values for the all-vs-all BLASTP comparison (e-value 1e-50) between 
selected marker genes shared by the 433 Bifidobacterium isolates.  
 
The results of this analysis identified a total of 46,766 clusters of orthologous genes, 
representing the pan-genome of the 433 Bifidobacterium isolates (Figure 5.7). 
Functional classification of the overall gene content resulted in the assignment of 
functional categories to 76.9% of ORFs, with the remaining 23.1% categorised as 
proteins of unknown function.  
Minimum identity values between marker genes (blastp, evalue 1e-50)
Gene Description Identity% (coverage%) Isolate
rpoB DNA-directed RNA polymerase, beta subunit 82.1 (100) B. catulorum MRM8_19 -> B. thermacidophilum subsp. thermacidophilum LMG 21395
rpoC DNA-directed RNA polymerase, beta' or beta" subunit 76.8 (99) B. callitrichos UMA 51804 -> LH_687
clpC ATP-dependent Clp protease 78.6 (98) B. bombi DSM 19703 -> LH_687
rplJ ribosomal protein L10 68.8 (100) B. dentium 1893B -> LH_709
smpB SmpB protein 71.6 (99) B. anseris Goo31D -> LH_935
serS seryl-tRNA synthetase 72.8 (99) B. bohemicum DSM 22767 -> LH_912
rpsB ribosomal protein S2 69.4 (100) B. coryneforme DSM 20216 -> LH_543
rnc ribonuclease III 54.8 (93) B. animalis subsp. lactis S7 -> LH_439_A
pgk phosphoglycerate kinase 76.1 (100) B. asteroides ESL0200 -> B. catulorum MRM8_19
rplE ribosomal protein L5 78.4 (98) B. criceti Ham19E -> LH_709
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Figure 5.7 Pan-genome of the genus Bifidobacterium.  
(A) The internal pie chart summarises the pan-genome of 433 isolates and shows the core genes 
(n=403, black), the soft core genes (n=130, red), the shell genes (n=1,847, light purple) and the cloud 
genes (n=44,386, light blue) determined based on the default Roary thresholds. The external pie 
chart represents the COG classification of the whole Bifidobacterium pan-genome, with specific 
categories highlighted in different colours. The values for the most abundant categories are 
presented in the diagram. Summary of COG categories identified in the Bifidobacterium pan-genome: 
[A] RNA processing and modification; [C] Energy production and conversion; [D] Cell cycle control, 
cell division, chromosome partitioning; [E] Amino acid transport and metabolism; [F] Nucleotide 
transport and metabolism; [G] Carbohydrate transport and metabolism; [H] Coenzyme transport and 
metabolism; [I] Lipid transport and metabolism; [J] Translation, ribosomal structure and biogenesis; 
[K] Transcription; [L] Replication, recombination and repair; [M] Cell wall/membrane/envelope 
biogenesis; [N] Cell motility; [O] Post-translational modification, protein turnover, and chaperones; 
[P] Inorganic ion transport and metabolism; [Q] Secondary metabolites biosynthesis, transport, and 
catabolism; [S] Function unknown; [T] Signal transduction mechanisms; [U] Intracellular trafficking, 
secretion, and vesicular transport; [V] Defence mechanisms; [Z] Cytoskeleton. 
(B) Pan-genome (dashed teal line) and core genome (solid red line) of the genus Bifidobacterium. The 
pan-genome and core genome are represented as sizes of their gene pools versus the analysed 433 
bifidobacterial genomes. The x axis represents the number of genomes, whereas the y axis 
represents the number of genes. 
 
Carbohydrate transport and metabolism was identified as second most abundant 
category and constituted 10.6% of Bifidobacterium pan-genome, reflecting the 
saccharolytic lifestyle of members of this genus. This value is within the range 
previously reported for bifidobacteria (162, 293) (Figure 5.7 & Table S5.4). Other 
abundant functional categories included genes involved in amino acid metabolism 
(9.66%) and genes related to translation, ribosomal structure and biogenesis 
(8.34%). 
Plotting the pan-genome size versus the number of genomes included in the 





the addition of new genome sequences to the pan-genome would still increase the 
total gene pool. This suggest that there is scope for further discovery of diversity 
within the Bifidobacterium genus. 
Notably, 403 genes were shared among all the isolates, constituting the core 
genome. These findings resonate with observations from previous studies with 
fewer genomes, which reported the number of genes in the core genome of genus 
Bifidobacterium to range between 400 and 500 genes (27, 29, 31). Plotting the 
number of identified core genes as a function of the total number of genomes 
included in the analysis showed that the trendline had reached a plateau, 
suggesting that the addition of further genome sequences to the pan-genome 
would not reduce the core genome of the genus significantly.  
Inclusion of genome sequences of other members of the family Bifidobacteriaceae, 
namely Alloscardovia omnicolens DSM 21503T, Alloscardovia omnicolens F0580 and 
Gardnerella vaginalis JCM 11026T, generated a set of 392 core genes shared by all 
included isolates. Concatenated sequences for these genes were used to construct 
the family phylogeny (Figure 5.8). The structure of the generated phylogenomic 
tree was similar to previously reported phylogenies generated based on the  
16S rRNA gene and various sets of core genes (25, 286), and clearly delineated the 
presence of seven previously described bifidobacterial phylogenetic groups, i.e.  
B. adolescentis, B. asteroides, B. bifidum, B. boum, B. longum, B. pseudolongum, 
and B. pullorum. The members of the same taxonomic species clustered together. 
In contrast to previous observations positioning the B. asteroides phylogroup in the 
deepest branches of the lineage, the deepest branches of the phylogeny 
corresponded to isolates belonging to Bifidobacterium tsurumiense species and the 
bird-associated strain LH_491, representative of a potential novel Bifidobacterium 
species. 
Comparison between the phylogenetic relatedness and the host groups indicated 
that there was a statistically significant association between the isolation source 
and the phylogenetic distribution of Bifidobacterium (ANOSIM: R = 0.4016,  
P < 0.001). In particular, strains derived from primates, insects and rodents seemed 
to cluster closely within their respective phylogroups. This clustering was not 
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perfect however, with clades of strains from mixed isolation sources present within 
distinct phylogenetic groups in the tree (e.g. in the B. pseudolongum phylogroup). 
In these cases, the tendency for strains recovered from particular host groups to 
cluster together was more apparent at the higher taxonomic level of the host, for 
example for orders Artiodactyla (strains isolated from ruminants, non-ruminant 




Figure 5.8 Phylogenomic overview of the genus Bifidobacterium.  
Maximum likelihood phylogeny was based on concatenated sequences for 392 core genes, 
employing the ‘GTR’ model with 1000 bootstrap iterations. Bootstrap values above 70% are 
displayed on tree branches. Grey shading depicts the prominent recognised Bifidobacterium species, 
while blue shading marks isolates identified in this study as belonging to putative novel 
Bifidobacterium species. The sequences of Alloscardovia omnicolens DSM 21503T, Alloscardovia 






Given that carbohydrate metabolism and transport was the second most abundant 
functional group identified in the Bifidobacterium pan-genome, I next sought to 
investigate the genetic repertoire predicted to be involved in carbohydrate 
processing. In silico analysis performed using dbCAN2 identified carbohydrate-
active enzymes (CAZymes) in genomes of analysed isolates (Table S5.5). Previous 
findings on CAZyme abundances in strains isolated from different hosts and 
environments indicated that, on average, Bifidobacterium isolated from non-human 
primates encoded the highest number of CAZymes (84 genes ± 20 sd), whereas 
those recovered from wastewater carried the fewest genes associated with 
carbohydrate metabolism (42 genes ± 10 sd) (31). The predictions generated for 
433 Bifidobacterium isolates were in line with these observations, with average 
numbers of predicted CAZymes overall higher across host groups (103.81 genes ± 
23.09 sd for primate category and 57.00 genes ± 11.63 sd for sewage, respectively). 
 
Figure 5.9 Abundance of glycosyl hydrolase families in isolates derived from (A) multiple hosts and 
environments and (B) humans.  
The crosses represent the mean of each boxplot. The letters above each boxplot in the multiple host 
comparison diagram (A) represent the post hoc comparisons using Dunn’s test, with groups sharing a 




Furthermore, the results indicated that over 50% of CAZymes in each host category 
belong to glycosyl hydrolase class of enzymes (range between 51% and 63%), with 
an exception of sewage; in this group GHs constituted 40% of predicted 
carbohydrate-active enzymes (Table S5.6). Comparison of glycosyl hydrolase 
numbers across different host groups revealed significant differences in GH 
abundance between categories (Kruskal-Wallis c2 = 151.2, P < 0.001, df = 13) 
(Figure 5.9). Isolates belonging to the primate group carried the highest average 
number of GH genes (65.68 genes ± 19.17 sd), while those associated with sewage 
harboured the fewest (22.75 genes ± 9.21 sd). In contrast, the abundance of GHs 
between human-derived infant and adult strains did not differ significantly 
(unpaired two-sample t-test, P > 0.05). On average, adult isolates harboured slightly 
fewer glycosyl hydrolase genes (46.00 genes ± 9.58 sd) compared to infant-
associated Bifidobacterium (47.09 genes ± 11.08 sd). 
 
Figure 5.10 Distribution of selected GH families across Bifidobacterium isolates.  
(A) Proportional distribution of the most abundant GH families in the GH repertoire of 
Bifidobacterium. (B) Proportional distribution of the three most abundant GH families across host 
groups. (C) Abundance of genes within unique GH families identified across host groups. (D) 





A total of 80 GH families were identified across the 433 members of the genus 
Bifidobacterium. GH13 constituted the predominant GH family of the genus (24.3%) 
(Figure 5.10 A & B). As stated in Chapters 3 and 4, enzymes belonging to this family 
hydrolyse a wide range of complex carbohydrates, including starch, glycogen and 
related substrates, as well as stachyose, raffinose, palatinose, and melibiose. The 
complete breakdown of the latter group of carbohydrates has been shown to 
involve enzymes belonging to the GH36 family, which was also ubiquitous across 
the analysed host categories (421). On average, Bifidobacterium strains harboured 
11.86±3.51 GH13 genes per genome, with an exception of insect-associated 
isolates, whose genomes contained 3.21±1.61 predicted GH13 genes (Table S5.6). 
Other major ubiquitous GH families included GH43 and GH3, both associated with 
the degradation of plant-derived carbohydrates, with strains harbouring an average 
of 5.23±4.44 and 4.27±3.26 GH genes per genome, respectively. These 
observations are in line with previous findings resulting from the analysis of 47 
Bifidobacterium type strains (38).  
Eight GH families were unique to subsets of isolates in particular host groups 
(Figure 5.10 C). Further examination of these results indicated that the unique GH 
families with the highest abundance of GH genes, namely GH55 (exo- and endo-b-
1,3-glucanases, n=5 genes) and GH137 (β-L-arabinofuranosidases, n=4 genes), were 
predicted in primate- and insect-associated isolates identified as members of two 
distinct potentially novel Bifidobacterium species (species ‘5’ and species ’15’, 
respectively) (Table S5.6). 
As stated previously, various species and strains of Bifidobacterium have been 
shown to possess enzymes involved in the degradation of host-associated glycans, 
e.g. milk oligosaccharides and mucin. Examples of such enzymes include members 
of families GH33 (exo-sialidases), GH29 and GH95 (a-fucosidases), GH20 (enzymes 
with hexosaminidase and lacto-N-biosidase activities), GH112 (lacto-N-biosidases), 
GH38 and GH125 (α-mannosidases), as well as GH101 and GH129 (α-N-
acetylgalactosaminidases) (38). Evaluation of the presence of these GH families 
across the host groups revealed that sewage-associated isolates did not harbour 
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any of the genes associated with the metabolism of host-derived carbohydrates 
(Figure 5.10 D). Furthermore, dairy-, reptile- and ruminant-associated isolates 
possessed a more limited repertoire of host glycan-associated GH families 
compared to the remaining host groups, with members of GH95, GH101, GH112 
and GH129 absent from their genomes. Overall, these results illustrate the 




This work provides new insights into the diversity of a substantial animal-associated 
Bifidobacterium sample set and associated genomic dataset. Over 100 unduplicated 
Bifidobacterium isolates were recovered from a range of animal hosts, including 
previously unreported species of rodents (Azara’s agouti), reptiles (tortoises) and 
insects (Madagascan hissing cockroach). Genomic-based approaches, namely the 
ANI analysis and the multilocus sequence analysis, primarily identified 44 isolates as 
members of 19 putative novel Bifidobacterium species. 
Previous studies have suggested  a link between bacterial genome size and the 
habitats occupied by organisms, exploring the concept that particular habitats 
harbour a specific range of genome sizes, which are related to factors intrinsic to 
these given habitats (463, 474, 475). Metagenomic studies of bacterial communities 
correlated average genome length with habitat dynamicity, according to the 
hypothesis that organisms with larger genomes can thrive in complex habitats by 
encoding a wider repertoire of proteins with functions related to metabolism and 
stress tolerance (477-479). Environmental pressures acting on organisms over time, 
coupled with vertical inheritance of genes through phylogenetic descent, have been 
named as factors shaping the content of microbial genomes (474, 480). One 
outcome of such processes is the genome reduction in bacteria adapted to 
symbiotic lifestyles (463, 481, 482), described for example for insect-associated 
obligate symbionts (483, 484).     
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Comparison of bifidobacterial genomic signatures across the host groups revealed 
significant differences between several host categories in terms of genome size and 
abundance of genes involved in carbohydrate metabolism. In particular, genomes 
of strains associated with non-human primates were significantly larger than any 
other group. These strains also harboured the highest number of predicted 
CAZymes, and consequently, the highest number of genes encoding glycosyl 
hydrolases. These results may be explained in part, by the varied plant diets of 
primates. Based on the detailed dietary information obtained from collaborators at 
the Banham Zoo, the diet of Bifidobacterium-positive primates consisted of, 
alongside protein sources, a large variety of fruit and vegetables, Arabic gum and 
commercial dietary formulations for primates containing various complex 
carbohydrates, such as pectins, hemicelluloses, celulloses, lignins and starches. 
Additionally, complexity and diversity of primate milk oligosaccharides may 
contribute to the increased repertoire of genes involved in the degradation of 
complex carbohydrates in this group (485). The search for the presence of GH 
families previously linked to metabolism of host-derived glycans in humans  
(e.g. milk oligosaccharides and mucin), revealed that primate-associated isolates 
possessed a repertoire of these GH families similar to that of human-associated 
Bifidobacterium (Figure 5.10) (295). 
In contrast, insect-associated Bifidobacterium isolates displayed the smallest 
genome size and relatively low abundance of glycosyl hydrolases. In particular, their 
genomes were predicted to encode a very limited repertoire of genes belonging to 
GH13, compared to Bifidobacterium isolates associated with other host groups. 
These observations reflect the findings from previous studies, which suggested that 
the low abundance of GH13 genes in insect-associated Bifidobacterium type strains 
recovered from honey bees and bumblebees may be linked to their particular diet 
essentially lacking carbohydrates with a-glucoside linkages (nectar and pollen)  
(38, 486). When compared to bee-associated isolates, those recovered from 
cockroaches had a higher average number of GH13 genes in their genomes, 6.00 
genes ± 0.00 sd vs. 2.76 genes ± 1.23 sd. These findings may result from differences 
in the diet between the insect hosts. According to the metadata obtained from the 
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Zoo, the cockroach diet consisted of fresh fruit, vegetables and leaf litter, likely to 
contain carbohydrates prone to the action of GH13 enzymes. 
Comparison within the human category revealed that genomes of isolates 
associated with infants appeared to be significantly larger, on average, than those 
of isolates recovered from adults. This observation conflicts with the work of 
Rodriguez and Martiny (31), who did not find differences between these groups. 
These opposing results may be explained by the fact that the data subset analysed 
here contained an overall higher number of human-associated isolates (n=46 [n=34 
infant and n=12 adult] compared to n=20 [n=10 infant and n=10 adult]) and 
encompassed higher strain diversity, including a higher number of B. longum subsp. 
infantis isolates, which are characterised by larger genome sizes compared to other 
species associated with infant hosts. In line with previous findings (31), comparison 
of the abundance of GH families between infant- and adult-associated isolates did 
not reveal significant differences. 
Exploring similarities between host groups and across the phylogenetic tree 
revealed that Bifidobacterium isolates recovered from the same host or 
environment were non-randomly associated with their phylogenetic distribution. 
These results are consistent with previous findings form studies with fewer 
genomes (31). It has been hypothesized that certain species of Bifidobacterium 
prefer particular hosts, while others exhibit more a more “cosmopolitan” host 
distribution (487). Several studies found that isolates associated with the same 
host, or a specific group of hosts, tended to form phylogenetic subclusters (31, 293, 
487). While this pattern was present for some of the species represented by fewer 
strains, e.g. B. ruminantium or B. boum, many other isolates from the same host 
could be found within several clades and subclusters (e.g. B. animalis). These 
results suggested that bifidobacteria may not exhibit strict host specialisation, 
however the analysis of a larger dataset encompassing larger sample sizes and a 
wider host range would allow for more robust observations. 
Several studies have analysed the Bifidobacterium pan-genome, with the number of 
included isolates ranging from 14 to 215 (27-31), with all studies suggesting an 
open pan-genome. Doubling the number of genomes (n = 433) in this analysis 
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indicated the pan-genome is still open, which suggest a continuous Bifidobacterium 
expansion, potentially driven by a range of evolutionary mechanisms, such as HGT, 
speciation and evolutionary selection pressure acting on members of the genus 
(30). Gene gain and loss events, corresponding to changes in bacterial physiology 
and lifestyle, shape the gene repertoire of species and reflect their ability to adapt 
to a wide range of ecological niches and to respond to the environmental pressures 
(488). Given that the 433 Bifidobacterium isolates inhabit a wide range of hosts, 
and based on the results of this preliminary analysis, I expect that significant inter- 
and intra-species variations exist within the genus, leading to niche-specific 
genomic adaptations. Future work would test this hypothesis.  
 
5.5 Future work 
 
Through a combination of bacterial isolation, sequencing, and bioinformatic 
analysis, this study sought to provide additional insights into the diversity of animal-
associated members of the genus Bifidobacterium. The isolation efforts resulted in 
the recovery of a substantial number of isolates from different hosts and the 
identification of strains representative of almost 20 putative novel Bifidobacterium 
species. Candidates for biochemical characterisation as type strains would be 
selected from the latter pool of isolates, and complementary bioinformatic analyses 
would be performed according to the proposed standards for the use of genome 
sequences for the taxonomic classification of bacteria (308). As part of the zoo 
microbiome project, all animal faecal samples subjected to the isolation 
experiments were also processed for 16S rRNA gene sequencing, and this data 
would be analysed to gain insight into the environment the Bifidobacterium isolates 
were recovered from (i.e. wider bacterial community), and assess the relative 
abundance of members of this genus in different animal hosts. 
Although this analysis represents the largest to date, preliminary observations 
indicate that the gene content of the genus has not yet been resolved (open pan-
genome), and there are significant differences in genomic signatures  
(e.g. genome size, number of GHs) between isolates associated with specific host 
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categories. More detailed examination of the functional aspects of the pan-genome 
would allow to further assessment of inter- and intra-species variation within and 
across host categories. Finer-scale evolutionary mechanisms, including for example 
glycosyl hydrolase gene gain and loss events or horizontal gene transfer events, 
would be explored through further strain-level bioinformatic analyses. Based on the 
results of these analyses, a subset of isolates displaying interesting (e.g. health-
promoting or previously unreported) features could be selected, and experimental 
validation of the computational results carried out. For example, the assessment of 
carbohydrate metabolism profiles of selected isolates and their co-operation with 
other members of the gut bacterial community could result in findings leading to 
potential application in the veterinary or animal husbandry industry.  
Broader assessments of the diversity of Bifidobacterium and the complete 
resolution of their pan-genome would not be possible without the inclusion of 
additional isolates. Currently, the sampling among host animals is quite uneven, 
and certain host categories are significantly underrepresented (e.g. insects and 
reptiles). In addition, data on Bifidobacterium distribution and prevalence in wild 
animals are lacking. Further isolation efforts from larger sample sizes among a 
broader range of hosts, e.g. birds, reptiles and insects, and the subsequent 
generation of genomic datasets would strengthen the results of diversity analyses. 
Additionally, targeting as yet uncultured species and strains of Bifidobacterium for 
genome sequencing would improve the representation of the true diversity of the 
genus in their habitats.  
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Bifidobacterium are key members of the gut microbiota and are widely distributed 
in the animal kingdom (6). While the true diversity of animal-associated 
Bifidobacterium has yet to be evaluated, human-associated members of this genus 
predominate the gut microbiota during early life, with many strains capable of 
metabolising breast milk-derived HMOs (133). Bifidobacterium from later life points 
have been shown to carry genes for the degradation of plant-derived complex 
carbohydrates (33). Overall, in this thesis I have shown an association between host 
diet and Bifidobacterium species and strains in both humans and animals. 
Bioinformatic and experimental approaches revealed genomic flexibility and growth 
plasticity within Bifidobacterium, which may be the feature that allows colonisation 
of a wide range of hosts and is linked to the ability of particular species and strains 
to metabolise distinct dietary components.  
The high abundance of Bifidobacterium in early infancy, and strains of B. longum in 
particular, has been linked to nutrient availability, however longitudinal 
assessments of these bacteria during the crucial transition from milk-based diet to 
solid foods have been lacking. This aspect has been explored as part of my PhD 
through the genomic analysis of 75 B. longum strains isolated from nine individual 
infants at different dietary stages, i.e. pre-weaning, weaning and post-weaning, 
with a particular focus on their potential carbohydrate utilisation capabilities. The 
analysed strains showed intra-individual and diet-related differences in their 
genomic content, which could be associated with their ability to degrade specific 
dietary components. 
Genomic analysis revealed genome flexibility within B. longum, with intra-
subspecies differences in GH family content between strains. B. infantis was found 
to predominantly contain GH families implicated in the fermentation of host-
derived glycans like HMOs, which property could confer a particular advantage for 
this subspecies and facilitate their establishment in the early life microbiota. In 
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contrast, B. longum predominantly contained GH families involved in the 
degradation of plant-derived substrates, which could influence their ability of to 
persist within individual hosts. Indeed, I observed that particular strains of  
B. longum could persist in individuals through infancy, for at least 18 months, 
despite significant changes in diet. At the same time new strains displaying different 
genomic content and potential carbohydrate metabolism capabilities appeared be 
acquired, possibly in response to the changing nutritional environment. These 
results were further supported by subspecies-specific differences in GH content 
between pre- and post-weaning strains, and across the B. longum subspecies 
between strains isolated from breast-fed and formula-fed strains at different 
dietary stages. 
The complementary phenotypic growth data suggested that Bifidobacterium 
possess an overall very broad repertoire of carbohydrate utilisation genes that may 
be differentially switched on and off in response to the presence of specific dietary 
components (392, 393) This was reflected in differential growth of genotypically 
similar B. longum strains on various carbohydrate sources. The experimental data 
from formula-fed isolates were particularly interesting, with several closely related 
weaning and post-weaning strains from one baby able to metabolise selected 
HMOs. All babies recruited for this study only received standard formula not 
supplemented with any prebiotics or synthetic HMOs. 
Collectively, results from genomic and phenotypic analyses indicated a strong 
association between host diet and Bifidobacterium species and strains, which 
seemed to align with changes to the nutritional environment during weaning. 
However, the assessment of B. infantis, in particular in formula-fed babies, requires 
further efforts. Limited availability of isolates made it impossible to examine 
properties of B. infantis within this dietary group and make comparisons with 
breast-fed strains. Although B. infantis is primarily associated with the degradation 
of HMOs in breast-fed infants, I recorded growth of one of the B. infantis strains 
from formula-fed baby on xylose, albeit with inconsistent outcomes between 
experiments. Further experimental assays using a larger number of isolates would 
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be required to fully assess the ability of this subspecies to degrade a wider range of 
non-HMO carbohydrates in early life. 
Human-associated bifidobacteria have received much attention in the recent years 
due to their probiotic properties and associated beneficial health outcomes for the 
host. However, members of Bifidobacterium have a wide host range and have been 
extensively detected in the gut of non-human mammals, birds and social insects (6). 
Despite an increase in the availability of genomic data, studies focusing on 
members of Bifidobacterium in animals have been lacking, with the pan-genome 
and phylogenetic relationship of the genus unresolved. The sampling among host 
animals is quite uneven, and certain host categories are significantly 
underrepresented (e.g. insects and reptiles). An important aspect of this PhD 
project was the isolation of Bifidobacterium from a range of animal hosts, with 
pioneering examination of members of this genus in wild mice populations. These 
efforts, coupled with sequencing and bioinformatic analysis, resulted in the 
recovery of a substantial number of isolates (over 100) from various animals, 
including previously unreported species of rodents, reptiles and insects, and in the 
identification of strains representative of almost 20 putative novel Bifidobacterium 
species. 
Global examination of over 400 Bifidobacterium genomes, including publicly 
available sequences, revealed significant differences in genomic signatures  
(e.g. genome size and abundance of glycosyl hydrolases) between isolates 
associated with different host groups, supporting the notion that particular habitats 
harbour a specific range of genome sizes, which are related to factors intrinsic to 
these given habitats (463, 474, 475). Differences in the presence and the 
abundance of particular GH families in various host groups could be explained in 
part by host diet. Presence of high numbers of GH families associated with 
degradation of plant-derived carbohydrates in primate-associated Bifidobacterium 
isolates could be linked to varied plant components consumed by primates. 
Similarly, the identification of previously unreported GH46 family containing 
chitosanases in genomes of B. castoris associated with wild rodents could 
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potentially be explained by the presence of fungal component in the host diet 
(443). 
The exploration of similarities between host groups and across the phylogenetic 
tree revealed non-randomly association between Bifidobacterium isolates 
recovered from the same host or environment and their phylogenetic distribution. 
It has previously been proposed that certain species of Bifidobacterium prefer 
particular hosts, while others exhibit a more global host distribution (487), and that 
isolates associated with the same host, or a specific group of hosts, tended to form 
phylogenetic subclusters (31, 293, 487). This pattern was observed in this work for 
some of the Bifidobacterium species represented by fewer strains, but other 
isolates from the same host could be found within several clades and subclusters in 
the tree, suggesting that bifidobacteria may not exhibit strict host specialisation. 
Interestingly, to date all B. castoris isolates have been recovered from rodents. 
Additional isolation or high-resolution metagenomic efforts would be required to 
establish whether this species is restricted to this particular host group. Overall, the 
analysis of a larger dataset encompassing larger sample sizes and a wider host 
range would allow for more robust observations on Bifidobacterium specificity. 
The pan-genomic analysis in this work represents the largest to date, with 
preliminary observations indicating that the gene content of the genus has not yet 
been resolved and suggesting an open pan-genome. These results are in line with 
the findings from previous studies with fewer genomes (27-31), and are an 
indication of a continuous Bifidobacterium expansion, potentially driven by a range 
of evolutionary mechanisms, such as horizontal gene transfer events, speciation 
and evolutionary selection pressure acting on members of the genus (30). 
Significant inter- and intra-species variations leading to niche-specific genomic 
adaptations are expected to exist within the genus. More detailed examination of 
the functional aspects of the Bifidobacterium pan-genome, coupled with the 
bioinformatic exploration of finer-scale evolutionary mechanisms, such as glycosyl 
hydrolase gene gain and loss events or HGT events, would allow further assessment 
of this expected diversity within and across host groups.  
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Subsequent experimental validation of isolates presenting health-promoting or 
previously unreported properties could reveal potential for industrial applications, 
for example in animal husbandry or captive animal welfare. The identification of 
predicted GH families GH46 and GH49 in B. castoris, and families GH55 and GH137 
in putative novel Bifidobacterium species isolated from primates and insects, 
respectively, offers prospect for further investigation. Experimental confirmation of 
functionality coupled with transcriptomic and proteomic analysis could lay 
foundation for the characterisation of catalytic activity of recombinant enzymes.  
Potentially, Type II CRISPR-Cas systems can be exploited to create new tools for 
genome editing and engineering. Additional bioinformatic investigations could 
reveal the presence of CRISPR-Cas systems in newly isolated animal-associated 
Bifidobacterium. The identification of the complete Type II CRISPR-Cas system in  
B. castoris is promising and could be followed by bioinformatic analysis of 
protospacer adjacent motifs (PAMs) and further experimental approaches to 
investigate whether the identified CRISPR-Cas systems are actively transcribed and 
protect against invasive DNA, e.g. prophages.  
The results of the investigation of prophages in B. castoris genomes could be 
further strengthened by integration of data from other available software to 
improve the identification of prophage-associated genes. A similar approach could 
be used to screen for prophage elements in the genomes of newly isolated 
Bifidobacterium. These data could then be explored to assess whether 
experimental prophage induction is possible. Successful phage isolation would 
significantly expand the currently very limited data on Bifidobacterium-associated 
phages. 
Overall, this PhD research has contributed significantly to the current 
understanding of genomic and phenotypic properties of Bifidobacterium. These 
data should lay the foundation for future in-depth research aiming at the 
assessment of the extensive diversity of animal-associated members of this genus 
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